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Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia.1 Currently, 
the prevalence is 5.5% in the Netherlands, increasing with age to almost 20%.2 
Due to the aging population the prevalence will increase even more. It is currently 
estimated that the prevalence will double over the next 30-50 years.1-3 AF is 
associated with increased cardiovascular mortality and morbidity. The death rate 
is doubled in patients with AF.4-6 Stroke is one of the major complications of the 
arrhythmia, and in about 20% of patients stroke is the first presentation of AF.7 
Strokes associated with AF have a worse prognosis.8,9 In addition, AF can cause 
or deteriorate heart failure, and AF is independently associated with a worse 
prognosis in retrospective analyses of patients with heart failure.10-16 Patients with 
AF also have an increased bleeding risk due to the use of oral anticoagulation. In 
addition, the number of hospitalizations for AF increases, especially in the elderly.17,18 
This, in turn, increases the burden of AF on the health care system.19 Furthermore, 
AF reduces exercise capacity and quality of life.20-24 Hence, AF is not a benign disease.
 The first published observation of AF was by Bouilland in 1835. 
He described it as an irregular rhythm and unequal force of the heartbeat.25 Nothnagel 
gave it the term ‘delirium cordis’, due to the irregular arterial pulse.26 In 1908 the first 
electrocardiogram of AF was published.27 Treatment options at that time were limited. 
To reduce the ventricular rate digoxin was given; the reduction of ventricular rate 
due to digoxin was already discovered by William Withering in 1785.28 Furthermore, 
quinidine could be used to convert AF to sinus rhythm.29,30 It was not until 
the 1960’s that the electrical cardioversion was introduced by Bernard Lown.31 
Despite this new method which converted AF to sinus rhythm in a high percentage 
of patients, AF remained a progressive arrhythmia,31-33 since the success of rhythm 
control, i.e. long term maintenance of sinus rhythm, was and is limited.34-38 
Moreover, the adverse effects of rhythm control drugs are substantial. Nevertheless, 
assuming that sinus rhythm would improve prognosis, for years the initial goal 
was prevention of recurrent AF, i.e. rhythm control. AF was accepted only when 
rhythm control failed. It was not until the beginning of this decade that it became 
apparent that there was no difference in outcome between rate and rhythm 
control.39-43 The Atrial Fibrillation Follow-up Investigation of Rhythm Management 
(AFFIRM)40 and Rate Control versus Electrical Cardioversion for Persistent Atrial 
Fibrillation (RACE)41 were the first two studies which elucidated a comparable 
prognosis during rate and rhythm control (Table 1). In AFFIRM and RACE together 
more than 4500 patients were randomized to either rate or rhythm control. The primary 
outcome of AFFIRM, all cause mortality, did not differ between rate and rhythm 
control. The primary outcome of RACE, a composite of cardiovascular morbidity and 
mortality, was also similar between rate and rhythm control. The Pharmacological 
Intervention in Atrial Fibrillation (PIAF) showed that there was no difference in AF 
related symptoms between rate and rhythm control.39 After the first two landmark 
studies investigating cardiovascular morbidity and mortality, the Strategies of 
Treatment of Atrial Fibrillation (STAF)42, the How to Treat Chronic Atrial Fibrillation 
(HOT CAFE)43, and the Japanese Rhythm Management Trial for Atrial Fibrillation 
( J-Rhythm)44 studies confirmed the equality between rate and rhythm control. 
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The absence of a benefit of rhythm control is caused by the inefficacy and also by 
the adverse effects of antiarrhythmic drugs. At the time the abovementioned studies 
were performed, pulmonary vein isolation (PVI) was not yet a widespread method to 
treat patients with especially paroxysmal AF. It is therefore not clear what the effect 
of rhythm control, including PVI, on mortality would be. Although PVI is nowadays 
the cornerstone of rhythm control management in paroxysmal AF patients without 
severe co-morbidity, success rates are still low in patients with longstanding persistent 
and permanent AF.1
 As mentioned, the AFFIRM, RACE, PIAF, STAF, and HOT CAFE, 
J-Rhythm, and Atrial Fibrillation and Congestive Heart Failure (AF-CHF) studies 
demonstrated that rate control was comparable to rhythm control regarding prognosis 
in patients with AF (Table 1).39-45 From that moment on, rate control became frontline 
therapy in older patients with few or acceptable symptoms of AF. However, the rate 
control criteria used in the rate versus rhythm control trials were not homogeneous 
(Table 1). In addition, the rate control criteria used in previous guidelines were not 
evidence based.46 Digoxin was the cornerstone of AF treatment during the largest part 
of the last century. Although digoxin was used since the 18th century,47 it only became 
apparent in the 1970’s that treatment with digoxin alone did not decrease the heart 
rate adequately during exercise.48,49
 Newer rate control drugs became available much later. Since then, drugs 
frequently used to institute rate control consist of beta-blockers, nondihydropiridine 
calcium-channel blockers and, as mentioned, digoxin. From the 70’s of the last century 
until now several studies have been performed evaluating the effect of negative 
dromotropic drugs (beta-blockers, nondihydropiridine calcium-channel blockers, 
Cardiovascular death, hospitalization for heart failure, thromboembolic complications, bleeding, pacemaker implantation, and severe adverse 
effects or antiarrhythmic drugs
All cause mortality, stroke or transient ischemic attack, systemic embolism, and cardiopulmonary resuscitation 
All cause mortality, thromboembolic complications and intracranial or other major hemorrhage
All cause mortality, symptomatic cerebral infarction, systemic embolism, major bleeding, hospitalization for heart failure, physical/ psychological 





Primary outcome Heart rate criteria
AFFIRM40 All-cause mortality ≤80 beats/min, and ≤110 beats/min during moderate 
exercise. On Holter mean heart rate ≤100 beats/min, and 
not >110% of the maximum predicted heart rate
RACE41 Composite endpoint* <100 beats/min
PIAF39 Symptoms related to 
atrial fibrillation
Diltiazem 90mg, 2-3 times per day, additional rate control 
therapy at discretion of physician
STAF42 Composite endpoint† -
HOT CAFE43 Composite endpoint‡ 70-90 beats/min, <140 beats/min during moderate exercise
AF-CHF45 Cardiovascular death ≤80 beats/min, and ≤110 beats/ min during 6-min walk test
J Rhythm44 Composite endpoint# 60-80 beats/min
Table 1. Heart rate criteria in the rate versus rhythm control trials
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digoxin, amiodarone, and dronedarone) on heart rate during AF. At first, the focus 
was on heart rate during rest and exercise.50-54 It was expected that exercise capacity 
would improve due to a reduction in heart rate. However, later studies showed no 
improvement of exercise capacity with a more physiological rate response during 
exercise.55-61 A number of studies assessed hemodynamics and gas exchange during 
AF. Several negative dromotropic drugs were compared with placebo or comparisons 
between different negative dromotropic drugs were evaluated. Though these studies 
also showed a reduction in heart rate during exercise, no improvement of maximal 
oxygen uptake was observed.56,57,60,62,63 This is of major importance considering that 
maximal oxygen uptake is an indicator for left ventricular function.64
 One of the first studies that evaluated left ventricular function with regard 
to different rate control strategies was performed by Khand and colleagues.65 
The investigators observed an improvement of left ventricular function in patients 
treated with carvedilol on top of digoxin. This improvement was not observed in 
patients treated with placebo and digoxin. There were no differences in 6-minute 
walking distances or brain natriuretic peptide. A large retrospective analysis of the 
AFFIRM evaluated the effect of heart rate on prognosis.66 All patients randomized 
to rate control who were in AF at baseline and at 2 months follow-up were included 
in this analysis. There was no difference in cardiovascular hospitalization or death 
between the quartiles of achieved heart rate at rest at 2 months follow-up. Resting 
heart rate was not a predictor for all cause mortality or cardiovascular hospitalization.
 The AFFIRM and RACE studies used different definitions of adequate 
rate control. In the AFFIRM the following rate control approach was used: resting 
heart rate below 80 beats per minute, and a heart rate below 110 beats per minute 
during a 6-minute walk test or a mean heart rate during 24 hour Holter monitoring 
below 100 beats per minute and no maximum heart rate above 110% of the maximum 
predicted heart rate.67 In the RACE the rate control criterion was a resting heart rate 
below 100 beats per minute.41 A pooled analysis of AFFIRM and RACE evaluated 
differences in outcome between the studies.68 The mean heart rate was lower in the 
patients included in the AFFIRM trial. There was no difference in outcome between 
the patients included in AFFIRM or RACE, though a heart rate >100 beats per 
minute was associated with a worse outcome.
 All available studies on heart rate control during permanent AF were 
retrospective analyses. These retrospective data indicated that there was no benefit of 
a strict rate control approach compared with a more lenient rate control approach in 
terms of cardiovascular morbidity and mortality. Furthermore, strict rate control was 
difficult to achieve. In the AFFIRM trial a strict rate control approach was used, as 
mentioned above. To achieve these strict criteria, frequent medication changes and 
drug combinations were needed. Eventually about two thirds of patients were treated 
according to the protocol.69 This indicates that a strict rate control approach is not 
attainable in all patients with AF.
 Quality of life and heart rate are also assumed to be related. A higher heart 
rate could cause more or more severe symptoms than a lower heart rate. However, 
instituting a stricter rate control strategy requires more negative dromotropic drugs. 
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The possible adverse side effects of more and higher dosages of negative dromotropic 
drugs could reduce the beneficial effect of a lower heart rate. In a sub-analysis of 
AFFIRM there was no relation between quality of life and achieved resting heart rate 
at 2 months follow-up.66 Prospective data on quality of life and heart rate in patients 
with permanent AF are lacking.
 The current data indicate that cardiovascular morbidity, mortality, and quality 
of life are not influenced by heart rate. However, as mentioned, all available data on 
ventricular frequency during AF are retrospective. Thus, prospective data on heart rate 
control in patients with permanent AF should give us better insight in how to treat 
this specific patient cohort.70
Aim of this thesis
Rate control is frontline therapy in patients with AF, especially in those without severe 
symptoms, or after failure of rhythm control. However, an evidence based strategy 
concerning the treatment of patients with permanent AF is lacking. The aim of this 
thesis is to evaluate rate control strategies in patients with permanent AF, in terms of 
cardiovascular morbidity, mortality, all cause hospitalizations, and quality of life. 
 In chapter 2 we describe patients with persistent AF randomized to the 
rate control arm of the RACE trial. We evaluated cardiovascular morbidity, mortality, 
echocardiographic parameters, and quality of life. 
 Previously, no randomized clinical trial was performed evaluating different 
rate control strategies. Therefore a randomized clinical trial was performed evaluating 
lenient and strict rate control in terms of cardiovascular morbidity and mortality, i.e. 
the Rate Control Efficacy in Permanent Atrial Fibrillation: a comparison between 
Lenient and Strict Rate Control II (RACE II) study. The hypothesis was that there 
was no difference in outcome between lenient and strict rate control. The results of the 
RACE II are presented in chapter 3. 
 Strict rate control is a challenging treatment strategy since it is difficult to 
achieve. The strict rate control approach used in AFFIRM was attained in about two 
thirds of the patients. Perhaps the assumed equality between lenient and strict rate 
control strategies regarding outcome is caused by the failure of achieving strict rate 
control. In chapter 4 we investigated whether outcome was comparable between 
patients included in RACE II with successful strict, failed strict, or lenient rate control. 
 When instituting rate control in a patient with AF, clinicians often use AF-
related symptoms as a marker for adequate rate control. The evaluation of quality 
of life in the RACE II study is therefore of major importance, especially since the 
study hypothesized that outcome would be comparable between lenient and strict rate 
control, and future therapy could be guided on symptoms experienced by the patients. 
In chapter 5 we present the results of the quality of life analyses in the RACE II. 
 The most firm outcome parameter assessing different treatment strategies is 
all-cause mortality. However, the RACE II was not powered to evaluate differences 
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in all-cause mortality between lenient and strict rate control. An alternative outcome 
parameter is cardiovascular hospitalization. We therefore performed a post-hoc 
analysis of RACE II evaluating possible differences between lenient and strict rate 
control in all-cause mortality and cardiovascular and non-cardiac hospitalizations. 
These results are presented in chapter 6. 
16 Chapter 1
Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: The Task 
Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). 
Europace 2010;12:1360-420. 
Heeringa J, van der Kuip DA, Hofman A et al. Prevalence, incidence and lifetime risk of atrial 
fibrillation: the Rotterdam study. Eur Heart J 2006;27:949-53. 
Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national 
implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in 
Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5. 
Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation 
on the risk of death: the Framingham Heart Study. Circulation 1998;98:946-52. 
Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing 
conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2N-9N. 
Wachtell K, Hornestam B, Lehto M et al. Cardiovascular morbidity and mortality in hypertensive 
patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in 
Hypertension (LIFE) study. J Am Coll Cardiol 2005;45:705-11. 
Jorgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Acute stroke with atrial fibrillation. The 
Copenhagen Stroke Study. Stroke 1996;27:1765-9. 
Lin HJ, Wolf PA, Kelly-Hayes M et al. Stroke severity in atrial fibrillation. The Framingham Study. 
Stroke 1996;27:1760-4. 
Lamassa M, Di Carlo A, Pracucci G et al. Characteristics, outcome, and care of stroke associated 
with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The 
European Community Stroke Project). Stroke 2001;32:392-8. 
Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation 
is associated with an increased risk for mortality and heart failure progression in patients with 
asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the 
SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998;32:695-703. 
Crijns HJ, Tjeerdsma G, de Kam PJ et al. Prognostic value of the presence and development of atrial 
fibrillation in patients with advanced chronic heart failure. Eur Heart J 2000;21:1238-45. 
Middlekauff HR, Stevenson WG, Stevenson LW. Prognostic significance of atrial fibrillation in 
advanced heart failure. A study of 390 patients. Circulation 1991;84:40-8. 
Olsson LG, Swedberg K, Ducharme A et al. Atrial fibrillation and risk of clinical events in chronic 
heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in 
Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll 
Cardiol 2006;47:1997-2004. 
Van den Berg MP, van Gelder IC, van Veldhuisen DJ. Impact of atrial fibrillation on mortality in 
patients with chronic heart failure. Eur J Heart Fail 2002;4:571-5. 
Wang TJ, Larson MG, Levy D et al. Temporal relations of atrial fibrillation and congestive heart failure 


















Mamas MA, Caldwell JC, Chacko S, Garratt CJ, Fath-Ordoubadi F, Neyses L. A meta-analysis of the 
prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail 2009;11:676-83. 
Stewart S, MacIntyre K, MacLeod MM, Bailey AE, Capewell S, McMurray JJ. Trends in hospital 
activity, morbidity and case fatality related to atrial fibrillation in Scotland, 1986--1996. Eur Heart J 
2001;22:693-701. 
Frost L, Engholm G, Moller H, Husted. Decrease in mortality in patients with a hospital diagnosis of 
atrial fibrillation in Denmark during the period 1980-1993. Eur Heart J 1999;20:1592-9. 
Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fibrillation in the 
United States, 1985 through 1999: implications for primary prevention. Circulation 2003;108:711-6. 
Miyasaka Y, Barnes ME, Gersh BJ et al. Secular trends in incidence of atrial fibrillation in Olmsted 
County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 
2006;114:119-25. 
Nieuwlaat R, Prins MH, Le Heuzey JY et al. Prognosis, disease progression, and treatment of atrial 
fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. Eur Heart 
J 2008;29:1181-9. 
Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical 
classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. 
JAMA 2001;285:2864-70. 
Dorian P, Jung W, Newman D et al. The impairment of health-related quality of life in patients with 
intermittent atrial fibrillation: implications for the assessment of investigational therapy. J Am Coll 
Cardiol 2000;36:1303-9. 
Hagens VE, Ranchor AV, Van Sonderen E et al. Effect of rate or rhythm control on quality of life in 
persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) 
Study. J Am Coll Cardiol 2004;43:241-7. 
Bouilland J. Traité clinique des maladies du coeur. JB Bailliere 1835:141-2. 
Nothnagel H. Ueber Arythmische Herzhatigkeit. Deutsches Archiv fur klinische Medizin 1876: 
190-220. 
Hering HE. Das Elektrocardiogramm des irregularis perpetuus. Deutsches Archiv fur klinische 
Medizin 1908:205-8. 
Buchtel L, Ventura HO. Lunar Society and the discovery of digitalis. J La State Med Soc 2006;158: 
26-30. 
Drury AN, Iliescu CC. The Restoration of the Normal Cardiac Mechanism in Cases of Auricular 
Fibrillation by Means of Quinidine Sulphate. Br Med J 1921;2:511-4. 
Lewis T, Drury AN, Iliescu CC, Wedd AM. The Manner in which Quinidine Sulphate Acts in 
Auricular Fibrillation. Br Med J 1921;2:514-5. 
Lown B, Amarasingham R, Neuman J. New method for terminating cardiac arrhythmias. Use of 
synchronized capacitor discharge. JAMA 1962;182:548-55. 
Brown KW, Whitehead EH, Morrow JD. Treatment of Cardiac Arrhythmias with Synchronized 



















McDonald L, Resnekov L, O’Brien K. Direct-Current Shock in Treatment of Drug-Resistant Cardiac 
Arrhythmias. Br Med J 1964;1:1468-70. 
Crijns HJ, Van Gelder IC, Van Gilst WH, Hillege H, Gosselink AM, Lie KI. Serial antiarrhythmic 
drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or 
atrial flutter. Am J Cardiol 1991;68:335-41. 
Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study 
in awake chronically instrumented goats. Circulation 1995;92:1954-68. 
Kopecky SL, Gersh BJ, McGoon MD et al. The natural history of lone atrial fibrillation. A population-
based study over three decades. N Engl J Med 1987;317:669-74. 
Van Gelder IC, Crijns HJ, Van Gilst WH, Verwer R, Lie KI. Prediction of uneventful cardioversion and 
maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation 
and flutter. Am J Cardiol 1991;68:41-6. 
Rensma PL, Allessie MA, Lammers WJ, Bonke FI, Schalij MJ. Length of excitation wave and 
susceptibility to reentrant atrial arrhythmias in normal conscious dogs. Circ Res 1988;62:395-410. 
Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation--Pharmacological 
Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000;356:1789-94. 
Wyse DG, Waldo AL, DiMarco JP et al. A comparison of rate control and rhythm control in patients 
with atrial fibrillation. N Engl J Med 2002;347:1825-33. 
Van Gelder IC, Hagens VE, Bosker HA et al. A comparison of rate control and rhythm control in 
patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-40. 
Carlsson J, Miketic S, Windeler J et al. Randomized trial of rate-control versus rhythm-control in 
persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll 
Cardiol 2003;41:1690-6. 
Opolski G, Torbicki A, Kosior DA et al. Rate control vs rhythm control in patients with nonvalvular 
persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT 
CAFE) Study. Chest 2004;126:476-86. 
Ogawa S, Yamashita T, Yamazaki T et al. Optimal treatment strategy for patients with paroxysmal atrial 
fibrillation: J-RHYTHM Study. Circ J 2009;73:242-8. 
Roy D, Talajic M, Nattel S et al. Rhythm control versus rate control for atrial fibrillation and heart 
failure. N Engl J Med 2008;358:2667-77. 
Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 Guidelines for the Management of 
Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart 
Association Task Force on Practice Guidelines and the European Society of Cardiology Committee 
for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management 
of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm 
Association and the Heart Rhythm Society. Circulation 2006;114:e257-354. 
Moore B. The Effects upon the Heart of Soluble Digitoxin, an Isolated Glucoside of the Digitalis 
Group. Br Med J 1912;1:60-6. 
Chamberlain DA, White RJ, Howard MR, Smith TW. Plasma digoxin concentrations in patients with 


















Redfors A. Digoxin dosage and ventricular rate at rest and exercise in patients with atrial fibrillation. 
Acta Med Scand 1971;190:321-33. 
Yahalom J, Klein HO, Kaplinsky E. Beta-adrenergic blockade as adjunctive oral therapy in patients 
with chronic atrial fibrillation. Chest 1977;71:592-6. 
David D, Segni ED, Klein HO, Kaplinsky E. Inefficacy of digitalis in the control of heart rate in 
patients with chronic atrial fibrillation: beneficial effect of an added beta adrenergic blocking agent. 
Am J Cardiol 1979;44:1378-82. 
Stern EH, Pitchon R, King BD, Guerrero J, Schneider RR, Wiener I. Clinical use of oral verapamil in 
chronic and paroxysmal atrial fibrillation. Chest 1982;81:308-11. 
Lang R, Klein HO, Weiss E et al. Superiority of oral verapamil therapy to digoxin in treatment of 
chronic atrial fibrillation. Chest 1983;83:491-9. 
Panidis IP, Morganroth J, Baessler C. Effectiveness and safety of oral verapamil to control exercise-
induced tachycardia in patients with atrial fibrillation receiving digitalis. Am J Cardiol 1983;52:1197-
201. 
DiBianco R, Morganroth J, Freitag JA et al. Effects of nadolol on the spontaneous and exercise-
provoked heart rate of patients with chronic atrial fibrillation receiving stable dosages of digoxin. Am 
Heart J 1984;108:1121-7. 
Myers J, Atwood JE, Sullivan M et al. Perceived exertion and gas exchange after calcium and beta-
blockade in atrial fibrillation. J Appl Physiol 1987;63:97-104. 
Atwood JE, Myers JN, Sullivan MJ, Forbes SM, Pewen WF, Froelicher VF. Diltiazem and exercise 
performance in patients with chronic atrial fibrillation. Chest 1988;93:20-5. 
Koh KK, Song JH, Kwon KS et al. Comparative study of efficacy and safety of low-dose diltiazem 
or betaxolol in combination with digoxin to control ventricular rate in chronic atrial fibrillation: 
randomized crossover study. Int J Cardiol 1995;52:167-74. 
Koh KK, Kwon KS, Park HB et al. Efficacy and safety of digoxin alone and in combination with 
low-dose diltiazem or betaxolol to control ventricular rate in chronic atrial fibrillation. Am J Cardiol 
1995;75:88-90. 
Atwood JE, Myers J, Quaglietti S, Grumet J, Gianrossi R, Umman T. Effect of betaxolol on the 
hemodynamic, gas exchange, and cardiac output response to exercise in chronic atrial fibrillation. Chest 
1999;115:1175-80. 
Farshi R, Kistner D, Sarma JS, Longmate JA, Singh BN. Ventricular rate control in chronic atrial 
fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug 
regimens. J Am Coll Cardiol 1999;33:304-10. 
Matsuda M, Matsuda Y, Yamagishi T et al. Effects of digoxin, propranolol, and verapamil on exercise 
in patients with chronic isolated atrial fibrillation. Cardiovasc Res 1991;25:453-7. 
Lundstrom T, Ryden L. Ventricular rate control and exercise performance in chronic atrial fibrillation: 
effects of diltiazem and verapamil. J Am Coll Cardiol 1990;16:86-90. 
Wolfe LA, Cunningham DA, Davis GM, Rosenfeld H. Relationship between maximal oxygen uptake 


















Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JG. Carvedilol alone or in combination 
with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol 
2003;42:1944-51. 
Cooper HA, Bloomfield DA, Bush DE et al. Relation between achieved heart rate and outcomes 
in patients with atrial fibrillation (from the Atrial Fibrillation Follow-up Investigation of Rhythm 
Management [AFFIRM] Study). Am J Cardiol 2004;93:1247-53. 
Atrial fibrillation follow-up investigation of rhythm management -- the AFFIRM study design. The 
Planning and Steering Committees of the AFFIRM study for the NHLBI AFFIRM investigators. 
Am J Cardiol 1997;79:1198-202. 
Van Gelder IC, Wyse DG, Chandler ML et al. Does intensity of rate-control influence outcome 
in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. Europace 
2006;8:935-42. 
Olshansky B, Rosenfeld LE, Warner AL et al. The Atrial Fibrillation Follow-up Investigation of 
Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll 
Cardiol 2004;43:1201-8. 
Van Gelder IC, Van Veldhuisen DJ, Crijns HJ et al. RAte Control Efficacy in permanent atrial 
fibrillation: a comparison between lenient versus strict rate control in patients with and without heart 







21Intensity of rate control on outcome
2Does Intensity of Rate Control Influence Outcome in Persistent Atrial FibrillationData of the RACE studyHessel F. GroenveldHarry J.G.M. CrijnsMichiel RienstraMaarten P. van den BergDirk J. van VeldhuisenIsabelle C. van Gelderfor the RACE investigators




Large trials have demonstrated that rate control is an acceptable alternative for 
rhythm control.  However, optimal heart rate during AF remains unknown. Aim of 
this analysis was to compare outcome between rate control above and below 80 beats 




In the RAte Control versus Electrical cardioversion for persistent atrial fibrillation 
(RACE) study, 522 patients were included, 256 were randomized to rate control. 
This post-hoc analysis included patients randomized to rate control. Patients were 
divided according to their mean resting heart rate during follow up, <80 bpm (n=75) 
or ≥80 bpm (n=139). The endpoint, a composite of cardiovascular mortality, heart 
failure, thromboembolic complications, bleeding, pacemaker implantation and severe 
drug side effects, was compared between both groups.
During follow-up (2.3±0.6 years) a significant difference between both groups 
in heart rate was observed (72±5 bpm vs. 90±8 bpm, p<0.001). Rate control drugs 
were not significantly different between both groups. NYHA class and fractional 
shortening remained unchanged in both groups. There were 17 (23%) endpoints 
in the low heart rate group and 24 (17%) in the higher heart rate group (absolute 
difference 5.4[-7.3-8.2], p=ns). Independent predictors for the primary endpoint were 
coronary artery disease, digoxin use and interrupted anticoagulation, not high heart 
rate. Quality of life was comparable in both groups during follow-up.
In patients treated with a rate control strategy no differences were observed in terms 
of cardiovascular morbidity, mortality and quality of life between the observed 
differences in level of rate control throughout follow-up.
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Introduction
In many patients rate control is the first choice therapy of atrial fibrillation 
(AF).1-4 However, the optimal heart rate during AF remains unknown.5,6 The current 
American College of Cardiology/ American Heart Association /European Society of 
Cardiology guidelines on AF recommend a resting heart rate between 60-80 beats 
per minute (bpm) and a heart rate between 90-115 bpm during moderate exercise.7 
Management of rate control differs however.8 Furthermore, randomized clinical trials 
investigating the optimal heart rate during AF are lacking.
 Intuitively, strict rate control should be associated with fewer symptoms, 
better quality of life, lower incidence of heart failure, and as a consequence a better 
survival. Strict rate-control with more drugs and higher doses, on the other hand, 
could lead to drug-related adverse effects, causing symptomatic bradycardia, leading to 
falls, syncope, trauma, and preventable pacemaker implantation. The latter is supported 
by data from the Atrial Fibrillation Follow-up Investigation of Rhythm Management 
(AFFIRM) and a pooled analysis of the AFFIRM and RAte Control versus Electrical 
cardioversion (RACE) study.6,9
 In the RACE study, the target heart rate in the rate control arm was a resting 
heart rate less than 100 bpm. The aim of the present post-hoc analysis of the RACE 
study was to compare rate control-randomized patients with an achieved mean resting 
heart rate <80  bpm versus patients with a mean heart rate ≥80 bpm during all follow-
up visits with regard to long term outcome i.e. cardiovascular morbidity and mortality, 
quality of life and echocardiographic parameters.
Methods
Study design of the RACE study
The study design, patient characteristics and results of the RACE study have previously 
been published.2 In short, 522 patients were included with recurrent persistent AF and 
randomized to either rate (n=256) or rhythm control (n=266). Patients were seen in 
the outpatient clinic 1, 3, 6, 12, 24 months after randomization and at the end of follow 
up (maximum of 3 years). At each visit cardiovascular events were documented and a 
12-lead electrocardiogram was obtained. Aspirin (80 to 100 mg daily) was allowed in 
patients who were less than 65 years old and had lone AF. All other patients received 
oral anticoagulant therapy with acenocoumarol or fenprocoumon (target international 
normalized ratio (INR) 2.5 to 3.5). 
 The authors are solely responsible for the design and conduct of this study, all 
analysis, the drafting and editing of the paper and its final contents. The RACE study 
was supported by grants from the Center for Health Care Insurance (OG96-047) 
and the Interuniversity Cardiology Institute, The Netherlands, and by an unrestricted 











Age (years) 70±8 68±10 0.09
Total AF duration (days) 662 (66-14909) 408 (14-4219) 0.04
Duration present episode of AF (days) 40 (2-399) 34 (1-392) 0.2
Atrial fibrillation - % 96 98 0.4
Atrial flutter - % 4 2 0.4
Symptoms of AF - % 72 71 0.8
     Palpitations 29 25 0.5
     Dyspnea 25 37 0.7
     Fatigue 36 40 0.5
NYHA class for heart failure - %
     I 55 50 0.7
     II 43 47
     III 2 3
Table 1. Baseline characteristics
Study population
In the present analysis we included all patients randomized to rate control and having 
AF during the complete follow-up. In the RACE study cardioversion was allowed 
in patients randomized to rate control experiencing intolerable complaints of AF 
or unacceptable side effect of rate control medication or progressive left ventricular 
dysfunction. Alternatively, patients could be scheduled for atrioventricular node 
ablation and pacemaker implantation. Forty-two patients who were not continuously in 
AF during the total follow-up were therefore excluded. Of these patients 28 (67%) had 
a heart rate <80 bpm and 14 (33%) a heart rate >80 bpm. Mean heart rate was 75 bpm. 
Rate control was achieved with the administration of digitalis, a nondihydropyridine 
calcium-channel blocker, and a beta-blocker, alone or in combination.
 The rate control target in the RACE study was a resting heart rate less 
than 100 bpm (monitored with a 12 lead resting electrocardiogram). In the RACE 
study no exercise test was performed to assess rate control. After randomization, 
patients were instituted on rate control medication to reach the target of a heart rate 
<100 bpm. Therefore, in this sub-analysis the adequacy of rate control was assessed 
at 1 month and subsequent visits until the end of study. Heart rate at baseline was not 
taken into account because adaptations of rate control medication was performed after 
baseline visit. Patients were assigned based on the mean heart rate over all subsequent 
follow-up visits (3 and 6 month, 1 year,  2 year and 3 year). Heart rate below (low heart rate) 
and above (high heart rate) 80 bpm during total follow-up was the designated boundary.
AF - atrial fibrillation; NYHA - New York Heart Association functional classification of heart failure
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Underlying diesease - %
     Coronary artery diesease 27 27 0.9
     Valve disease 21 17 0.3
     Cardiomyopathy 5 17 0.02
     Hypertension 45 39 0.3
     No heart disease 19 22 0.6
     Chronic obstructive pulmonary disease 23 22 0.3
     Diabetes mellitus 9 12 0.5
     Ischemic thrombo-embolic complication 27 11 0.003
     Hemorrhagic complication 7 8 0.7
Treatment - %
     Digitalis 21 25 0.6
     Beta-blocker 20 22 0.6
     Verapamil or diltiazem 9 5 0.2
     Digitalis and beta-blocker 24 22 0.6
     Digitalis and calcium antagonist 15 18 0.5
     Beta-blocker and calcium antagonist 4 3 0.5
     Digitalis, beta-blocker, and calcium 
     antagonist
- 1 0.2
     No rate control drugs 7 4 0.4
     ACE-inhibitor 24 25 0.9
     ARB 9 7 0.5
Blood pressure - mm Hg
     Systolic 143±21 143±22 0.9
     Diastolic 84±11 85±11 0.4
Table 1. Baseline characteristics (continued)
Endpoints
The primary end point was a composite of cardiovascular death, heart failure, 
thromboembolic complications, bleeding, severe adverse effects of antiarrhythmic 
drugs and pacemaker implantations. All events that occurred between randomization 
and the end of study were recorded. Definitions of the composites of the primary end 
point have been described before.2 A committee of experts, who were unaware of the 
treatment assignments, adjudicated all reported end points.
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Quality of life questionnaire
Quality of life was determined using the Dutch version of the Medical Outcomes 
Study Short-form health survey (SF-36) questionnaire as has been described before.10 
In short, the SF-36 contains items to assess physical health (general health perception, 
physical functioning, role limitations due to physical problems and bodily pain), 
as well as mental health (social functioning, role limitations due to emotional problems, 
mental health and vitality). Quality of life was assessed at baseline, after 1 year, and at 
the end of the study in 50 of the 75 patients (67%) with a mean heart rate <80 bpm 
and in 98 of 139 patients (71%) with a mean heart rate ≥80 bpm.
Statistica analysis
Baseline descriptive statistics are presented as mean ± standard deviation (SD) or 
median (range) for continuous variables and counts with percentages for categorical 
variables. Differences between groups, in terms of patient characteristics, were 
evaluated by Students t-test or Mann-Whitney U-test, depending on normality 
of the data, for continuous data and by Fisher exact test or Chi-square test for 
categorical data. Kaplan Meier and Cox regression analyses were performed to assess 
the influence of mean heart rate during follow up on the occurrence of the primary 
endpoint and its components over time. Linearity of the continuous variables with 
respect to the response variable was assessed by determining the quartiles of their 
distribution. Thereafter hazard ratios for each quartile were calculated. In case of a 
linear trend in the estimated hazard ratios, the variable was introduced in the model 
as continuous. If no linearity was demonstrated, the variable was further categorized 
by taking together the quartiles with hazard ratios similar in magnitude, primarily the 
median value or otherwise based on clinical relevance. All patient characteristics, drug 
therapy, including interrupted oral anticoagulation use, blood pressure, atrial sizes 
and left-ventricular dysfunction at baseline were included. All univariate predictors 
with p<0.1 were tested in a multivariate model, using a stepwise approach. In the 
multivariate model a variable was excluded when p≥0.05. In all analyses a value of 
p<0.05 was considered statistically significant. All analyses were performed according 
to the intention-to-treat principle.
Results
Patient characteristics
Twohundred-fourteen patients with permanent AF were included in this substudy. 
The low heart rate group consisted of 75 patients, 139 patients comprised the high 
heart rate group (Table 1). Baseline characteristics are listed in Table 1. In patients in 
the low-rate group duration of AF was longer and patients had more often endured an 
ischemic thromboembolic complication. No other differences were observed.
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Mean follow-up was 2.3±0.6 years. During total follow-up a significant difference in 
mean heart rate between both groups was observed (72±5 bpm, range 54–80 in the 
low versus 90±8 bpm, range 80–125 in the high heart rate group, p<0.001, Figure 1). 
NYHA class and blood pressure remained unchanged in both groups. From baseline 
to 3 years of follow-up, atrial sizes increased in both groups. No significant differences
Follow-up
Figure 1. Mean heart rate during follow-up
Heart rate ≥80 beats per minute
Heart rate <80 beats per minute
* P<0.05 between groups
Table 2.  Echocardiographic measurements according to heart rate group
Baseline 3 years P Value
Left ventricular end systolic diameter
   <80 beats per minute 36±9 35±10 0.9
   ≥80 beats per minute 37±8 37±9 0.5
Left ventricular end diastolic diameter
   <80 beats per minute 52±7 52±9 0.6
   ≥80 beats per minute 53±7 53±8 0.7
Left atrial size, long axis view
   <80 beats per minute 45±7 46±8 0.2
   ≥80 beats per minute 45±6 47±6 0.1
Left atrial size, apical view
   <80 beats per minute 65±8 71±9 0.002
   ≥80 beats per minute 64±9 68±9 0.001
Right atrial size, apical view
   <80 beats per minute 59±8 66±10 0.02
















Table 2. Echocardiographic measurements (continued)
The primary end point occurred in 17 patients (23%) in the low heart rate group 
versus 24 patients (17%) in the high heart rate group (Table 4, Figure 2).No 
significant differences in cardiovascular mortality were observed between both groups. 
Table 3. Combinations of rate control drugs during follow-up
Baseline End of study








Digitalis 21 25 11 23
Beta-blocker 20 22 16 19
Verapamil 9 5 13 7
Digitalis and beta-blocker 24 22 24 27
Digitalis and verapamil 15 18 20 15
Beta-blocker and verapamil 4 3 4 1
Digitalis, beta-blocker, and verapamil - 1 7 6
No rate control drugs 7 4 4 2
Cardiovascular morbidity and mortality
were present between both groups at the end of follow up (Table 2). Also, no significant 
impairment of left ventricular function occurred in either group. All echo parameters 
were comparable between both groups during follow up. The type and combinations 
of rate control drugs did not differ between both groups (Table 3). In addition, no 
differences in the incidence of drug changes were observed (data not shown). The 
use of anticoagulation was interrupted in 28 (13%) of all patients (7 [9%] in the low 
versus 21 [15%] in the high heart rate group, p=0.3), because of (non)cardiac surgery 
or presence of lone AF.
Baseline 3 years P Value
Fractional shortening
   <80 beats per minute 32±9 34±11 0.2
   ≥80 beats per minute 29±10 31±9 0.3
Septal wall thickness
   <80 beats per minute 11±2 11±3 0.6
   ≥80 beats per minute 10±2 10±2 0.2
Posterior wall thickness
   <80 beats per minute 10±2 10±2 0.5
   ≥80 beats per minute 9±2 10±2 0.4
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Hospitalization for heart failure, thromboembolic complications and bleeding occurred 
in similar proportions in both groups. In both groups one severe adverse effect of rate 
control drugs was observed, AV nodal escape rhythm due to digoxin intoxication in 
the low heart rate group and symptomatic bradycardia with AV nodal escape rhythm 
during beta-blocker therapy in combination with digoxin in the high heart rate group. 
In the high heart rate group three patients were treated with atrioventricular node 
ablation and pacemaker implantation because of intolerable symptoms of AF.
Figure 2. Kaplan-Meier estimates according to heart rate group
No. at Risk
Heart rate <80 bpm       75                                           58                                           39                                            0
Heart rate ≥80 bpm      139                                          86                                           62                                           40
Heart rate <80 beats per minute














rate <80 beats 
per minute
Mean heart 




End point 17 (23) 24 (17) 5.4 (-7.3-18.2)
Deaths from cardiovascular cause 5 (7) 9 (7) 0.2 (-7.0-7.4)
     Sudden death 2 (3) 4 (3) -0.2 (-4.9-4.4)
     Heart failure 1 (1) 2 (1) -0.1 (-3.4-3.2)
     Thromboembolic complication - - -
     Bleeding 2 (3) 3 (2) 0.5 (-3.9-4.9)
Heart failure 4 (5) 3 (2) 3.2 (-5.3-8.9)
Thromboembolic complication 5 (7) 7 (5) 1.6 (-5.3-8.6)
Bleeding 5 (7) 6 (4) 2.4 (-2.4-9.1)
Severe adverse effects antiarrhythmic drugs 1 (1) 1 (1) 0.6 (-2.4-3.6)
Pacemaker implantation - 3 (2) -2.2 (-4.6-0.3)
Table 4. Incidence of the primary endpoint and its components
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Discussion
Hazard ratio  
univariate 
(95% CI)




Mean heart rate ≥80 beats per minute 1.0 (0.5-2.1) 0.9 1.03 (0.5-2.1) 0.9
Coronary artery disease 3.1 (1.6-6.1) 0.001 3.8 (1.9-7.6) <0.001
Digoxin use during study 2.4 (0.9-6.2) 0.06 2.8 (1.1-7.4) 0.03
Interrupted OAC use 2.0 (0.9-4.7) 0.08 2.4 (1.0-5.6) 0.04
Valvular heart disease 2.2 (1.1-4.5) 0.03 -
Previous bleeding 2.5 (1.0-6.6) 0.05 -
Reduced fractional shortening 0.5 (0.3-1.1) 0.09 -
Table 5. Uni- and multivariate predictors of primary outcome
This post-hoc analysis of the RACE study shows no differences in cardiovascular 
morbidity and mortality and quality of life between patients having a higher or 
lower heart rate during AF. Therefore, it suggests that differences in the level of rate 
control observed in this post-hoc analysis do not influence outcome in patients with 
permanent AF. Instead, prognosis seems determined by the underlying cardiovascular 
disease, the use of digoxin and interrupted use of oral anticoagulation. Furthermore, 
no differences in quality of life and changes in left ventricular function nor atrial sizes 
between both levels of rate control were observed.
Heart rate during rate control strategy and prognosis
In many patients rate control is the first choice therapy in AF, also in patients with 
heart failure.3 Data on the level of rate control, however, are limited. The effect of heart 
rate on cardiovascular morbidity and mortality, and quality of life has not been studied 
before in randomized trials. For the levels of rate control observed in the present 
Quality of life
Quality of life was comparable between both groups at baseline and during follow up. 
No important changes in quality of life occurred in both groups (Table 6). Also no 
differences between both groups were found in regard to complaints of AF (data not 
shown).
 We identified, by multivariate Cox regression analyses, coronary artery 
disease, the use of digoxin and interrupted oral anticoagulation use as independent 
predictors of cardiovascular morbidity and mortality (Table 5), but not mean heart 
rate ≥80. In addition, no influence of the mean heart rate divided on the median value 
(83 bpm), instead of 80 bpm, was found (data not shown).
CI - confidence interval; OAC oral anticoagulation
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SF-36 Subscale Heart rate -
beats per minute




General health <80 58±19 59±17 0
≥80 54±18 56±18 3
Physical functioning <80 64±24 59±24 -5
≥80 62±25 58±25 -4
Role physical <80 50±46 56±47 5
≥80 48±46 51±43 4
Bodily pain <80 80±20 80±33 0
≥80 81±23 78±23 -2
Mental health <80 77±16 79±16 3
≥80 75±18 75±18 2
Social functioning <80 79±23 84±22 5
≥80 78±22 79±22 2
Role emotional <80 77±39 73±41 -5
≥80 72±42 73±39 2
Vitality <80 65±22 63±17 -2
≥80 60±21 57±23 -3
Table 6. SF-36 quality of life scores (mean)
analysis (mean 72 bpm versus a mean of 90 bpm), this post-hoc analysis of RACE 
study suggests that rate control according to the current guidelines is not superior to a 
heart rate above the recommended frequency.
 In a previous post-hoc analysis we compared data from AFFIRM and RACE, 
since these trials used different definitions of adequate rate control.6 In AFFIRM 
adequate rate control was defined as a resting heart rate below 80 bpm and either a 
maximum heart rate during a 6-minute walk test below 110 bpm or an average heart 
rate during 24-hour Holter ECG monitoring below 100 bpm and no heart rate above 
110% of maximum predicted heart rate.1 In RACE a more lenient approach was used, 
a resting heart rate below 100 bpm. This analysis of the comparison between both 
studies suggested that the stringency of rate control does not influence mortality and 
cardiovascular morbidity.6 
 Stringent rate control, as performed in AFFIRM, was associated with 
similar rates of a composite endpoint of major clinical events and with similar 
overall survival rates but with more pacemaker implantations.6 In 5.3% of included 
patients of AFFIRM a pacemaker-implantation and atrioventricular node ablation 
was performed to obtain adequate rate control. In an additional 7.3% of patients a 
pacemaker implantation was performed for symptomatic bradycardia. In only 1.2% of 
the patients in the RACE study, however, pacemaker implantation and atrioventricular 
node ablation occurred.
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Heart rate and quality of life
Quality of life is reduced in patients with AF.16,17 Maintenance of sinus rhythm 
is associated with improvement of quality of life.18,19 Quality of life, however, is 
comparable between rhythm and rate control strategies.16,20 This study shows that 
there are no differences in quality of life between a high and low level of rate control.
 Data from the AFFRIM showed that strict rate control was difficult to 
achieve. It could be achieved successfully in two thirds of the patients.9 Strict rate 
control though may be, beneficial in selected patient groups. Khand et al. observed 
that in patients with an impaired left ventricular function and AF, a more strict 
rate control approach may be beneficial.11 They randomized patients with heart 
failure (left ventricular ejection fraction averaging 24%) and AF to carvedilol 
plus digoxin or to digoxin alone. After a follow-up of 4 months, heart rate was 
significantly lower in the patients treated with the combination of drugs, compared 
to the patients who were treated with digoxin alone. Compared to placebo, the 
addition of carvedilol to digoxin significantly improved left ventricular ejection 
fraction (24±7% to 31±10%, p<0.05).  In contrast to the findings of Khand et al, an 
observational study by Rienstra et al. found that a lower heart rate was associated 
with a poorer prognosis. This cohort also had a reduced LVEF (23±8%) and AF.12 
Whether the observation by Khand et al. is due to heart rate control itself or a salutary 
effect of beta-blockade in patients with congestive heart failure cannot be determined. 
Furthermore, whether such more stringent heart rate control translates into a survival 
benefit and reduced morbidity remains to be seen. In this respect, Fauchier et al. 
recently showed that patients with AF and heart failure who were treated with beta-
blocker therapy showed a significant lower mortality compared to a control group who 
were not treated with beta-blockers.13 Furthermore, they also showed that patients on 
digoxin alone had a worse survival than patients on beta-blockers (with or without 
digoxin), similar to patients without rate control drugs. In this respect it is noteworthy 
that in our analysis the use of digoxine also deteriorated prognosis.
 The low occurrence of serious adverse effects of rate control drugs in the 
present analysis is noteworthy. In the rate control group of the RACE study no 
pacemakers were implanted because of bradycardias. Amiodarone can also be used 
for rate control. In the RACE study this was discouraged because of (non)cardiac 
side effects. Dronedarone, a new antiarrhythmic drug based on amiodarone is well 
tolerated, with no organ toxicities or proarrhythmia, may become an additional drug 
to control ventricular rate during AF in the near future.14 Compared with placebo, the 
mean reduction with dronedarone was 12 bpm during 24 hours (p<0.0001) and of 25 
bpm during maximal exercise (p<0.0001). It also successfully reduced the heart rate at 
the moment of a relapse of AF.15
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Heart rate and left ventricular function and atrial diameters
No data are available on left ventricular function and atrial sizes in patients treated 
with different stringencies of rate control. The present study observed no differences 
in echocardiographic parameters between both groups.
Predictors for cardiovascular morbodoty and mortality
The strongest independent predictor for the composite endpoint was the presence of 
coronary artery disease. Post-hoc analysis of the AFFIRM21 and RACE4 also showed 
that the presence of coronary artery disease was associated with prognosis in patients 
with AF. Outcome of this analysis underlines that the focus in patients with AF 
should not be on heart rate but on underlying heart disease.
 Interrupted use of oral anticoagulation was identified as another independent 
predictor of prognosis. In 28 patients of the present cohort anticoagulation was 
interrupted (7 in the low vs. 21 in the high heart rate group) because of (non)cardiac 
surgery or presence of lone AF. According to the guidelines oral anticoagulation 
is nowadays prescribed according to the CHADS2 risk score and is continued 
independent of the rhythm. At the moment the RACE study was conducted, after 
acceptance of AF patients discontinued oral anticoagulation and started aspirin in case 
of absence of risk factors. (Re-)initiation of oral anticoagulation increases the risk of 
bleeding. In the ACTIVE W trial a lower risk of major bleeding was seen in patients 
already on anticoagulation, randomized to oral anticoagulation, compared to patients 
not already on this treatment.22 In accordance with this finding, the ISCOAT study 
showed that bleeding risk was increased during the first 90 days of treatment.23 These 
imbalanced situations might explain the increased risk of mortality and morbidity 
caused by interrupted oral anticoagulation use.
 Not only the stringency of heart rate reduction but also the medication 
instituted to achieve adequate rate control is controversial. The positive effect of beta-
blockers in heart failure is indisputable in patients with sinus rhythm.24 It is, however, 
unknown whether heart rate reduction with digoxin also improves survival. Patients 
with sinus rhythm and heart failure have no survival benefit with the use of digoxin.25 
It is furthermore suggested that digoxin increases mortality in patients with AF.26 
The present post-hoc analysis of the RACE study confirms the negative association 
between digoxin use and prognosis. The increased risk on cardiovascular morbidity 
and mortality in patients treated with digoxin remains difficult to explain, especially 
in this population without severe heart failure. More data on this issue are certainly 
warranted.
Limitations
In the RACE study adequate rate control was defined by resting heart rate on a 12 
lead ECG. No evaluation of rate control during exercise was performed. Furthermore 
no 24-hour Holter ECG registration was performed which precludes evaluation of 
rate control during the whole day. Therefore data on rate control during the day and 
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Conclusion
In patients treated according to rate control strategy no differences were observed 
between patients with high or low heart rate in terms of cardiovascular morbidity, 
mortality and quality of life. Randomized studies, e.g. RACE II, assessing stringency 
of rate control are eagerly awaited.5
during exercise are lacking. In RACE follow-up was limited to 3 years. In this post-
hoc analysis patients were divided according to the mean heart rate during follow up, 
no randomization was performed to either a strict or lenient approach of rate control. 
Furthermore, the number of included patients in this post-hoc analysis is limited. 
Considering the non randomized design of this study, the limited sample size and 
restricted follow-up, no definite conclusions can be made on how to treat patients 
according to a rate control strategy. These issues can only be resolved with randomized 
trials assessing different rate control strategies.
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Rate control is often the therapy of choice for atrial fibrillation. Guidelines recommend 
strict rate control, but this is not based on clinical evidence. We hypothesized that 
lenient rate control is not inferior to strict rate control for preventing cardiovascular 




We randomly assigned 614 patients with permanent atrial fibrillation to undergo 
a lenient rate-control strategy (resting heart rate <110 beats per minute) or a strict 
ratecontrol strategy (resting heart rate <80 beats per minute and heart rate during 
moderate exercise <110 beats per minute). The primary outcome was a composite of 
death from cardiovascular causes, hospitalization for heart failure, and stroke, systemic 
embolism, bleeding, and life-threatening arrhythmic events. The duration of followup 
was at least 2 years, with a maximum of 3 years. 
The estimated cumulative incidence of the primary outcome at 3 years was 12.9% 
in the lenient-control group and 14.9% in the strict-control group, with an absolute 
difference with respect to the lenient-control group of −2.0 percentage points (90% 
confidence interval, −7.6 to 3.5; P<0.001 for the prespecified noninferiority margin). 
The frequencies of the components of the primary outcome were similar in the two 
groups. More patients in the lenient-control group met the heart-rate target or targets 
(304 [97.7%], vs. 203 [67.0%] in the strict-control group; P<0.001) with fewer total 
visits (75 [median, 0], vs. 684 [median, 2]; P<0.001). The frequencies of symptoms and 
adverse events were similar in the two groups.
In patients with permanent atrial fibrillation, lenient rate control is as effective as strict 
rate control and is easier to achieve.
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Introduction
Atrial fibrillation is not a benign condition.1 It may cause symptoms and is associated 
with stroke and heart failure. Previous studies have established that the rates of 
complications and death were similar in patients with atrial fibrillation receiving 
rate-control therapy and in those receiving rhythm-control therapy.2,3 Therefore, rate 
control has become front-line therapy in the management of atrial fibrillation. The 
optimal level of heart-rate control, however, is unknown, as is whether strict rate 
control is associated with an improved prognosis as compared with a more lenient 
approach.2-6 Guidelines, though empirical and not evidence-based, recommend 
the use of strict rate control1 to reduce symptoms, improve the quality of life and 
exercise tolerance, reduce heart failure (and hence bleeding7 and stroke8), and improve 
survival. On the other hand, strict rate control could cause drug-related adverse effects, 
including bradycardia, syncope, and a need for pacemaker implantation. Thus, the 
balance between benefit and risk in terms of cardiovascular morbidity and mortality, 
quality of life, exercise tolerance, and disease burden remains unknown. Therefore, 
we conducted a multicenter, prospective, randomized trial to test the hypothesis that 
lenient rate control is not inferior to strict rate control in preventing cardiovascular 
events in patients with permanent atrial fibrillation. 
Methods
Study design
The Rate Control Efficacy in Permanent Atrial Fibrillation: a Comparison between 
Lenient versus Strict Rate Control II (RACE II) study was a prospective, multicenter, 
randomized, open-label, noninferiority trial designed to compare two ratecontrol 
strategies in patients with permanent atrial fibrillation. The design of the study 
has been described previously.6 Recruitment started in January 2005 and 
ended in June 2007. 
 The study was initiated and coordinated by the Interuniversity Cardiology 
Institute of the Netherlands, the University Medical Center Groningen, and the 
Working Group on Cardiovascular Research the Netherlands. The study was funded 
by a major grant from the Netherlands Heart Foundation and by unrestricted 
educational grants from pharmaceutical and device companies. None of the sponsors 
were involved in the study design, data collection, data analysis, or manuscript 
preparation. The steering committee was responsible for the design and conduct 
of the study, the data analysis and reporting, and manuscript preparation. Study 
monitoring, data management, and validation were independently performed at the 
Trial Coordination Center (University Medical Center Groningen, the Netherlands). 
The study was approved by the institutional review boards of all participating centers. 
All authors reviewed a previous version of the manuscript and vouch for the accuracy 
and completeness of the data and analyses.
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The study was conducted in 33 centers in the Netherlands. Eligibility criteria were 
as follows: permanent atrial fibrillation for up to 12 months, age of 80 years or 
younger, mean resting heart rate above 80 beats per minute, and current use of oral 
anticoagulation therapy (or aspirin, if no risk factors for thromboembolic complications 
were present). Reasons for exclusion were described previously.6
Study participants
Randomization and treatment
After providing written informed consent, all trial participants were randomly 
assigned, in an open label fashion, to undergo either a lenient rate-control strategy 
or a strict rate-control strategy. Randomization was accomplished by means of a 
central, interactive, automated telephone system, with the use of permuted blocks 
of various sizes. 
 During the dose-adjustment phase, patients were administered one or more 
negative dromotropic drugs (i.e., beta-blockers, nondihydropyridine calcium-channel 
blockers, and digoxin), used alone or in combination and at various doses, until the 
heart-rate target or targets were achieved. Patients assigned to undergo the lenient-
control strategy (which allowed for a higher heart-rate target than strict control) 
had a target resting heart rate of below 110 beats per minute. Patients assigned to 
undergo the strict-control strategy had a target resting heart rate of below 80 beats per 
minute — lower than the target in the lenient control group — and a target heart rate 
of below 110 beats per minute during moderate exercise. The resting heart rate was 
measured in both groups by means of 12-lead electrocardiography after 2 to 3 minutes 
of rest in the supine position. In the strict-control group only, the heart rate during 
exercise was measured during  moderate exercise performed for a duration corresponding 
to 25% of the maximal time achieved on bicycle exercise testing. After the heart-
rate targets were reached, 24-hour Holter monitoring was performed to check for 
bradycardia, in the strict control group only.
 Follow-up outpatient visits occurred every 2 weeks until the heart-rate 
target or targets were achieved and in all patients after 1, 2, and 3 years. Follow-up 
was terminated after a maximum follow-up period of 3 years or on June 30, 2009, 
whichever came first. 
 During the follow-up period, the resting heart rate (and the exercise heart 
rate, in the strict-control group) was assessed by the attending physician at each visit. 
If rate-control drugs had to be adjusted, 24-hour Holter monitoring was repeated 
to check for bradycardia, in the strict-control group only. If the heart-rate target or 
targets could not be achieved or patients remained symptomatic, the study protocol 
permitted further adjustment of rate-control drugs or doses, electrical cardioversion, 
or ablation at the discretion of the attending physician.
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Outcomes
The primary outcome was a composite of death from cardiovascular causes, 
hospitalization for heart failure, and stroke, systemic embolism, major bleeding, and 
arrhythmic events including syncope, sustained ventricular tachycardia, cardiac arrest, 
life-threatening adverse effects of rate-control drugs, and implantation of a pacemaker 
or cardioverter–defibrillator. Secondary outcomes included the components of the 
primary outcome, death from any cause, symptoms, and functional status. All reported 
primary-outcome events were adjudicated by an independent adjudication committee 
that was unaware of the randomized treatment assignments. Only deaths classified as 
having a cardiac arrhythmic, cardiac nonarrhythmic, or noncardiac vascular cause were 
included in the analysis of the primary end point.9,10
 Heart failure was defined as heart failure necessitating hospitalization and 
the start of or increase in dose of diuretics. Stroke was defined as the sudden onset 
of a focal deficit consistent with occlusion of a major cerebral artery (documented 
by means of imaging) and categorized as ischemic, hemorrhagic, or indeterminate. 
Systemic embolism was defined as an acute vascular occlusion of an extremity or 
organ as documented with the use of imaging, surgery, or autopsy. Major bleeding was 
defined as a reduction in the hemoglobin level by at least 20 g per liter, transfusion of 
at least 2 units of blood, or symptomatic bleeding in a critical area or organ. Syncope 
was defined as a transient loss of consciousness that may have been caused by a rhythm 
disorder. Sustained ventricular tachycardia was defined as ventricular tachycardia lasting 
more than 30 seconds or requiring electrical termination owing to hemodynamic 
compromise. Cardiac arrest was defined as circulatory arrest necessitating resuscitation 
and hospitalization. Life-threatening adverse effects of rate-control drugs included 
digitalis intoxication and conduction disturbances necessitating hospitalization.
Pacemaker implantations for clinically significant bradycardia and cardioverter–
defibrillator implantations for sustained ventricular arrhythmias were the only types 
of implantations included in the primary analysis.
Statistical analysis
The trial was designed to determine whether a strategy of lenient rate control was 
as effective as (i.e., noninferior to) a strategy of strict rate control. The study size was 
determined on the basis of an expected rate of the primary outcome of 25% at 2.5 
years in both treatment groups and a requirement that the study had 80% power 
to rule out an absolute increase of 10 percentage points in the rate of the primary 
outcome at 2.5 years in the lenient-control group, with a one-sided alpha level of 0.05. 
Pretrial estimates of the expected event rates were based on the observed event rate in 
the (lenient) rate-control group of the Rate Control versus Electrical Cardioversion 
for Persistent Atrial Fibrillation (RACE) trial.3 The noninferiority boundary in the 
present study was similar to that in the previous RACE trial, which implied that 
noninferiority of lenient rate control to strict rate control was to be determined by 
the same criteria by which we had previously shown the noninferiority of (lenient) 
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Age - yr 69±8 67±9 68±8
Male sex - no. (%) 205 (65.9) 198 (65.3) 403 (65.6)
Duration of any atrial fibrillation - mo
     Median 16 20 18
     Interquartile range 6-54 6-64 6-60
Duration of permanent atrial fibrillation - mo
     Median 3 2 3
     Interquartile range 1-6 1-5 1-6
Previous electrical cardioversion - no (%) 221 (71.1) 220 (72.6) 441 (71.8)
Hypertension 200 (64.3) 175 (57.8) 375 (61.1)
Coronary artery disease 67 (21.5) 44 (14.5) 111 (18.1)
Valvular heart disease 64 (20.6) 60 (19.8) 124 (20.2)
Chronic obstructive pulmonary disease 36 (11.6) 43 (14.2) 79 (12.9)
Diabetes mellitus 36 (11.6) 32 (10.6) 68 (11.1)
Lone atrial fibrillation† 5 (1.6) 6 (2.0) 11 (1.8)
Previous hospitalization for heart failure 28 (9.0) 32 (10.6) 60 (9.8)
CHADS2 score‡ 1.4±1.0 1.4±1.2 1.4±1.1
     0 or 1 178 (57.2) 195 (64.4) 373 (60.7)
     2 94 (30.2) 65 (21.5) 159 (25.9)
     3-6 39 (12.5) 43 (14.2) 82 (13.4)
Symptoms – no. (%) 173 (55.6) 175 (57.8) 348 (56.7)
     Palpitations 62 (19.9) 83 (27.4) 145 (23.6)
     Dyspnea 105 (33.8) 109 (36.0) 214 (34.9)
     Fatigue 86 (27.7) 97 (32.0) 183 (29.80)
Body mass index – kg/m2 29±5 29±5 29±5
Blood pressure – mmHg
     Systolic 137±19 135±16 136±18
     Diastolic 85±11 82±11 83±11
Heart rate in rest –  beats per minute 96±14 96±12 96±13
† Lone atrial fibrillation was defined as atrial fibrillation in the absence of cardiovascular disease and extracardiac precipitating causes 
   of atrial fibrillation.
‡ The CHADS2 score is a measure of the risk of stroke in which congestive heart failure, hypertension, an age of 75 years or older, and 
    diabetes are each assigned 1 point and previous stroke or transient ischemic attack is assigned 2 points; the score is calculated by summing 
   al the points for a given patient.8
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New York Heart Association functional class
     I – no. (%) 206 (66.2) 194 (64.0) 400 (65.1)
     II – no. (%) 89 (28.7) 96 (31.7) 185 (30.2)
     III – no. (%) 16 (5.1) 13 (4.3) 29 (4.7)
Rate control medications in use – no. (%)
     No rate control drugs 36 (11.6) 27 (8.9) 63 (10.3)
     Beta-blocker alone 140 (45.0) 136 (44.9) 276 (45.0)
     Verapamil/diltiazem alone 18 (5.8) 19 (6.3) 37 (6.0)
     Digoxin alone 20 (6.4) 24 (7.9) 44 (7.2)
     Beta-blocker + verapamil/diltiazem 7 (2.3) 11 (3.6) 18 (2.9)
     Beta-blocker +  digoxin 53 (17.0) 49 (16.2) 102 (16.6)
     Verapamil/diltiazem + digoxin 14 (4.5) 14 (4.6) 28 (4.6)
     Beta-blocker + verapamil/diltiazem + digoxin 2 (0.6) 5 (1.7) 7 (1.1)
     Sotalol 18 (5.8) 13 (4.3) 31 (5.0)
     Amiodarone 3 (1.0) 5 (1.7) 8 (1.3)
Other medications in use at baseline – no. (%)
     ARB or ACE inhibitor 166 (53.4) 140 (46.2) 306 (49.8)
     Diuretic 134 (43.1) 113 (37.3) 247 (40.2)
     Statin# 103 (33.1) 74 (24.4) 177 (28.8)
     Vitamin K antagonist 308 (99.0) 298 (98.3) 606 (98.7)
     Aspirin 4 (1.3) 6 (2.0) 10 (1.6)
Echocardiographic parameters – mm
     Left atrial size, long axis 46±6 46±7 46±7
     Left ventricular end-diastolic diameter 51±7 51±8 51±7
     Left ventricular end-systolic diameter 36±8 36±9 36±8
     Left ventricular ejection fraction –  % 52±11 52±12 52±12
          ≤ 40% – no. (%) 45 (14.5) 48 (15.8) 93 (15.1)
ARB denotes angiotensin-receptor blocker, and ACE angiotensin-converting enzyme.
# Statins are defined here as 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.
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Results
A total of 614 patients were enrolled in the study: 311 in the lenient-control group and 
303 in the strict-control group (Table 1 and Fig. 1). The groups were well matched, 
with the exception of a higher prevalence of coronary artery disease and statin use, and 
a slightly higher diastolic pressure, in the lenient-control group.
Patients
rate control to rhythm control. A sample size of 250 patients in each group with a 
median follow-up of 2.5 years satisfied the statistical requirements, allowing for an 
attrition rate of less than 5% of patients. In the course of the trial, we found that the 
primary outcome occurred less frequently than anticipated. We increased the number 
of patients to 300 in each group and extended the follow-up period to June 30, 2009, 
with a maximum duration of 3 years. 
 The primary analysis for efficacy (in the intention-to-treat population) 
consisted of a comparison between the lenient-control group and the strict-control 
group of the time to the first occurrence of the composite primary outcome as assessed 
by Kaplan–Meier curves. The follow-up data were censored for patients who had a first 
occurrence of one of the primary-outcome events, had informed consent withdrawn, 
had died from a noncardiovascular cause, were lost to follow-up, had been in the trial 
for 3 years, or had been followed through June 30, 2009 — whichever event came first. 
The observation time was calculated as the time from randomization until either the 
occurrence of the primary outcome or the moment of censoring.
 To satisfy the criterion for noninferiority, the upper bound of the 90% 
confidence interval for the absolute difference between the two treatment groups in 
the estimated rate of the primary outcome needed to be less than 10 percentage points 
(erroneously specified in our design paper as a relative 10% difference, when in fact it 
is a 10-percentage-point absolute difference6). Because the treatment period had been 
extended, we eventually used the estimated cumulative incidences at 3 years to assess 
noninferiority.
 The difference between the two groups in the 3-year cumulative incidence 
was calculated by subtracting the Kaplan–Meier estimated event rate in the lenient-
control group from that in the strict control group. The 90% confidence interval for the 
difference was calculated with the use of the standard errors from the Kaplan–Meier 
curves. We also tested for noninferiority by comparing the upper bound of the 90% 
confidence interval for the hazard ratio (calculated from the Cox proportional-hazards 
model) for the primary outcome in the lenient-control group as compared with the 
strict-control group with a margin of 1.40, which was derived (post hoc) as 25% 
divided by (25% + 10%). There were no prespecified subgroup analyses. The results of 
post hoc subgroup analyses are presented for descriptive purposes. No formal interim 
analyses were planned or performed. The data and safety monitoring board monitored 
the occurrence of clinical events from the standpoint of safety.
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Rate control target or targets achieved - no (%) 304 (97.7) 203 (67.0) <0.001
Resting heart rate – no.(%)
     < 70 beats/min 1 (0.3) 67 (22.1) <0.001
     70 to 80 beats/min 5 (1.6) 161 (53.1) <0.001
     81 to 90 beats/min 112 (36.0) 39 (12.9) <0.001
     91 to 100  beats/min 123 (39.5) 20 (6.6) <0.001
     >100  beats/min 70 (22.5) 16 (5.3) <0.001
Resting heart-rate target achieved – no.(%) 304 (97.7) 228 (75.2) <0.001
Exercise heart-rate achieved – no.(%) 220 (72.6)
     Mean heart rate – beats/min 99±16
     Mean duration of exercise with target 
     achieved – sec
94±44
Holter monitoring
     Mean heart rate – beats per minute 78±11
     Maximal RR interval – seconds 2.3±0.6
Visits to achieve rate control target – no. 75 684 <0.001
     Median 0 2
     Interquartile range 0-0 1-3
Reasons failure rate control target– no. (%) <0.001
     Drug related adverse events 0/7 25/100 (25.0)
     No or acceptable complaints 7 (100) 53/100 (53.0)
     Target impossible to achieve with drugs 0/7 22/100 (22.0)
Rate control medication – no. (%)
     No rate control drugs 32 (10.3) 3 (1.0) <0.001
     Beta-blocker alone 132 (42.4) 61 (20.1) <0.001
     Verapamil/diltiazem alone 18 (5.8) 16 (5.3) 0.78
     Digoxin alone 21 (6.8) 5 (1.7) 0.002
     Beta-blocker + verapamil/diltiazem 12 (3.9) 38 (12.5) <0.001
     Beta-blocker + digoxin 60 (19.3) 113 (37.3) <0.001
     Verapamil/diltiazem + digoxin 18 (5.8) 29 (9.6) 0.08
     Beta-blocker + verapamil/diltiazem + digoxin 3 (1.0) 27 (8.9) <0.001
Table 2. Rate control targets and drug therapy at the end of the dose-adjustment-
              phase, according to treatment group
47Lenient versus strict rate control
Table 2. Rate control targets and drug therapy at the end of the dose-adjustment-








Rate control medication dose - mg. (no.)
Beta-blocker (adjusted to metoprolol) 120±78 (210) 162±85 (243) <0.001
Verapamil 166±60 (46) 217±97 (105) <0.001
Diltiazem 232±74 (5) 217±64 (7) 0.72
Digoxin 0.19±0.8 (109) 0.21±0.8 (180) 0.06
Primary outcome
Heart rates
Data recorded at the end of the dose-adjustment phase are reported in Table 2. 
The mean (±SD) resting heart rate at the end of the dose-adjustment phase was 
93±9 beats per minute in the lenientcontrol group, as compared with 76±12 beats 
per minute in the strict-control group (P<0.001). After 1 and 2 years and at the 
end of the follow-up period, the resting heart rates in the lenient-control group 
were 86±15, 84±14, and 85±14 beats per minute, respectively, as compared 
with 75±12, 75±12, and 76±14 beats per minute, respectively, in the strict-control 
group (P<0.001 for all comparisons between the two groups). During the follow-up 
period, 18 patients in the lenient-control group and 22 patients in the strict-control 
group had conversion to sinus rhythm (P = 0.60). Nine patients in both groups were in 
sinus rhythm at the end of follow-up (P = 0.96). There was no difference between the 
two groups in the mean percentage of the study period during which the international 
normalized ratio was within the target range.
A total of 81 patients (38 in the lenient-control group and 43 in the strict-control 
group) reached the primary outcome. Kaplan–Meier curves for the primary outcome 
are shown in Figure 2. The 3-year estimated cumulative incidence was 12.9% in 
the lenient-control group and 14.9% in the strict control group (Table 3), with an 
absolute difference between lenient control and strict control of −2.0 percentage 
points (90% confidence interval [CI], −7.6 to 3.5) and a hazard ratio 
of 0.84 (90% CI, 0.58 to 1.21). As compared with strict rate control, lenient rate 
control was noninferior with regard to the prevention of the primary outcome, for 
both the criteria of the difference in risk (P<0.001) and the hazard ratio (P = 0.001). 
The hazard ratio was 0.80 (90% CI, 0.55 to 1.17) after statistical adjustment for the 
unbalanced distribution of the presence of coronary artery disease, the use of statins, 
and the diastolic blood pressure. The cumulative incidences of components of the 
primary outcome are shown in Table 3.
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Other outcomes
Death from any cause occurred in 17 patients in the lenient-control 
group (5.6% at 3 years), as compared with 18 (6.6% at 3 years) in the strict-control 
group (hazard ratio 0.91; 90% CI, 0.52 to 1.59). Death from noncardiovascular causes 
occurred in 8 patients in the lenient-control group as compared with 7 in the strict-
control group.
 At the end of the follow-up period, 129 of 283 patients (45.6%) in the 
lenient-control group and 126 of 274 patients (46.0%) in the strict-control group 
had symptoms associated with atrial fibrillation (P = 0.92): dyspnea (30.0% vs. 29.6%, 
P = 0.90), fatigue (24.4% vs. 22.6%, P = 0.63), and palpitations (10.6% vs. 9.5%, P = 
0.66). In addition, at the end of the follow-up period, in the lenient-control group and 
the strict-control group, 70.0% and 70.4% of patients, respectively, were in New York 
Heart Association functional class I, 23.3% and 23.4% were in class II, and 6.7% and 
6.2% were in class III (P = 0.74 for all comparisons). Frequencies of hospitalizations 
and adverse events were similar in the two groups (Table 4).
          No. at Risk
          Strict control         303                  282                   273                  262                   246                  212                  131



















Figure 2. Kaplan-Meier estimates of the cumulative incidence of the primary    






Among the 241 patients with a CHADS2 score of 2 or more, the primary outcome 
occurred in 17 of the 133 patients in the lenient-control group and in 25 of the 108 
patients in the strict-control group (P<0.001 for noninferiority). Among the 373 
patients with a CHADS2 score below 2, the primary outcome occurred in 21 of the 
178 patients in the lenient-control group and in 18 of the 195 patients in the strict-
control group (P = 0.02 for noninferiority). The primary outcome event rates were 
similar across heart-rate categories at the end of the dose-adjustment phase (Table 5). 
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no. of patients (%)
Composite primary outcome 38 (12.9) 43 (14.9) 0.84 (0.58 – 1.21)
Individual components
     Death from cardiovascular cause 9 (2.9) 11 (3.9) 0.79 (0.38 – 1.65)
          From cardiac arrhythmia 3 (1.0) 4 (1.4)
          From cardiac cause, no arrhythmia 1 (0.3) 2 (0.8)
          From noncardiac vascular cause 5 (1.7) 5 (1.9)
     Heart failure 11 (3.8) 11 (4.1) 0.97 (0.48 – 1.96)
     Stroke 4 (1.6) 11 (3.9) 0.35 (0.13 – 0.92)
          Ischemic 3 (1.3) 8 (2.9)
          Hemorrhagic 1 (0.3) 4 (1.5)
     Systemic embolism 1 (0.3) 0
     Bleeding 15 (5.3) 13 (4.5) 1.12 (0.60 – 2.08)
          Intracranial 0 3 (1.0)
          Extracranial 15 (5.3) 10 (3.5)
     Syncope 3 (1.0) 3 (1.0)
     Life threatening AE of rate control drugs 3 (1.1) 2 (0.7)
     Sustained VT or VF 0 1 (0.3)
     Cardioverter-defibrillator implantation 0 1 (0.4)
     Pacemaker implantation 2  (0.8) 4 (1.4)
AE - adverse event; CI - confidence Interval; VT - ventricular tachycardia; VF - ventricular fibrillation
Discussion
We found that lenient rate control was noninferior to strict rate control in the 
prevention of major cardiovascular events in patients with permanent atrial fibrillation. 
The primary outcome occurred in 12.9% of patients in the lenient-control group, as 
compared with 14.9% of patients in the strict-control group. The heart rates achieved 
in the strict-control group were similar to those observed in the Atrial Fibrillation 
Follow-up Investigation of Rhythm Management (AFFIRM) trial.11 We confirmed 
a post hoc comparison of data from the AFFIRM study and the first RACE trial, 
demonstrating that the stringency of rate control was not associated with significant 
differences in outcome.2,3,5
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Hospitalizations 78 (25.1) 83 (27.4) 0.5
     Hospitalization for cardiac surgery 5 (1.6) 2 (0.7) 0.2
     Hospitalization for cardiac reasons 24 (7.7) 17 (5.6) 0.2
          Acute coronary syndrome 3 (1.0) 0 (0) 0.1
          Percutaneous coronary intervention 2 (0.6) 2 (0.7) 0.9
          Other 19 (6.1) 15 (5.0) 0.5
     Hospitalization for noncardiac surgery 35 (11.3) 39 (12.9) 0.5
     Hospitalization for transient ischemic attack 0 (0) 2 (0.7) 0.1
     Hospitalization for infection 22 (7.1) 24 (7.9) 0.6
     Hospitalization for other noncardiac reasons 11 (3.5) 13 (4.3) 0.6
Adverse events of rate control drugs 62 (19.9) 72 (23.8) 0.2
     Dizziness 9 (2.9) 16 (5.3) 0.1
     Fatigue 5 (1.6) 9 (3.0) 0.1
     Dyspnea 11 (3.5) 11 (3.6) 0.9
     Other 42 (13.5) 40 (13.2) 0.9
 Why was lenient rate control not associated with more cardiovascular 
morbidity and mortality? First, the incidence of heart failure was similar between the 
two groups. A major concern with lenient rate control is the induction or worsening 
of heart failure.12-15 This concern was not confirmed by our observations. Apparently, a 
resting heart rate below 110 beats per minute was low enough to prevent an increased 
number of hospitalizations for heart failure. This observation is consistent with the 
notion that beta-blockers do not improve the prognosis of patients with heart failure 
with atrial fibrillation.16,17
 Second, the incidence of death from cardiovascular causes was similar 
between the two groups. Approximately half the deaths in our study were of vascular 
origin, rather than arrhythmia or heart failure. Third, the rate of adverse effects of 
drugs, syncope, and pacemaker implantation was similar between the two groups. 
This observation is inconsistent with data from the AFFIRM trial.5,11 In that 
trial, the rate of pacemaker implantation was 7.3% over 3.5 years, as compared 
with 1.4% over 3 years in the strict-control group in our trial. Reasons for this 
discrepancy may be that we administered rate-control drugs rather gradually. 
Alternatively, the thresholds for pacemaker implantation may have varied.
 Finally, we did not find significant differences in the prevalence of symptoms 
associated with atrial fibrillation. Almost 60% of the patients in both groups were 







Total group 13.9 (81 of 614) 12.9 (38 of 311) 14.9 (43 of 303)
     Heart rate <70 beats/min 21.6 (14 of 68)  - (1 of 1) 20.4 (13 of 67)
     Heart rate 70-80 beats/min 12.0 (19 of 166) 20.0 (1 of 5) 11.7 (18 of 161)
     Heart rate 81-90 beats/min 13.9 (20 of 151) 15.0 (16 of 112) 10.7 (4 of 39)
     Heart rate 91-100 beats/min 8.6 (12 of 143) 9.1 (11 of 123) 5.6 (1 of 20)
     Heart rate >100 beats/min 19.9 (16 of 86) 14.1 (9 of 70) 46.4 (7 of 16)
Table 5. Incidence of primary outcome according to heart rate at the end of 
              dose-adjustment phase 
symptomatic at baseline; this fraction decreased to 46% by the end of the follow-up 
period, a decline that may be related to underlying disease rather than to the heart 
rate driving symptoms.18 Although the prevalence of symptoms was similar in the 
two groups in our study, we cannot rule out potential differences in the severity of 
symptoms between the groups. We included physically active patients, rather than 
sedentary patients, in our trial, because we chose to assess rate control by means of 
exercise testing in the strict-control group. Thus, we excluded patients with a previous 
stroke, resulting in a low-risk study population. These choices may have resulted in the 
lower-than-expected primary outcome event rate. Although we increased the number 
of patients from 250 to more than 300 in each treatment group, the overall frequency 
of the primary outcome events remained relatively low.
 A trial evaluating high and low resting heart rates in patients with atrial 
fibrillation would ideally ensure that the relevant rate targets were met in all patients. 
In our strict-control group, the resting and exercise targets were achieved in 67.0% of 
the patients, whereas in the lenient control group the target rate was virtually always 
reached, without much change in therapy. We cannot rule out the possibility that 
we would have found significant differences between the two groups had we used a 
more effective means of strict rate control and had we kept heart rates just below 
110 beats per minute in the lenient-control group or if we had followed patients 
beyond 3 years. Although we enrolled relatively low-risk patients, the subgroup 
analysis revealed that our results also apply to higher-risk patients (i.e., those with a 
CHADS2 score8 of 2 or more).
In conclusion, as compared with strict rate control, lenient rate control was noninferior 
in terms of major clinical events. Furthermore, for both patients and health care 




The RACE II was funded by a major grant obtained from the Netherlands Heart Foundation and 
unrestricted educational grants from AstraZeneca, Biotronik, Boehringer Ingelheim, Boston Scientific, 
Medtronic, Roche and Sanofi Aventis France paid to the Interuniversity Cardiology Institute Netherlands.
Members of the RAte Control Efficacy in Permanent Atrial Fibrillation: a Comparison Between Lenient 
Versus Strict Rate Control (RACE) II) study group are as follows:
Writing committee: I.C. Van Gelder (chair), J.G. Tijssen, H.J. Crijns, H.L. Hillege. M.P. Van den Berg. 
Steering committee: I.C. Van Gelder (chair), J.G. Tijssen, H.J. Crijns, H.L. Hillege, Y.S. Tuininga, A.M. 
Alings, H.A. Bosker, J.H. Cornel, O. Kamp, D.J. Van Veldhuisen, M. Van den Berg. 
Adjudication committee:  J. Van der Meer† 2009, G. Luijckx, J. Brügemann. Data Safety Monitoring Board: 
H.J. Wellens, R.N. Hauer, A.A. Wilde. 
Investigators: 
University Medical Center Groningen, The Netherlands - I. Van Gelder, D. Van Veldhuisen, H. Groenveld, 
M. Van den Berg; 
Kennemer Hospital, Haarlem, The Netherlands - M. Janssen, R. Tukkie; 
Elkerliek Hospital, Helmond The Netherlands - P. Bendermacher, H. Olthof; 
Hospital Leyenburg, The Hague, The Netherlands - R. Robles De Medina; 
Hospital Bernhoven, Oss, The Netherlands - P. Kuijer, P. Zwart; 
Maastricht University Medical Center, Maastricht, The Netherlands - H. Crijns; 
Amphia Hospital, Breda The Netherlands - M. Alings; 
Hospital Hengelo, The Netherlands - J. Fast; 
Hospital Gooi Noord, Blaricum The Netherlands - R. Peters, R. Van Stralen, E. Buys;
Jeroen Bosch Hospital, Den Bosch, The Netherlands - M. Daniëls; 
Spaarne Hospital, Hoofddorp, The Netherlands - A. Kuijper, D. Van  Doorn; 
Medical Spectrum Twente, Enschede, The Netherlands - A. Timmermans; 
Diaconessen Hospital, Meppel, The Netherlands - P. Hoogslag; 
Hospital Gelderse Vallei, Ede, The Netherlands - F. Den Hartog; 
Diaconessen Hospital, Leiden, The Netherlands - F. Van Rugge; 
Rijnstate Hospital, Arnhem, The Netherlands - R. Derksen, H. Bosker; 
Tweesteden Hospital, Tilburg, The Netherlands - K. Hamraoui; 
Hospital Hilversum, The Netherlands - P. De Milliano; 
VU University Medical Center, Amsterdam, The Netherlands - O. Kamp; 
Atrium Medical Center, Heerlen, The Netherlands - J. Kragten; 
Twenteborg Hospital, Almelo, The Netherlands - G. Linssen; 
Deventer Hospital, The Netherlands - E. Badings, Y. Tuininga; 
St Franciscus Hospital, Rotterdam, The Netherlands - P. Nierop; 
VieCurie, Venlo, The Netherlands - M. Veldhorst; 
IJsselland Hospital, Capelle aan de Ijssel, The Netherlands - S. Nio, W. Muys, B. Van den Berg; 
Maxima Medical Center, Veldhoven, The Netherlands - H. Thijssen; 
Bronovo Hospital, The Hague, The Netherlands - P. Van Dijkman; 
Medical Center Alkmaar, The Netherlands - J. Cornel; 
St. Lucas Hospital, Winschoten, The Netherlands - A. Van der Galiën; 
Delfzicht Hospital, Delfzijl, The Netherlands - J. Spanjaard; 
Martini Hospital, Groningen, The Netherlands - L. Bartels; 
St. Antonius Hospital, Nieuwegein, The Netherlands - L. Boersma; 
Zaans Medical Center De Heel, Zaandam, The Netherlands - P. Bronzwaer.
















Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 Guidelines for the Management of 
Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart 
Association Task Force on Practice Guidelines and the European Society of Cardiology Committee 
for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management 
of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm 
Association and the Heart Rhythm Society. Circulation 2006;114:e257-e354.
Wyse DG, Waldo AL, DiMarco JP et al. A comparison of rate control and rhythm control in patients 
with atrial fibrillation. N Engl J Med 2002;347:1825-33.
Van Gelder IC, Hagens VE, Bosker HA et al. A comparison of rate control and rhythm control in 
patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-40.
Rienstra M, Van Gelder IC, Van den Berg MP, Boomsma F, Hillege HL, Van Veldhuisen DJ. A 
comparison of low versus high heart rate in patients with atrial fibrillation and advanced chronic heart 
failure: effects on clinical profile, neurohormones and survival. Int J Cardiol 2006;109:95-100.
Van Gelder IC, Wyse DG, Chandler ML et al. Does intensity of rate-control influence outcome 
in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. Europace 
2006;8:935-42.
Van Gelder IC, Van Veldhuisen DJ, Crijns HJ et al. RAte Control Efficacy in permanent atrial 
fibrillation: a comparison between lenient versus strict rate control in patients with and without heart 
failure. Background, aims, and design of RACE II. Am Heart J 2006;152:420-6.
DiMarco JP, Flaker G, Waldo AL et al. Factors affecting bleeding risk during anticoagulant therapy 
in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of 
Rhythm Management (AFFIRM) study. Am Heart J 2005;149:650-6.
Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical 
classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. 
JAMA 2001;285:2864-70.
Hohnloser SH, Connolly SJ, Crijns HJ, Page RL, Seiz W, Torp-Petersen C. Rationale and design of 
ATHENA: A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 
400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts 
with Atrial fibrillation/atrial flutter. J Cardiovasc Electrophysiol 2008;19:69-73.
 
Hohnloser SH, Crijns HJ, van Eickels M et al. Effect of dronedarone on cardiovascular events in atrial 
fibrillation. N Engl J Med 2009;360:668-78.
Cooper HA, Bloomfield DA, Bush DE et al. Relation between achieved heart rate and outcomes 
in patients with atrial fibrillation (from the Atrial Fibrillation Follow-up Investigation of Rhythm 
Management [AFFIRM] Study). Am J Cardiol 2004;93:1247-53.
Anter E, Jessup M, Callans DJ. Atrial fibrillation and heart failure: treatment considerations for a dual 
epidemic. Circulation 2009;119:2516-25.
 
Lazzari JO, Gonzalez J. Reversible high rate atrial fibrillation dilated cardiomyopathy. Heart 
1997;77:486.
 
Nerheim P, Birger-Botkin S, Piracha L, Olshansky B. Heart failure and sudden death in patients with 






 Van Gelder IC, Crijns HJ, Blanksma PK et al. Time course of hemodynamic changes and improvement 
of exercise tolerance after cardioversion of chronic atrial fibrillation unassociated with cardiac valve 
disease. Am J Cardiol 1993;72:560-6.
Lechat P, Hulot JS, Escolano S et al. Heart rate and cardiac rhythm relationships with bisoprolol 
benefit in chronic heart failure in CIBIS II Trial. Circulation 2001;103:1428-33.
 
Van Veldhuisen DJ, Aass H, El Allaf D et al. Presence and development of atrial fibrillation in chronic 
heart failure. Experiences from the MERIT-HF Study. Eur J Heart Fail 2006;8:539-46.
 
Reynolds MR, Lavelle T, Essebag V, Cohen DJ, Zimetbaum P. Influence of age, sex, and atrial fibrillation 
recurrence on quality of life outcomes in a population of patients with new-onset atrial fibrillation: the 
Fibrillation Registry Assessing Costs, Therapies, Adverse events and Lifestyle (FRACTAL) study. Am 
Heart J 2006;152:1097-103.
55Lenient versus strict rate control
3Rate Control in Atrial FibrillationPaul DorianN Eng J Med 2010;362:1436-41
B
56 Chapter 3
57Lenient versus strict rate control
Untreated atrial fibrillation is usually associated with a rapid, irregular ventricular 
response and is often accompanied by symptoms including palpitations, fatigue, 
dyspnea, and dizziness. It is widely accepted that slowing the ventricular response, 
both at rest and during activity, with the use of drugs that prolong the refractory 
period of the atrioventricular (AV) node (so-called rate-control agents) will result 
in an improvement in symptoms and most likely reduce the future risk of adverse 
cardiovascular events. The strategy of rate control is preferred by most physicians to 
the strategy of rhythm control as initial therapy for patients with atrial fibrillation,1 
given the failure to show that rhythm-control strategies result in lower rates of death, 
stroke, or hospitalizations or better quality of life in large, well-conducted, randomized 
clinical trials.2
 When choosing to administer a rate-control agent to a patient, it seems 
reasonable to attempt to achieve ventricular rates similar to those present during sinus 
rhythm in patients with a similar degree of heart disease. These targets are based on the 
belief that lower heart rates will result in fewer symptoms, are likely to be associated 
with better cardiovascular function because of longer diastolic filling times and more 
satisfactory hemodynamics, and are associated with a lower risk of tachycardia-related 
cardiomyopathy. Extrapolation from epidemiologic studies  showing that faster heart 
rates in sinus rhythm are associated with increasing mortality from cardiovascular 
causes, and the documented clinical and quality-of-life benefits of the “pace and ablate” 
approach to ventricular rate control,3 also imply that the more closely ventricular 
rates  during atrial fibrillation approximate those during normal sinus rhythm, the 
better the outcome.
 These considerations have led to widely adopted guidelines for the ventricular 
rate targets in patients with atrial fibrillation,4 which recommend resting heart-rate 
targets of less than 80 beats per minute and targets during moderate physical activity 
of less than 110 beats per minute. These admittedly arbitrary targets, measured with 
the use of electrocardiography, are based on the expectation that the benefits of more 
intensive rate control outweigh its disadvantages and risks. 
 A number of previous lines of evidence, however, suggest possible flaws in 
the concept of targeting heart rates to near-normal levels. First, the relation between 
the achieved heart rate and the quality of life or symptoms is inconsistent, and the 
degree of symptoms during atrial fibrillation is more strongly related to severity of the 
underlying cardiac disease, age, and sex than it is to heart rate itself.5,6 In retrospective 
substudies of AFFIRM (the Atrial Fibrillation Follow-up Investigation of Rhythm 
Management) trial7 and the RACE (Rate Control versus Electrical Cardioversion 
for Persistent Atrial Fibrillation) trial,8 in which patients were randomly assigned to 
undergo a rate-control strategy or a rhythm-control strategy, there was no evidence of 
a reduction in morbidity or mortality or improved quality of life in patients with “tight” 
versus “less tight” rate control.6,9 In patients with heart failure, in whom the potential 
deleterious effects of a high ventricular rate might be particularly prominent, there is 
no evidence that bisoprolol, as compared with placebo, reduced the rates of death or 
hospitalization in a subgroup of patients who had atrial fibrillation at baseline.10 
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 In this issue of the Journal, Van Gelder and colleagues report on the 
RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation: a Comparison 
between Lenient versus Strict Rate Control II) trial (ClinicalTrials.gov number, 
NCT00392613).11 They have made an important contribution to our understanding 
of the potential benefits and risks of the current guideline-recommended approach to 
ventricular rate control in patients with persistent atrial fibrillation. 
 By means of a variety of AV nodal blocking agents, which included beta-
blocker therapy in 79% and calcium-blocker therapy in 37% of patients, a resting heart 
rate of less than 80 beats per minute at rest was achieved in 67% of patients who were 
randomly assigned to this strict rate-control target. In this group, the average (±SD) 
heart rate measured with the use of 24-hour Holter monitoring was 78±11 beats per 
minute, and 88% of patients had resting heart rates of 90 beats per minute or less after 
the dose-adjustment phase. Conversely, in the lenient control group, in which the 
resting heart-rate target was less than 110 beats per minute, 98% of patients achieved 
this target; resting heart rates were faster than 80 beats per minute in 98% and faster 
than 100 beats per minute in 23%. This less stringent rate-control target was achieved 
with the use of lower doses of beta-blockers, and beta-blockers were required in only 
65% of patients; a combination of AV nodal blockers was necessary in 30% of patients, 
in contrast to 69% in the strict-control group.
 Although the confidence intervals around the hazard ratios for the composite 
primary outcome and the components of the primary outcome are wide, there is no 
indication that there was any clinical benefit to strict rate control with respect to the 
risk of death, serious adverse outcomes (including heart failure), or symptoms. It is 
instructive to speculate that symptomatic adverse effects of rate-control drugs could 
offset the potential symptomatic benefits of strict rate control, given the minority 
of patients in both groups (24%) who had palpitation as a recorded symptom. In 
the strict-control group, the reason the target was not achieved was because of drug-
related adverse events in 25% of patients. These results suggest that the potential 
clinical benefits of a “conventional” approach to ventricular rate control, even if present, 
may be offset by the potential adverse effects of drugs used for this purpose. 
 A number of limitations of the RACE II study need to be borne in mind. 
First, it is possible that rapid ventricular rates may take many years to result in cardiac 
deterioration and illness or death, and thus there may be a benefit of more “strict” 
ventricular rate control over a period of decades or more. Patients with atrial fibrillation 
who also have very rapid ventricular responses, present with heart failure, and appear 
to have tachycardia-related cardiomyopathy may have particular benefit from strict 
rate control; this subgroup may have been underrepresented or not enrolled in the 
RACE II trial. The data on symptoms and quality of life collected in the study were 
somewhat limited, such that subtle benefits in this regard from stricter rate control 
may not have been easily ascertained. As in all randomized, clinical trials, selection bias 
most likely limited the enrollment of patients to those who were relatively clinically 
well, were somewhat younger than the average age for patients with atrial fibrillation, 
and had some degree of rate control at study entry (mean heart rate in both groups 
at baseline, 96 beats per minute). Two thirds of the patients were men; women are 
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known to have more severe symptoms than men during atrial fibrillation, possibly in 
association with more rapid ventricular rates on average.12
 What clinical inferences can be drawn from the RACE II study, given the 
previous state of knowledge regarding rate control? First, a heartrate target of less 
than 110 beats per minute at rest, although it may make physicians feel uncomfortable, 
is probably as useful as the current guideline-recommended target heart rates at rest 
and during exercise, at least in the medium term. Many patients will continue to be 
symptomatic under the rate-control approach, whether a strict or more lenient target 
heart rate is used. The RACE II study does not suggest that ventricular rate control is 
not needed, only that the conventional therapeutic target needs to be reassessed. At a 
minimum, the study indicates that reflexive, “recipe-based” adherence to a rate-control 
target does not seem sensible and that an approach emphasizing the adjustment of 
therapy on the basis of symptoms and general well-being can be safely recommended. 
 As in many other clinical situations, in patients with atrial fibrillation, 
treating a laboratory test is not a good substitute for targeting overt clinical outcomes. 
This important study serves as a reminder that it is better to treat the patient and not 
the electrocardiogram.
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The RACE II study showed no difference in outcome between lenient and strict rate 
control in patients with permanent atrial fibrillation (AF). However, in the strict group 
not all patients achieved the predefined heart rate target. We aimed to investigate 
differences in outcome between patients treated with successful strict, failed strict and 
lenient rate control.
The primary outcome was a composite of cardiovascular morbidity and mortality. For 
the current analysis outcome events were analyzed from end of the dose-adjustment 
phase until end of follow-up (median 2.9 [interquartile range 2.4-3.0] years). 608 of 
614 patients completed the dose-adjustment phase, 301 in the strict (resting heart rate 
<80 beats per minute [bpm] and during moderate exercise <110 bpm) and 307 in the 
lenient group (resting heart rate <110 bpm). In the strict group, 203 of 301 patients 
achieved the rate control target, 98 failed.
Heart rate was different after the dose-adjustment phase between the successful strict 
(72±7 bpm), failed strict (86±14 bpm), and lenient (93±8 bpm) group (p<0.001), and 
remained significantly different during follow up. The primary outcome was reached 
in 27 of 203 (14.2% KM estimates) in the successful strict versus 14 of 98 (15.0%) in 
the failed strict versus 35 of 307 (12.1%) in the lenient group (p=0.5). The components 
of the primary outcome and quality of life were similar in the groups.
In patients with permanent AF, successful strict rate control does not improve 
outcome. Lenient rate control may therefore be frontline therapy.
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Introduction
Rate control is frontline therapy in patients with permanent atrial fibrillation 
(AF).1,2 Evidence is accumulating that lenient rate control is a reasonable strategy 
in patients with permanent AF. Post-hoc analyses of the Atrial Fibrillation Follow-
up Investigation of Rhythm Management (AFFIRM) and RAte Control versus 
Electrical cardioversion (RACE) study showed a comparable outcome between 
patients with permanent AF with higher and lower heart rates.3-5 The RAte Control 
Efficacy in permanent atrial fibrillation II (RACE II) trial prospectively evaluated 
the effect of lenient versus strict rate control in patients with permanent AF,6 and 
showed no difference in outcome between the lenient and strict rate control groups 
in terms of cardiovascular morbidity, mortality, and quality of life.7,8 However, not all 
patients achieved the heart rate target, especially not in the strict group.7 The inability 
of achieving the strict rate control target may have influenced outcome, in favor of 
lenient rate control. The current post-hoc analysis evaluates the difference in outcome 
between patients treated with successful strict, failed strict and lenient rate control.
Methods
The study design and results of the RACE II have been published previously.6,7 
The study was approved by the institutional review boards of all participating 
centers, and all patients gave written informed consent. Patients were randomized 
to lenient (resting heart rate <110 beats per minute [bpm]) or strict rate control 
(resting heart rate <80 bpm, and a heart rate <110 bpm during moderate exercise). 
The primary outcome was a composite of cardiovascular morbidity and mortality 
RACE II study design
 Randomization 
n=614 
Strict rate control 
n=303 
Lenient rate control 
n=311 
Excluded from current analyses 
n=2 
Hospitalization for heart failure (n=1) 
Pacemaker implantation (n=1) 
Excluded from current analyses 
n=4 
Bleeding (n=1) 
Cardiovascular death (n=1) 
Hospitalization for heart failure (n=1) 
Refusal further study participation (n=1) 
 







Figure 1.  Study flow-chart, randomization and success of rate control
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Table 1. Rate control targets and drug therapy at the end of the dose-
              adjustment phase
* not all patients performed exercise test due to unexpected physical limitations, eg. recent surgery (n=9)
as described previously.7 Patients in the strict group who failed one of the heart 
rate criteria were classified as failed strict, the remaining patients were classified as 
successful strict rate control. Reasons for failure of strict rate control could be drug 
related adverse events, no or tolerable symptoms, or heart rate target unattainable with 
drugs.













Rate-control target or targets achieved 203 (100) 0 (0) 302 (98.4)
Heart rate at the end of the dose-
adjustment phase – beats/min 
72±7 86±14 93±8 <0.001
Resting heart rate distribution at the end 
of the dose-adjustment phase
     <70 beats/min 61 (30.0) 6 (6.1) 1 (0.3) <0.001
     70-80 beats/min 142 (70.0) 19 (19.4) 5 (1.6)
     81-90 beats/min 0 38 (38.8) 111 (36.2)
     91-100 beats/min 0 20 (20.4) 122 (39.7)
     >100 beats/min 0 15 (15.3) 68 (22.2)
Resting heart rate target achieved 203 (100) 25 (25.5) 302 (98.4) <0.001
Exercise heart rate target achieved 192 (94.6)* 27 (27.6) - <0.001
     Mean heart rate 94±12 112±16 - <0.001
     Mean duration of exercise with target 
     achieved – sec 
90±42 103±47 - 0.049
Holter monitoring
     Mean heart rate 76±10 82±13 - <0.001
     Max RR interval – sec 2.3±0.5 2.3±0.6 - 0.9
Visits to achieve rate-control target(s) 424 255 74 <0.001
     Median (interquartile range) 2 (1-3) 2 (1-3) 0 (0-0) <0.001
Reason for failure to achieve rate-control 
target or targets 
<0.001
     Drug related adverse events 0/0 25/98 0/4
     No symptoms or symptoms tolerated 0/0 52/98 4/4
     Target impossible to achieve with drugs 0/0 21/98 0/4
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Design of current analysis
For the current analysis outcome events in the strict rate control group were analyzed 
from end of the dose-adjustment phase, i.e. the moment the heart rate targets were 
either achieved or deemed impossible or unnecessary (due to absence of complaints) 
to achieve, until end of follow-up. In the lenient rate control group the endpoints were 
analyzed from 9 days after randomization, the mean duration of the dose-adjustment 
phase in the lenient group, until end of follow-up. Patients with a primary outcome 
event occurring during the dose-adjustment phase in the strict group and before 9 days 
after randomization in the lenient group were not included in the present analysis.
Table 1. Rate control targets and drug therapy at the end of the dose-














Rate control medications in use at the end 
of the dose-adjustment phase – no. (%)
     No rate control drugs 1 (0.5) 2 (2.0) 32 (10.4) <0.001
     Beta-blocker alone 41 (20.2) 20 (20.4) 131 (42.7) <0.001
     Verapamil/diltiazem alone 10 (4.9) 6 (6.1) 18 (5.9) 0.9
     Digoxin alone 4 (2.0) 1 (1.0) 21 (6.8) 0.015
     Beta-blocker + verapamil/diltiazem 27 (13.3) 11 (11.2) 12 (3.9) 0.001
     Beta-blocker + digoxin 74 (36.5) 38 (38.8) 59 (19.2) <0.001
     Verapamil/diltiazem + digoxin 21 (10.3) 8 (8.2) 16 (5.2) 0.1
     Beta-blocker + verapamil/diltiazem + 
     digoxin
18 (8.9) 8 (8.2) 3 (1.0) <0.001
Dose at the end of the dose-adjustment 
phase – mg
     Betablocker (adjusted to metoprolol) 161±81 165±95 121±78 <0.001
     Verapamil 212±94 233±102 168±60 0.004
     Diltiazem 225±50 207±90 230±87 0.9
     Digoxin 0.19±0.07 0.23±0.1 0.19±0.08 0.007
Quality of life
Quality of life was assessed with the Medical Outcome Study Short Form-36, AF 
severity scale, and Multidimensional Fatigue Inventory-20 as has been described 
previously.8-12
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Age – yr 68±8 66±9 68±8 0.1
Male sex – no. (%) 129 (63.6) 67 (68.4) 201 (65.8) 0.7
Total atrial fibrillation duration (months) 21 (6-59) 19 (5-68) 16 (6-54) 0.1
Duration permanent atrial fibrillation (months) 3 (1-7) 2 (1-5) 3 (1-6) 0.2
Hypertension – no. (%) 120 (59.1) 54 (55.1) 197 (64.2) 0.4
Coronary artery disease – no. (%) 34 (16.8) 10 (10.2) 65 (21.2) 0.1
Valvular heart disease – no. (%) 42 (20.7) 18 (18.4) 63 (20.5) 0.9
Chronic obstructive pulmonary disease – no. 
(%)
33 (16.3) 10 (10.2) 35 (11.4) 0.3
Diabetes mellitus – no. (%) 20 (9.9) 12 (12.2) 36 (11.7) 0.7
Lone atrial fibrillation* – no. (%) 3 (1.5) 3 (3.1) 5 (1.6) 0.8
Previous heart failure hospitalization – no. (%) 25 (12.3) 7 (7.1) 28 (9.1) 0.4
CHADS2 score† 1.4±1.2 1.4±1.1 1.4±1.0 0.9
     0 or 1 – no. (%) 130 (64.0) 64 (65.3) 176 (57.3) 0.3
     2 – no. (%) 44 (21.7) 20 (20.4) 93 (30.3)
     3-6 – no. (%) 29 (14.3) 14 (14.3) 38 (12.4)
Symptoms – no. (%) 119 (58.6) 55 (56.1) 169 (55.1) 0.5
     Palpitations 60 (29.6) 22 (22.5) 61 (19.9) 0.1
     Dyspnea 80 (39.4) 29 (29.6) 101 (32.9) 0.04
     Fatigue 67 (33.0) 29 (29.6) 85 (27.7) 0.6
New York Heart Association functional class
     I – no. (%) 123 (60.6) 69 (70.4) 206 (67.1) 0.1
     II – no. (%) 69 (34.0) 27 (27.6) 85 (27.7)
     III – no. (%) 11 (5.4) 2 (2.0) 16 (5.2)
Body-mass index 29±5 29±4 29±5 0.7
Blood pressure
     Systolic 135±17 135±15 137±19 0.4
     Diastolic 82±12 83±9 85±11 0.02
Heart rate in rest –  beats/minute 94±11 98±15 96±12 0.1
*  Lone atrial fibrillation was defined as AF in the absence of cardiovascular disease and extracardiac precipitating causes of AF 
† The CHADS2 score is a measure of the risk of stroke in patients with atrial fibrillation, with scores ranging from 0 to 6 and higher scores indicate a 
   greater risk. Congestive heart failure, hypetension, an age of 75 years or older, and diabetes are each assigned 1 point, and previous stroke or transient 
   ischemic attack is assigned 2 points; the score is calculated by summing all points for a given patient.
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Echocardiography parameters – mm
     Left atrial size, long axis 46±7 46±8 46±6 0.6
     Left atrial volume - mL 72±28 76±26 72±24 0.3
     Left ventricular end-diastolic diameter 51±8 52±8 51±7 0.8
     Left ventricular end-systolic diameter 36±8 37±9 36±8 0.8
     Left ventricular ejection fraction – % 52±12 53±13 52±11 0.6
          ≤ 40% – no. (%) 34 (16.7) 14 (14.3) 43 (15.6) 0.4
Rate control medications in use – no. (%)
     No rate control drugs 20 (9.9) 7 (7.1) 36 (11.7) 0.5
     Beta-blocker alone 93 (45.8) 42 (42.9) 139 (45.3) 0.9
     Verapamil/diltiazem alone 13 (6.4) 6 (6.1) 17 (5.5) 0.7
     Digoxin alone 15 (7.4) 9 (9.2) 19 (6.2) 0.6
     Beta-blocker + verapamil/diltiazem 7 (3.5) 4 (4.1) 7 (2.3) 0.8
     Beta-blocker + digoxin 26 (12.8) 22 (22.5) 53 (17.3) 0.2
     Verapamil/diltiazem + digoxin 11 (5.4) 3 (3.1) 14 (4.6) 0.8
     Beta-blocker + verapamil/diltiazem + 
     digoxin
5 (2.5) 0 (0.0) 2 (0.7) 0.2
     Sotalol or amiodarone 13 (6.4) 5 (5.1) 20 (6.5) 0.2
Dose – mg 
     Betablocker (adjusted to metoprolol) 124±65 115±67 114±71 0.6
     Verapamil 180±72 215±79 173±77 0.3
     Diltiazem 233±58 160±57 230±87 0.7
     Digoxin 0.17±0.06 0.22±0.06 0.19±0.08 0.1
Other medications in use – no. (%)
     ACE inhibitor and/ or ARB 94 (46.3) 45 (45.9) 165 (53.8) 0.2
     Diuretic 78 (38.4) 35 (35.7) 134 (43.7) 0.1
     Statin‡ 54 (26.6) 20 (20.4) 101 (32.9) 0.1
     Vitamin K antagonist 200 (98.5) 96 (98.0) 304 (99.0) 0.9
     Aspirin 4 (2.0) 2 (2.0) 4 (1.3) 0.9
ACE – angiotensin converting enzyme inhibitor, ARB – angiotensin II receptor blocker
‡ statins were defined as 3-hydroxy-3-methylglutaryl-coenzym A reductase inhibitors
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A total of 76 patients (27 of 203 in the successful strict and 14 of 98 in the failed strict 
group, and 35 of 307 in the lenient group) reached the primary outcome (Figure 2, 
Table 3A and B). The cumulative difference between successful strict and failed strict 
was -0.8 (90% CI -6.6 to 8.2, p for non-inferiority 0.02).  The cumulative difference 
between successful strict and lenient rate control was 0.2, 90% CI -7.4 to 3.2, p  for 
non-inferiority <0.001). There was no significant difference between the three groups 
considering the composites of the primary outcome, nor was there any difference in 
all cause mortality (Table 3). There was also no difference in primary outcome when 
analyzing patients with an ejection fraction <40% (data not shown, p=0.6).
Primary outcome after dose-adjustment phase
Heart rates were higher in the failed strict and lenient group as compared to the 
successful strict group (Table 1). 
 Median follow up was 2.9 (interquartile range 2.4-3.0) years. Clinical 
characteristics were almost comparable between the groups (Table 2). 
 After the dose-adjustment phase, more patients in the lenient group either 
used no rate control drugs, or a beta-blocker or digoxin alone. Fewer patients in the 
lenient group used a combination of drugs and used significantly lower dosages of 
beta-blockers and verapamil (Table 1). 
Patient characteristics
In the current analysis 608 patients were included. 203 patients had successful strict, 
98 failed strict, and 307 patients lenient rate control (Figure 1).  In 25 patients strict 
rate control failed due to drug related adverse events, 52 patients had no or tolerable 
symptoms, and in 21 patients the strict heart rate criteria were unattainable to achieve 
with drugs.
Rate control achievement during the dose adjustment phase
Results
Baseline descriptive statistics are presented as mean ± standard deviation (SD) or 
median (range) for continuous variables and counts with percentages for categorical 
variables. Differences between groups, in terms of patient characteristics, were 
evaluated by one-way ANOVA, Kruskal-Wallis test or Chi-square test, depending on 
normality and type of the data. Differences in quality of life between the groups were 
assessed with a general linear model and a general linear model repeated measures. In 
all analyses a value of p<0.05 was considered statistically significant. Kaplan-Meier 
analysis was performed to assess differences in outcome between the three groups. 
Non-inferiority was tested by comparing the upper boundary of the 90% confidence 
interval (CI) for the primary outcome.7
Statistical analysis
69Successful strict rate control and outcome




























Failed strict            98                     88                     86                     77                     69                     59                     21
Succesful strict      203                   191                   187                   181                   164                   145                    64
Lenient control     307                   297                   291                   284                   244                   214                   143
Additional visits, heart rate, left ventricular function and drug use during study
At 1 and 2 years follow-up more patients in the successful strict (17.7% and 12.3%) 
and failed strict (14.3% and 8.2%), as compared to the lenient (4.6% and 4.2%) group 
had at least one additional visit (p<0.001 and p=0.007 for 1 and 2 years of follow-up, 
respectively). There was no difference in additional visits between the successful strict 
and failed strict groups.
 Heart rates during the study and left ventricular ejection fraction during 
the study are shown in Table 4. During follow-up no significant changes in drug or 
combination of drugs occurred in any of the groups, nor were there significant changes 
in the dosages of the rate control drugs (data not shown).
Symptoms and quality of life
At the end of study fewer patients in the failed strict group had any symptom of AF 
(Table 5). At study entry nor at study end, there were no significant differences in the 
SF-36, MFI-20, and AF-severity scale between the groups (Figure 3). There was no 
effect of the different rate control strategies over time. 
Discussion
This analysis of RACE II shows no difference in cardiovascular outcome between 
successful strict, failed strict and lenient rate control in patients with permanent AF. 
In addition, quality of life was comparable between the groups at the end of follow-up.
70 Chapter 4
Table 3A. Cumulative Incidence* of the Composite Primary Outcome and its 








rate control  
(n=307)
Primary Outcome       No. of patients (%)‡      
Composite primary outcome 27 (14.2) 14 (15.0) 35 (12.1)
     Death from cardiovascular cause 5 (2.7) 6 (6.7) 7 (2.3)
          Cardiac arrhythmic death 1 (0.5) 3 (3.2) 2 (0.7)
          Cardiac nonarrhythmic death 0 2 (2.5) 1 (0.3)
          Noncardiac vascular death 4 (2.2) 1 (1.1) 4 (1.3)
     Heart failure 5 (2.9) 5 (5.8) 10 (3.5)
     Stroke 8 (4.2) 3 (3.2) 4 (1.6)
          Ischemic stroke 7 (3.7) 1 (1.1) 3 (1.3)
          Hemorrhagic stroke 2 (1.2) 2 (2.2) 1 (0.3)
     Systemic embolism 0 0 1 (0.3)
     Bleeding 9 (4.5) 4 (4.6) 14 (5.0)
          Intracranial bleeding 2 (1.0) 1 (1.1) 0
          Extracranial bleeding 7 (3.5) 3 (3.5) 14 (5.0)
     Syncope 2 (1.0) 1 (1.1) 3 (1.0)
     Life threatening adverse effects of 
     rate control drugs
1 (0.5) 1 (1.0) 3 (1.0)
     Sustained ventricular tachycardia or 
     ventricular fibrillation
1 (0.5) 0 0
     Implantable cardioverter 
     defibrillation implantation
1 (0.6) 0 0
     Pacemaker implantation 1 (0.6) 2 (2.1) 2 (0.8)
Death from any cause§ 10 (5.6) 8 (8.9) 15 (5.0)
 One of the comments on the RACE II study is that only 67% of the patients 
randomized to the strict group achieved the heart rate targets, as compared to 98% 
in the lenient group. The data of the present analysis confirm our prior findings that 
lenient rate control is not inferior to strict rate control, even not when the lenient 
strategy is compared to patients who were successfully treated with a strict rate control 
*  Composite primary outcome includes first event for each patient, component events include all such events. 
† Outcome event in the successful strict and failed strict rate control were analyzed from the end of the dose-adjustment phase until end of 
   study. In the lenient rate control group the outcome event were analyzed from 9 days, the mean duration of the dose-titration in the lenient 
   rate control group, until the end of follow-up. 
‡ The cumulative incidence at 3 years of follow-up was determined with use of the Kaplan-Meier curves. 
§ Death from any cause is not a composite of the primary outcome
CI – confidence interval
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Hazard Ratio
(95% Confidence Interval)






Composite primary outcome 1.17 (0.62-2.24) 1.23 (0.74-2.03) 1.44 (0.78-2.69)
     Death from cardiovascular 
     cause
2.66 (0.81-8.73) 1.08 (0.34-3.39) 2.86 (0.96-8.54)
     Heart failure 2.24 (0.65-7.73) 0.74 (0.25-2.18) 1.67 (0.57-4.88)
     Stroke 0.83 (0.22-3.14) 3.01 (0.91-10.02) 2.51 (0.56-11.23)
     Bleeding 0.97 (0.30-3.16) 0.97 (0.42-2.25) 0.95 (0.31-2.88)









     1 year 73±10 81±14 85±13 <0.001
     2 year 74±12 78±12 83±13 <0.001
     End of study 75±14 78±12 85±13 <0.001
Left ventricular ejection 
fraction at end of study
55±11 55±9 54±11 0.4
Table 4. Heart rate during follow-up and left ventricular ejection fraction at 
              end of study
strategy.1,2,7,13,14 Instead, the present analysis shows that attempts to achieve strict 
rate control targets are unsuccessful in one third of the patients and not necessary. 
The latter may not hold for every patient. If patients remain symptomatic or a 
tachycardiomyopathy develops lower hear rate targets may be indicated.
 In accordance with AFFIRM, we also showed that a strict rate control 
strategy is time consuming, necessitating more out-patient visits, more combinations 











Symptoms – no. (%) 97 (51.3) 29 (34.9) 129 (45.7) 0.03
     Palpitations 18 (9.5) 8 (9.6) 30 (10.6) 0.9
     Dyspnea 62 (32.8) 19 (22.9) 85 (30.1) 0.3
     Fatigue 45 (23.8) 17 (20.5) 69 (24.5) 0.7
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A - SF-36 Baseline
B - MFI-20 Baseline
C - AF Severity scale
D - SF-36 End of study
E - MFI-20 End of study
and higher dosages of rate control drugs.3,7,15 These differences emphasize the 
difference in strategy. Although the dissimilarity in heart rates between the groups 
was not as marked as may have been anticipated, strategies to obtain those heart rates 
were completely different.
 Why was successful strict rate control not associated with an improved 
outcome? First, the incidence of heart failure, being a major concern of lenient rate 
control, was not lower during successful strict rate control. Apparently, a heart rate 
<110 bpm was low enough to prevent heart failure, being in line with post-hoc analyses 
of large heart failure trials showing that beta-blockers do not improve outcome in 
patients with heart failure and AF.16-18 Secondly, patients with AF may need higher 
heart rates due to loss of the atrial kick and the irregular ventricular response.19 
 There were no differences in quality of life between the three rate control 
groups. Apparently, not heart rate alone but also the use of more and higher dosages 
of rate control drugs and the underlying disease influence quality of life.
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Limitations
The difference in heart rate between the groups was not as marked as would have 
been expected from the design of the study. However, the strategies to achieve those 
heart rates were completely different. Outcome might have been different when all 
patients in the lenient group would have had a heart rate >100 bpm.13 RACE II was 
not designed to assess differences between successful strict, failed strict and lenient 
rate control, therefore the current study is underpowered for this analysis. Follow up 
was limited to 3 years.
Conclusion
There is no difference in outcome between successful and failed strict rate control. 
Strict rate control seems to have no favorable effect in this group of permanent AF 
patients, even not when the heart rate targets are achieved. Lenient rate control, 
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The RAte Control Efficacy in permanent atrial fibrillation II (RACE II) trial showed 
that lenient rate control is not inferior to strict rate control in terms of cardiovascular 
morbidity and mortality. The influence of rate control on quality of life (QoL) is 
unknown. We hypothesized that QoL is comparable between patients randomized to 




In RACE II 614 patients with permanent atrial fibrillation (AF) were randomized 
to lenient (resting heart rate [HR]<110 bpm) or strict rate control (resting HR<80 
bpm, HR during moderate exercise <110 bpm). QoL was assessed in 437 patients 
using the Short Form (SF)-36 health survey questionnaire, AF severity scale, and 
Multidimensional Fatigue Inventory (MFI)-20, at baseline, 1 year and end of study. 
QoL changes were related to patient characteristics.
Median follow-up was 3 years. Mean age was 68±8 years, 66% were males. At the 
end of follow-up all SF-36 subscales were comparable between both groups. The AF 
severity scale was similar at baseline and end of study. At baseline and at end of study 
there were no differences in the MFI-20 subscales between the two groups. Symptoms 
at baseline, younger age, and less severe underlying heart disease, rather than assigned 
therapy or heart rate, were associated with QoL improvements. Female sex and 
cardiovascular endpoints during the study were associated with worsening of QoL.
Stringency of heart rate control does not influence quality of life. Instead, symptoms, 
gender, age and severity of the underlying heart disease influence QoL.
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Introduction
Atrial fibrillation (AF) causes symptoms like palpitations, dyspnea and fatigue.1 
Compared to healthy subjects, quality of life is reduced in patients with AF.2,3 
Restoration and maintenance of sinus rhythm improves quality of life,3-6 but sinus 
rhythm can be maintained in a minority of patients.7-9 The Atrial Fibrillation Follow-
up Investigation of Rhythm Management (AFFIRM) and Rate Control versus 
Electrical Cardioversion for Persistent Atrial Fibrillation (RACE) trials showed no 
improvement in cardiovascular morbidity and mortality and quality of life during 
a rhythm control strategy.7,8 Therefore rate control has become first choice therapy 
in elderly patients without severe symptoms. The optimal level of heart rate control, 
however, was unknown. Recently the Rate Control Efficacy in Permanent Atrial 
Fibrillation: a comparison between Lenient and Strict Rate Control II (RACE II) 
showed that lenient rate control is as effective as strict rate control with respect to 
morbidity and mortality.10 Strict rate control may improve quality of life due to a 
reduction of the heart rate. On the other hand, more negative dromotropic drugs and 
higher doses may reduce this positive effect on quality of life. 
 We hypothesized that quality of life is comparable between lenient and strict 
rate control. The aim of this predefined substudy of the RACE II trial was to assess 
the effect of stringency of heart rate control on quality of life measured with a general 
health, AF specific and fatigue questionnaire.11 In addition, we investigated patient 
characteristics associated with a low quality of life at baseline and changes in quality 
of life during follow-up.
Methods
Patient population
This study was performed in patients with permanent AF included in the 
RACE II study.10,11 The institutional review board of each participating hospital 
approved the study, and all patients gave written informed consent. We included 614 
patients who were randomized to lenient rate control (resting heart rate <110 beats/
min) or strict rate control (resting heart rate <80 beats/min, and heart rate <110 beats/
min during moderate exercise). Rate control was instituted with beta-blockers, non-
dihydropyridine calcium-channel blockers, and digoxin, alone or in combination and 
at various doses, until the heart rate target was achieved.11 Drug use at the end of 
the dose-adjustment phase was used as baseline medication in the current analysis. 
The primary outcome in the main study was a composite of cardiovascular death, 
hospitalization for heart failure, stroke, systemic embolism, major bleeding, or 
arrhythmic events, including syncope, sustained ventricular tachycardia, cardiac arrest, 
life-threatening adverse effects of rate control drugs, and pacemaker or cardioverter-
defibrillator implantation. The arrhythmic events were analyzed for the purpose of 
the present substudy as the occurrence of any composite arrhythmic endpoint. Both 
strategies were associated with a comparable rate of cardiovascular adverse events. 
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Age – yr 69±7 68±8 68±8
Male sex – no. (%) 157 (68.3) 133 (64.3) 290 (66.4)
Total atrial fibrillation duration (months) 17 (6 – 54) 19 (6 – 58) 18 (6 – 58)
Duration permanent atrial fibrillation (months) 3 (1-6) 3 (1-5) 3 (1-6)
Heart rate in rest –  beats per minute 95±14 95±11 95±12
Hypertension – no. (%) 144 (62.6) 120 (58.0) 264 (60.4)
Coronary artery disease – no. (%) 53 (23.0) 30 (14.5)* 83 (19.0)
Valvular heart disease – no. (%) 44 (19.1) 45 (21.7) 89 (20.4)
Chronic obstructive pulmonary disease – no. (%) 25 (11.6) 26 (14.2) 51(12.9)
Diabetes mellitus – no. (%) 21 (9.1) 19 (9.2) 40 (9.2)
Lone atrial fibrillation† – no. (%) 5 (2.2) 6 (2.9) 11 (2.5)
Previous heart failure hospitalization – no. (%) 19 (8.3) 18 (8.7) 37 (8.5)
CHADS2 score‡ – no. (%) 1.3±1.0 1.3±1.1 1.3±1.0
     0 or 1 143 (62.2) 139 (67.1) 282 (64.5)
     2 64 (27.8) 43 (20.8) 107 (24.5)
     3-6 23 (10.0) 25 (12.1) 48 (11.0)
Symptoms – no. (%) 127 (61.4) 127 (55.2) 254 (58.1)
     Palpitations 47 (20.4) 59 (28.5)* 106 (24.3)
     Dyspnea 77 (33.5) 84 (40.6) 161 (36.8)
     Fatigue 65 (28.3) 69 (33.3) 134 (30.7)
New York Heart Association functional class 
     I – no. (%) 153 (66.5) 124 (59.9) 277 (63.4)
     II – no. (%) 64 (27.8) 75 (36.2) 139 (31.8)
     III – no. (%) 13 (5.7) 8 (3.9) 21 (4.8)
Echocardiographic parameters – mm
     Left atrial size, long axis 46±7 46±7 46±7
     Left ventricular end-diastolic diameter 51±7 51±7 51±7
     Left ventricular end-systolic diameter 36±8 36±9 36±8
     Left ventricular ejection fraction – % 52±11 53±12 53±11
          ≤ 40% – no. (%) 28 (12.2) 32 (15.5) 60 (13.7)
† Lone atrial fibrillation was defined as AF in the absence of cardiovascular disease and extracardiac precipitating causes of AF
‡ The CHADS2 score is a measure of the risk of stroke in patients with atrial fibrillation, with scores ranging from 0 to 6 and higher scores 
   indicate a greater risk. Congestive heart failure, hypetension, an age of 75 years or older, and diabetes are each assigned 1 point, and previous 
   stroke or transient ischemic attack  is assigned 2 points; the score is calculated by summing all points for a given patient.
NYHA - New York Heart Association functional class for heart failure
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Heart rate distribution at the end of the 
dose adjustment phase
     < 70 beats per minute – no.(%) 1 (0.4) 45 (21.7) <0.001
     70 to 80 beats per minute – no.(%) 4 (1.8) 119 (57.5) <0.001
     81 to 90 beats per minute – no.(%) 81 (35.2) 24 (11.6) <0.001
     91 to 100  beats per minute – no.(%) 93 (40.4) 11 (5.3) <0.001
     >100   beats per minute – no.(%) 51 (22.2) 8 (3.9) <0.001
Rate control medications use at the end 
of the dose-adjustment phase – no. (%)
     No rate control drugs 24 (10.4) 2 (1.0) 26 (6.0)
     Beta-blocker alone 99 (43.0) 46 (22.2) 145 (33.2)
     Verapamil/diltiazem alone 13 (5.7) 11 (5.3) 24 (5.5)
     Digoxin alone 18 (7.8) 1 (0.5) 19 (4.4)
     Beta-blocker + verapamil/diltiazem 7 (3.0) 25 (12.1) 32 (7.3)
     Beta-blocker + digoxin 45 (19.6) 79 (38.2) 124 (28.4)
     Verapamil/diltiazem + digoxin 13 (5.7) 24 (11.6) 37 (8.5)
     Beta-blocker + verapamil/diltiazem +  
     digoxin
1 (0.4) 14 (6.8) 15 (3.4)
     Sotalol or amiodaron 10 (4.4) 5 (2.4) 15 (3.4)
Dose – mg (no. of patients)
     Beta-blocker (normalized to 
     metoprolol-equivalent doses)
119±81 (153) 169±87 (166) 145±88 (319)
     Verapamil 183±56 (30) 221±102 (69) 209±92 (99)
     Diltiazem 230±87 (4) 233±52 (6) 232 ±63 (10)
     Digoxin 0.19±0.8 (82) 0.21±0.9 (120) 197 ±83 (202)
Other medications in use at the end of 
the dose-adjustment phase – no. (%)
     ARB or ACE inhibitor 122 (53.0) 100 (48.3) 222 (50.8)
     Diuretic 98 (42.6) 81 (39.1) 179 (41.0)
     Statin§ 82 (35.7) 51 (24.6)* 133 (30.4)
     Vitamin K antagonist 228 (99.1) 203 (98.1) 431 (98.6)
     Aspirin 2 (0.9) 4 (1.9) 6 (1.4)
§ Statins were defined as 3-hydroxy-3-methylglutaryl-coenzym A reductase inhibitors
ACE inhibitor – Angiotensin-converting enzyme inhibitor, ARB – Angiotensin receptor blocker
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Patients were excluded from the present analyses when they did not complete one 
of the quality of life questionnaires during follow-up (64 patients in the lenient and 
78 patients in the strict-control arm). Patients who died during the study were also 
not included in the analysis (17 patients in the lenient and 18 in the strict-control 
group). Minimum follow-up was 2 years, maximal follow-up 3 years. Median follow-
up was 3 years (interquartile range [IQR] 2.2-3.1 years). Results of the questionnaires 
at baseline, 12 months and end of study are presented. Importantly, the 12 months 
follow-up was the first measurement of quality of life after the dose-adjustment phase. 
 Baseline characteristics were comparable between the excluded patients 
and included patients. Baseline characteristics of the included patients are shown in 
Table 1. With the exception of a higher prevalence of coronary artery disease and use 
of statins in the lenient group, baseline characteristics were comparable between both 
groups. After the dose adjustment phase 98% of the patients in the lenient group 
met the heart rate target versus 76% in the strict control group. Patients randomized 
to strict rate control used more and higher dosages of negative dromotropic drugs 
compared to lenient rate control (Table 1). During the total follow up the heart rate 
was significantly higher in the lenient compared to the strict rate control group (after 
dose adjustment 93±8 versus 76±11 beats per minute, at 1 year 84±13 versus 74±12 
beats per minute, at end of study 84±14 versus 75±14 beats per minute, all p<0.05).
Quality of life questionnaires
General health related quality of life was measured with The Medical Outcome Study 
Short Form-36 (SF-36). The SF-36 is a standardized, validated, general health survey 
that has been frequently used in arrhythmia studies.12 The SF-36 has been translated 
and validated in the Netherlands.13 It contains items to assess physical health (general 
health perception, physical functioning, role limitations due to physical problems and 
bodily pain) and mental health (social functioning, role limitations due to emotional 
problems, mental health, and vitality). The items for general health perception and 
vitality measure both physical and mental health. Each scale is composed of a number 
of multiple choice questions. For each of the eight subscales, scores are transformed to 
a scale ranging from 0-100, lower scores representing lower quality of life. 
 Severity of AF-related symptoms was assessed with the University of Toronto 
AF Severity Scale (AF severity scale).2,14,15 This is a disease-specific instrument intended 
to measure the patient’s perception of severity of arrhythmia-related symptoms. This 
is a seven-item questionnaire that included common AF symptoms (e.g. palpitations 
and dyspnea). Items are rated on a six-point scale. Scores range from 0-35, higher 
scores indicating greater AF symptoms severity. 
 Severity of fatigue was measured with the Multidimensional Fatigue 
Inventory-20 (MFI-20).16,17 The MFI-20 is a self-report instrument containing 20 
statements covering different aspects of fatigue. The 20 items are organized in 5 scales, 
general, physical and mental fatigue and reduced activity and motivation, ranging 
from 4-20. The scales are balanced to reduce influence of response tendencies.
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Statistical analysis
To analyze patient characteristics associated with low quality of life at baseline, 
patients with low scores (scores lower than the mean value –1SD) were identified. 
To assess relevant changes over time in SF-36 subscales, the changes over time were 
divided into relevant and irrelevant. A relevant change was pre-defined for each SF-36 
subscale. The relevant change was based on the number of steps the patient improved 
or worsened on the stepwise multiple choice questions that comprised each SF-36 
subscale between baseline, and end of study.3 The following changes in individual 
patients were regarded as relevant: one step for role limitation due to physical problems 
and role limitations due to emotional problems, two steps for social functioning 
and bodily pain, and three steps for general health perception, physical functioning, 
mental health, and vitality. Based on the above definition of relevant changes in the 
SF-36 subscales the relevant effect size of each SF-36 subscale was defined as 0.58 
standard deviation (SD) or higher from baseline.18 Also for the AF severity scale and 
the MFI-20 a relevant change was defined as an effect size of >0.58 SD in these 
questionnaires, which is in accordance with the literature which defines an effect size 
between 0.50 and 0.80 SD as a moderate change.18 
 Clinical correlates of change in quality of life, including clinical baseline and 
follow-up characteristics, were determined. The use of beta-blockers was included in 
this analysis, since beta-blockers effectively reduce heart rate, but may reduce exercise 
capacity and induce fatigue.19 Use of other negative dromotropic drugs or a combination 
of negative dromotropic drugs, and dosages were not included in this analysis. This 
was not performed because randomization strategy was our variable of interest, not 
different types or combinations of negative dromotropic drugs. Furthermore, due to 
the high number of possible combinations of negative dromotropic drugs and dosages, 
this would inappropriately complicate the analysis. 
 To examine changes over time for each quality of life questionnaire 
and subsequent subscale the method of repeated measures was performed. For 
comparison of scores between groups a general linear model and the Student t test 
for independent variables was used. Variables with a non-normal distribution were 
tested with the Mann-Whitney and the Wilcoxon test. Correlation between heart rate 
and quality of life was assessed with Pearson’s correlation. The univariate chi-square 
test and Student t test for independent variables, followed by multivariate stepwise 
logistic regression analyses were performed to determine predictors of relevant 
quality of life change over follow-up. Baseline characteristics, high baseline heart 
rate (>100 beats/min) in combination with a relevant (>20% heart rate reduction), 
occurrence of a primary endpoint and symptoms during the study were univariately 
tested in a logistic regression model. All univariate predictors with p <0.1 were 
tested in a multivariate logistic regression model using a stepwise approach. In the 
multivariate model, a variable was excluded when p ≥0.05. In all analysis a value of 
p <0.05 was considered statistically significant. All analyses were performed on an 
intention to treat basis.
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from baseline to 




 end of study (%)
General Health Lenient 59 (17) 58 (18) 59 (19) 19 16
Strict 58 (18) 59 (18) 58 (19) 16 23
Physical Lenient 70 (22) 69 (23) 65 (25) † 13 24
     functioning Strict 64 (25) 68 (24) † 62 (27) † 17  26
Physical role Lenient 64 (42) 62 (42) 69 (41) 24 24
     limitation Strict 58 (42) 68 (40) † 60 (44) 28 24
Bodily pain Lenient 84 (20) 84 (22) 81 (22)† 14 21
Strict 81 (22) 83 (21) 80 (23) 16 17
Mental Health Lenient 79 (17) 79 (16) 79 (18) 22 18
Strict 81 (15) 81 (14) 81 (14) 18 24
Social Lenient 84 (20) 85 (18) 84 (21) 15 13
     functioning Strict 82 (21) 84 (21) 81 (22) 17 15
Emotional role Lenient 78 (36) 79 (36) 82 (33) 21 17
     limitation Strict 78 (36) 81 (14) 81 (34) 22 13
Vitality Lenient 66 (20) 65 (18) 64 (21) 17 23
Strict 64 (19) 64 (19) 63 (20) 16 19
Table 2. SF-36 scores
† p< 0.05 compared to baseline score
Results
Symptoms of AF during study
At baseline 58% of patients experienced symptoms of AF, being predominantly 
dyspnea, fatigue, and palpitations (Table 1). At end of study 48% of patients 
experienced symptoms of AF, (dyspnea in 139 [32%], fatigue in 110 [25%], and 
palpitations in 49 [11%] patients). There were no differences in symptoms of AF at 
either baseline or at end of study between the lenient and strict group (Figure 1).
Quality of life at baseline
At study entry, SF-36 scales were comparable between the lenient and strict group 
(Table 2). Low SF-36 subscales scores (scores below the mean value minus 1 SD) at 
baseline were associated with the presence of symptoms (all SF-36 subscales), diabetes 
mellitus (subscale general health), and female sex (subscales physical functioning, 
physical role limitation, bodily pain, social functioning, and vitality). 
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At baseline no significant differences between the lenient (6 [interquartile range 
{IQR} 3-11]) and strict (7 [IQR 3-12]) groups existed in AF severity scale. High AF 
severity scale scores (indicating more symptoms of AF) at baseline (scores above the 
mean value + 1 SD) were associated with symptoms of AF and female sex.
 All subscales of the MFI 20 were comparable between both groups at 
baseline (Table 3). High scores (scores above the mean value + 1 SD) on the MFI-20 
subscales, indicating more symptoms of fatigue, were associated with symptoms of 
AF at baseline (general fatigue, physical fatigue, reduced activity, reduced motivation), 
and female sex (physical fatigue and reduced activity). There was also no difference in 
quality of life, in any of the questionnaires used, between patients with a high baseline 
heart rate (>100 beats/min) versus a normal baseline heart rate (data not shown). 






from baseline to 
end of study (%)
Relevant
 worsening 
from baseline to 
end of study (%)
General fatigue Lenient 11±5 11±5 12±5 21 24
Strict 11±5 11±5 12±5 19 22
Physical fatigue Lenient 11±5 11±5 11±5 17 27
Strict 11±5 11±5 12±5 21 25
Reduced Lenient 11±5 10±4 11±4 22 24
     activity Strict 11±5 11±4 11±5 20 26
Reduced Lenient 10±4 9±4 10±4 20 24
     motivation Strict 10±4 9±4 10±4 17 30
Mental fatigue Lenient 8±4 8±4 9±4 16 26
Strict 7±4 8±4 8±4 15 25
Table 3. MFI-20 scores





































Changes in quality of life from baseline to end of study
In the lenient group, no significant differences were found between baseline and 
12 months follow-up in the SF-36. However, at study end the subscales physical 
functioning and bodily pain significantly worsened compared to baseline (Table 2). In 
the strict group, at 12 months of follow-up, physical functioning and role limitations 
due to physical problems improved (Table 2). At 12 months of follow-up and at the end 
of study, no differences were present between the lenient and strict rate control groups 
in any of the SF-36 subscales (Table 2). There were also no significant correlations 
between heart rate at baseline, at the end of the dose-adjustment phase nor end of 
study, and the SF-36 subscales scores of baseline and study end, respectively. There was 
also no relation with heart rate and changes in quality of life. Comparable percentages 
of patients showed a relevant improvement or worsening from baseline to end of study 
in the different subscales. All effect sizes were <0.25, indicating small changes from 
baseline to end of study. 
 There were no significant differences in AF severity scale in either the lenient 
(6 [IQR 3-11]) and strict (6 [IQR 3-11]) group between baseline and end of study. At 
the end of follow-up the AF severity scale was comparable between both groups. At 
baseline and at end of study no correlation was found between heart rate and the AF 
severity scale. The relevant changes in the AF severity scale were comparable in the 
lenient (improvement 22%, worsening 26%) and strict (improvement 26%, worsening 
21%) group. All effect sizes (i.e. measurement of the magnitude of change over time) 
were 0, indicating no changes from baseline to end of study. 
 From baseline to 12 months of follow-up and till study end, there were no 
significant differences in either rate control strategy in any of the MFI subscales. There 
were also no differences between the lenient and strict rate control groups during total 
follow-up (Table 3). The MFI-20 subscales at baseline and end of study were not 
correlated with heart rate at baseline, at the end of the dose-adjustment phase, nor 
at end of study. All effect sizes were below or equal to 0.25, indicating small changes 
from baseline to end of study. 
Determinants of changes in quality of life
We investigated whether rate control strategy, baseline characteristics and follow-up 
parameters were associated with relevant changes in quality of life in each questionnaire, 
and their subscales. The parameters considered in this analysis were underlying disease, 
echocardiographic parameters at baseline, change in left ventricular ejection fraction 
from baseline to end of study, symptoms, heart rate at the end of the dose-adjustment 
phase, relevant heart rate reduction of a high baseline heart rate (>100 beats/min in 
combination with ≥20% reduction from baseline to the end of the dose-adjustment 
phase), occurrence of a primary endpoint and one of the composites of the primary 
endpoint: hospitalization for heart failure, stroke, major bleeding, and arrhythmic 
events. 
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Determinants of change OR (95% CI) P Value
Improvement in SF-36
     General Health No symptom at end of study 1.7 (1.0-3.0) 0.049
     Physical functioning - - -
     Physical role limitation Any symptom at baseline 2.0 (1.2-3.4) 0.013
LVEF per 10% 1.3 (1.0-1.7) 0.021
Septum per mm 0.9 (0.8-1.0) 0.043
     Bodily pain Any symptom at baseline 2.2 (1.2-3.9) 0.010
LVEF per 10% 1.3 (1.0-1.8) 0.032
     Mental health - - -
     Social functioning Any symptom at baseline 2.2 (1.2-4.0) 0.007
Age per 10 year 0.6 (0.4-0.9) 0.007
     Emotional role limitation Any symptom at baseline 2.7 (1.5-4.6) <0.001
     Vitality - - -
Worsening in SF-36
     General Health Any symptom at end of study 2.5 (1.4-4.3) 0.002
    Diabetes mellitus 2.4 (1.0-5.0) 0.041
Septum per mm 1.1 (1.0-1.3) 0.034
     Physical functioning Any symptom at end of study 2.0 (1.2-3.2) 0.007
Age per 10 year 1.7 (1.2-2.5) 0.003
     Physical role limitation Any symptom at end of study 1.9 (1.1-3.1) 0.017
Age per 10 year 1.6 (1.1-2.3) 0.016
     Bodily pain Any symptom at end of study 2.0 (1.2-3.3) 0.007
     Mental health Any symptom at end of study 2.1 (1.2-3.6) 0.011
Female sex 2.3 (1.3-4.2) 0.004
LVEF per 10% 0.7 (0.5-0.9) 0.004
Major bleeding during study 5.0 (1.7-23.7) 0.041
     Social functioning Any symptom at end of study 2.0 (1.1-3.5) 0.023
Previous hospitalization for HF 2.7 (1.1-6.2) 0.025
Arrhythmic event during study* 4.4 (1.2-15.8) 0.024
Beta-blocker use 2.6 (1.4-4.6) 0.002
     Emotional role limitation Any symptom at end of study 1.9 (1.1-3.3) 0.027
Previous hospitalization for HF 2.6 (1.1-5.9) 0.024
     Vitality Any symptom at end of study 2.0 (1.2-3.2) 0.008
Table 4. Patient characteristics associated with a relevant improvement or worsening 
 in SF-36 scores from baseline to end of study, described in odds ratio
* arrhythmic event defined as syncope, sustained ventricular tachycardia, cardiac arrest, life-threatening adverse effects of rate control drugs,          
  and pacemaker or cardioverter-defibrillator implantation.
  LVEF - Left ventricular ejection fraction, HF – Heart failure
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 Symptoms at baseline, absence of symptoms at end of study, higher left 
ventricular ejection fraction, lower age, and a thinner septum were determinants of 
improvement of the SF-36 (Table 4). Worsening of the subscales of the SF-36 were 
associated with the presence of symptoms at end of study, higher age, diabetes mellitus, 
thicker septum, female sex, lower left ventricular ejection fraction, beta-blocker use, 
hospitalization for heart failure, major bleeding and an arrhythmic event during 
the study (Tables 4). 
 Improvements in the AF severity scale were associated with symptoms at 
baseline (OR 4.1, 95% CI 2.2-7.4, p<0.001) and lower age (per 10 year OR 0.7, 95% CI 
0.5-0.9, p= 0.019). Worsening in the AF severity scale were associated with symptoms 
at end of study (OR 3.1, 95% CI 1.8-5.3, p<0.001). Worsening of the subscales of the 
MFI-20 were associated with the presence of symptoms at end of study, higher age, 
diabetes mellitus, thicker septum, female sex and lower left ventricular ejection fraction 
(Tables 5). Improvements and worsening were not associated with heart rate at the 
end of dose-adjustment phase or randomization strategy in any of the questionnaires 
used. Also a relevant heart rate reduction was not associated with improvements or 
worsening of quality of life in any of the questionnaires used. 
Table 5. Patient characteristics associated with a relevant improvement or worsening 
              in MFI-20 from baseline to end of study, described in odds ratio
 
Determinants of change OR (95% CI) P Value
Improvement in MFI-20
     General fatigue - - -
     Physical fatigue - - -
     Reduced activity - 
     Reduced motivation - - -
     Mental fatigue LVEF per 10% 0.8 (0.6-1.0) 0.033
Worsening in MFI-20
     General fatigue Any symptom at end of study 2.5 (1.5-4.2) <0.001
     Age per 10 year 1.4 (1.0-2.0) 0.045
     Physical fatigue Any symptom at end of study 2.2 (1.4-3.7) 0.002
No symptoms at baseline 1.7 (1.0-2.8) 0.036
Age per 10 year 1.6 (1.1-2.3) 0.008
No CAD 3.1 (1.6-6.3) 0.001
     Reduced activity Diabetes mellitus 2.9 (1.3-6.4) 0.008
Septum per mm 1.1 (1.0-1.2) 0.036
     Reduced motivation Age per 10 year 1.7 (1.2-2.4) 0.002
     Mental fatigue Female sex 1.6 (1.0-2.6) 0.039
CAD – Coronary artery disease; CI - confidence interval; LVEF - Left ventricular ejection fraction
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Discussion
The present analysis of the RACE II study suggests that stringency of rate control 
does not affect quality of life during treatment of patients with permanent AF. Of 
note, heart rate was not related to formal quality of life measures, both at inclusion 
and follow-up. In contrast, straightforward clinical AF symptoms did relate to formal 
quality of life measures, both at inclusion as well as during follow-up. However, 
symptoms were not affected by stringency of rate control and therefore, type of rate 
control did not affect quality of life. During follow-up minor changes in quality of life 
occurred, but again, stringency of rate control was not influential. In stead, changes in 
quality of life were related to age, symptoms at baseline and at end of study, severity of 
underlying disease and female sex. 
Quality of life in permanent atrial fibrillation
Compared to healthy subjects quality of life is reduced in patients with AF.2,3 Previous 
studies in patients with AF have shown that quality of life is comparable between 
rhythm and rate control strategies,3,4 although sinus rhythm is associated with an 
improvement in quality of life.3,5,6 There are, however, no prospective studies on the 
effect of stringency of rate control on quality of life. In a post-hoc analysis of AFFIRM 
no significant relation between heart rate and quality of life was found.20 A comparable 
subanalysis in the rate control arm of the first RACE study also showed no relation 
between achieved heart rate and quality of life.21 We also did not observe, in any of the 
questionnaires used in the present analysis, a relation between heart rate and quality 
of life, or rate control strategy and quality of life, not at baseline, nor at study end. In 
contrast, age, symptoms at baseline and at end of study, severity of underlying disease 
and female sex influenced quality of life. 
 Why does heart rate and stringency of heart rate control not affect quality 
of life in AF? One explanation from our data is that permanent AF patients may lack 
typical AF symptoms.22 In our study cohort almost half of the patients did not have AF 
related symptoms and overall patients were not highly symptomatic (see below). The 
lack of significant symptoms obviously limits the impact of rate control with respect to 
improving quality of life, irrespective of strategy. In addition, symptoms may be driven 
by underlying heart disease rather than the arrhythmia itself. This is reflected in the fact 
that dyspnea and fatigue were far more frequent than typical AF related palpitations. 
Finally, controlling rate does not preclude patients from being symptomatic due to 
ventricular irregularity and the latter may not be affected by stringency of rate control. 
In contrast to the above, however, our data do not rule out that strict rate control may 
have a beneficial effect on AF symptoms and quality of life in highly symptomatic AF 
patients, and that, on the other hand, more and higher dosages of rate control drugs 
may have negatively affected quality of life in the strict group. This is illustrated by the 
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association between worsening of social functioning and beta-blocker use, which may 
be caused by more symptoms of fatigue and a reduction in exercise capacity caused by 
beta-blockers.19 
 Patients included in RACE II were not highly symptomatic. About 40% 
of the included patients did not experience symptoms due to AF at all. This is also 
reflected in the scores of the SF-36 and the MFI-20 questionnaire. However, scores 
of both the SF-36 and the MFI-20 were less favourable compared to the general 
population,13,23 but comparable to the scores found in patients with cancer.24 Patients 
with chronic fatigue and patients with moderate heart failure, however, had less 
favourable scores on the MFI-20 questionnaire as compared to our patients.16,25 The 
relatively low symptom burden is also reflected in the scores on the AF severity scale 
in our study. A previous study in patients with highly symptomatic paroxysmal AF 
reported scores as high as 12 on the AF severity scale.17 Patients with permanent 
AF are well known to have less often symptoms as compared to paroxysmal AF.22,26 
Furthermore, the type of symptoms is different between patients with paroxysmal and 
permanent AF. Palpitations are the main complaint in paroxysmal AF, as compared 
to dyspnea in patients with persistent or permanent AF,26 which was also the case 
in our patient group. Notwithstanding the above, presence of symptoms was related 
to quality of life as well as changes in quality of life over time and the latter was 
not affected by stringency of rate control. Obviously, in highly symptomatic patients 
with uncontrolled heart rate well above 110 at rest, rate control would significantly 
affect quality of life. However, our study did not focus on these highly symptomatic 
acute patients in whom some sort of rate control is unavoidable. In stead, we included 
patients with on average 2-3 months of AF with or without rate control drugs 
who - as a matter of daily clinical fact - were relatively stable. The present analysis 
suggests that type of rate control does not matter in terms of improvement 
in quality of life. 
 Gender importantly influenced quality of life. In the general population 
women also showed a lower quality of life.27 In addition, previous AF trials showed 
lower quality of life in women compared to men with persistent AF, 3,28,29 and with 
paroxysmal AF.28 In the Euro Heart Survey on Atrial Fibrillation,30 and in a Canadian 
cohort women also demonstrated to have a lower quality of life.31 It is still unknown 
why women with AF have a lower quality of life. Comparable observations are 
known from women with a previous myocardial infarction.32 Since men are often 
overrepresented in clinical trials, more data on women are clearly warranted.
Limitations
The outcome of this quality of life analysis can not be generalized to all patients with 
AF, since all patients had permanent AF and were not highly  symptomatic. A trial 
evaluating high and low heart rates in AF would ideally bring all patients to the 
relevant heart rate targets. Although the differences in achieved heart rates between 
both groups were smaller than might have been expected, strategies to achieve the 
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heart rate targets were completely different, which may have led to differences in 
quality of life between both groups. Although the quality of life questionnaires we 
used are validated, it remains possible that these questionnaires were too insensitive to 
detect true changes in quality of life.
Conclusion
In patients with permanent AF quality of life are not affected by stringency of rate 
control. In stead, symptoms, female sex, age, severity of underlying disease, and 
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“Cure sometimes, treat often, comfort always.” Hippocrates1
Guidelines for the management of atrial fibrillation (AF) increasingly emphasize 
patient well-being as one of the most important outcomes of successful therapy. 
Unfortunately, no AF therapy has been clearly shown to reduce mortality, and data 
demonstrating a reduction in major morbidity, apart from the clearly understood 
reduction of stroke, are limited.2,3 Practitioners are thus aware that a primary goal of 
AF management is to reduce or mitigate symptoms related to AF and its treatment. 
For most patients, this will involve slowing of the rapid and irregular ventricular rate 
that usually accompanies AF, either as the initial or the exclusive goal of treatment (in 
addition to the crucially important need to assess stroke risk and treat appropriately).
However, patient well-being, often expressed as health related quality of life (QOL), 
is difficult to measure precisely or even describe using commonly understood 
terminology. Components of QOL are by definition subjective, and understanding 
the impact of the AF condition in a particular patient requires the disentanglement 
of those aspects of the illness that are directly or indirectly related to AF from other 
symptoms or difficulties related to coexisting llnesses (e.g., heart failure, pulmonary 
disease), symptoms or mental states associated with other health-related problems, or 
the effect of issues such as physical deconditioning, emotional difficulties, and financial 
problems on health status. Furthermore, an accurate understanding of the impact of 
AF requires that patients be able and willing to accurately articulate the extent to 
which the illness affects their daily life functioning, as well as their assessment of the 
consequences the illness and its treatment have on their individual perceived health 
status. This is a difficult task.
 It is tempting, and seems at first glance reasonable, to use readily available 
and objective measures of cardiac function in patients with AF as a surrogate for 
the assumed impact on QOL. For example, many physicians may assume that a 
rapid and irregular heart rate is undesirable, and implicitly subjectively undesirable, 
compared with a slower, more well-controlled rate. Similarly, it is often assumed 
that sinus rhythm maintenance and restoration ought to be associated with better 
QOL than persisting AF. Groenveld et al.,4 in the current issue of the Journal, have 
contributed importantly to our understanding of the connection between objective, 
electrocardiography-based measures of cardiac function and subjective patient-related 
outcomes. In a substudy of the RACE II (Rate Control Efficacy in Permanent Atrial 
Fibrillation II) study (a randomized trial of “strict” versus “lenient” rate control in 
patients with permanent AF), they have added to the primary observation that “strict 
rate control” (targeting a resting heart rate of <80 beats/min) compared with “lenient 
rate control” (targeting a heart rate of <110 beats/min at rest) does not produce 
meaningful improvement in major morbidity and mortality.5 In this companion study, 
they assessed QOL in 437 of the 614 patients enrolled in the RACE II study, using 
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both generic measures of QOL, such as the Medical Outcomes Study 36-item Short-
Form Health Survey (SF-36), and more disease-related measures, including the AF 
severity scale and the Multidimensional Fatigue Inventory-20, at baseline and during 
long-term follow-up. In short, there were no differences in general or disease-specific 
measures of QOL or symptoms between the strict and lenient rate control groups, 
and no meaningful changes over time in these measures. QOL, as well as changes 
in this factor, was, however, related to age, the severity of underlying heart disease, 
the severity of symptoms, and sex. These results are consistent with observations that 
have been made in both cross-sectional and longitudinal studies of patients with AF 
(population-based cohort studies as well as randomized studies), which have shown 
that the strategy of AF treatment (i.e., rate vs. rhythm control strategy) has limited to 
no impact on QOL, and that the most important determinant of general QOL is the 
degree of symptoms specifically related to AF (e.g., dyspnea, palpitations, fatigue).6,7 
In the FRACTAL (Fibrillation Registry Assessing Costs, Therapies, Adverse Events 
and Lifestyle) cohort study of 963 patients with AF, the presence of AF and the “AF 
burden” was not related to impairment in QOL,8 similar to observations from the 
AFFIRM (Atrial Fibrillation Follow-up Investigation of Rhythm Management) study.7 
There are some limitations to our ability to generalize from the important observations 
of Groenveld et al.4 First, patients in this study had long-standing permanent AF, a 
condition that has been suggested to be less consequential on QOL than paroxysmal or 
persistent AF early in the disease onset. Second, the differences in average ventricular 
rate between the “strict” and the “lenient” groups of patients were relatively modest, 
potentially limiting the ability to perceive potential differences in QOL that may be 
present between heart rates in the normal range (e.g., 60 to 70 beats/min) and heart 
rates near the upper limit of guideline-recommended rates for adequate rate control 
(e.g., 100 to 109 beats/min). Patients in the RACE II trial had impaired QOL, but 
overall SF-36 scores were intermediate between age-standardized normal controls and 
SF-36 scores in patients reported in previous trials of AF, including in the RACE I 
study of rate versus rhythm control published by the same research group.9 The results 
of this trial may thus apply primarily to patients with long-standing and not terribly 
symptomatic AF. 
 However, in support of the generalizability of the results from Groenveld 
et al.,4 previous studies of the relation between heart rate and outcomes have shown 
directionally similar results. For example, there is no relation between heart rate and 
exercise capacity as measured by maximum oxygen consumption in patients with 
AF.10 Other studies have also failed to note a relation between heart rates at rest 
and with exercise,11 or the ventricular rate after treatment,12 and general well-being. 
In a large cohort study of patients with recent-onset AF, baseline heart rate was 
not related to QOL.13 In a study of various therapies to slow ventricular responses 
during exercise, beta-blockers were more effective than calcium-channel blockers at 
limiting maximum exercise heart rate but were not associated with changes in QOL 
or exercise tolerance, whereas calcium-channel blockers tended to improve QOL.11 In 
a summary analysis of multiple small randomized trials of digoxin, beta-blockers, and 
calcium-channel blockers for rate control during exercise in AF, beta-blockers were 
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more effective at slowing peak ventricular response but did not increase or decrease 
maximum exercise tolerance. Calcium-channel blockers, conversely, were less effective 
at heart rate slowing but improved or had no effect on exercise tolerance.14 These 
observations suggest that, at least for betablocker therapy, the potential benefits of 
stricter rate control on exercise capacity and well-being may be offset by adverse effects 
such as fatigue or effort intolerance. The lack of QOL benefit from strict rate control 
in the RACE II study may  in part be due to a potential symptomatic benefit from 
lower heat rates offset by adverse effects resulting from the need for more frequent use 
of beta-blockers, in higher doses, in the strict rate control group compared with the 
lenient rate control group. 
 In contrast to the disconnect between rate and rhythm and QOL, studies 
consistently show that there are individual patient characteristics that tend to 
be associated with poor QOL in AF. The most prominent of these are female sex, 
invariably associated with poorer QOL than in men for the same apparent degree 
of illness burden,8,15,16 the presence of depression or pessimism as a stable personality 
trait,17 and personality traits relating to the response to physical and emotional stressors, 
such as anxiety sensitivity and somatization,18 as well as more obvious factors, such as 
the presence of heart failure and coexisting illnesses, which are associated with poorer 
QOL. Older patients are often less symptomatic than younger patients and tend to 
have a different symptom pattern, with fatigue and dyspnea being more prominent, 
whereas palpitations (an unpleasant awareness of cardiac action) is more prominent in 
younger patients.8,16 
 Treatment of AF by catheter ablation may prove to be an exception to the 
disappointingly small effect of strict rate or rhythm control on QOL. Among patients 
with symptomatic, medically refractory paroxysmal AF, catheter ablation has been 
associated with a marked and sustained improvement of QOL.19 However, these 
results are tempered by a recent study of 323 patients in which the improvement 
of SF-36 QOL indices was unrelated to the ablation outcome itself.20 This finding 
highlights the difficulty in objectively assessing the QOL effect of AF ablation and 
raises the possibility that the QOL benefits of AF ablation may in part be related to a 
placebo effect of the procedure.20 
 What clinical lessons can we draw from the observations of Groenveld et 
al.?4 Most important, it is insufficient to merely examine the electrocardiogram of 
patients in AF to assess the impact of their illness on their well-being. For example, 
a resting ventricular response rate in AF of 100 beats/min does not necessarily imply 
the patient is worse off than if his or her heart rate was 60 beats/min and should not 
necessarily prompt the practitioner to intensify rate control therapy. Because QOL is 
subjective, it has to be assessed subjectively. There is no laboratory test, per se, for QOL. 
Questionnaires used in research studies are valid measures of the seemingly ethereal 
concept but are impractical for routine clinical use. Global bedside estimations of 
QOL have been proposed, including the Canadian Cardiovascular Society’s Severity 
of Atrial Fibrillation scale21 and the European Society of Cardiology’s European Heart 
Rhythm Association scale.2 These are simple-to-use global measures of the impact of 
AF and its treatment on patient well-being. Clinicians need to be aware that patient 
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personality, treatment expectations, and factors unrelated to the arrhythmia itself will 
have important, potentially determining influences on the extent to which AF causes 
suffering. 
 In an era of increasingly sophisticated and complex technologies used to 
investigate and treat atrial fibrillation, it is worth heeding the advice of Hippocrates22: 
“It is far more important to know what person the disease has than what disease the 
person has.”
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Atrial fibrillation (AF) is the most common arrhythmia and associated with an 
increased morbidity and mortality. We investigated differences in all-cause mortality 
and cardiovascular hospitalization between patients with permanent AF treated with 
lenient versus strict rate control.
In the current analysis the primary outcome was a composite of all-cause mortality 
and cardiovascular hospitalization. The outcome events include the first event 
for each patient. Cardiovascular hospitalizations were determined by primary 
diagnosis at discharge. All 614 patients were included in the present analysis, 311 
patients were randomized to lenient rate control (resting heart rate <110 beats per 
minute [bpm]), and 303 to strict rate control (resting heart rate <80 bpm and during 
moderate exercise <110 bpm).
Mean age was 68±8 years, 66% were male and 61% had hypertension. During a 
median follow-up of 2.9 years all-cause mortality and cardiovascular hospitalization 
occurred in 64 of 311 (21.7%) in the lenient group and 67 of 303 (23.5%) patients 
the strict group (p=0.6). All-cause mortality occurred in 17 (5.6%) versus 18 (6.6%) 
in the lenient versus strict group, cardiovascular hospitalization in 57 (21.0%) versus 
57 (22.2%), respectively. There was also no difference in the total number of all-cause 
hospitalization 96 (33.4%) versus 105 (38.2%) in the lenient versus strict group.
There is no difference in all-cause mortality and cardiovascular hospitalization 
between lenient and strict rate control, again in favor of lenient rate control being 
frontline therapy in patients with permanent AF. Hospitalizations are common in this 
frail patient group.
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Introduction
Atrial fibrillation (AF) is the most common arrhythmia, and its prevalence is 
increasing.1 AF is not benign and is associated with a doubled risk of death and an 
increased risk of cardiovascular hospitalizations especially due to stroke, heart failure 
and bleeding.1-4 The latter is caused by the associated co-morbidities as well as the 
arrhythmia itself.5-10 This leads to frequent hospitalizations, in turn being a burden on 
the health care system.11,12 The aim of the current post-hoc analysis was to explore the 
incidence of all-cause mortality and cardiovascular hospitalizations in patients with 
permanent AF included in the RACE II and to assess differences between lenient and 
strict rate control.
Methods
RACE II study design
The study design and results of the RACE II have been published previously.13,14 The 
study was approved by the institutional review boards of all participating centers, and 
all patients gave written informed consent. Eligibility criteria were permanent AF 
for up to 12 months, age of 80 years or younger, mean resting heart rate >80 beats 
per minute, and current use of oral anticoagulation therapy. The rate control targets 
in the strict group were a resting heart rate <80 beats per minute, and a heart rate 
<110 beats per minute during moderate exercise. The rate control target in the lenient 
group was a resting heart rate <110 beats per minute. During the dose-adjustment 
phase, patients were administered one ore more negative dromotropic drugs (i.e., beta-
blockers, nondihydropiridine calcium-channel blockers, and digoxin), used alone or in 
combination and at various doses, until the heart rate targets were achieved. Follow-up 
at the outpatient department occurred every 2 weeks until the heart rate targets were 
achieved. After the dose-adjustment phase follow-up outpatient visits occurred after 
1, 2, and 3 years. Follow-up was terminated after a follow-up period of 3 years or on 
June 30, 2009, whichever came first.13,14 
 The primary outcome in RACE II was a composite of cardiovascular 
death, hospitalization for heart failure, stroke, systemic embolism, major bleeding, or 
arrhythmic events, including syncope, sustained ventricular tachycardia, cardiac arrest, 
life-threatening adverse effects of rate control drugs, and pacemaker or cardioverter-
defibrillator implantation. All reported primary outcome events were adjudicated 
by an independent adjudication committee unaware of the randomized treatment 
assignments.
 A total of 614 patients were included in the RACE II, 303 were randomized 
to strict rate control and 311 to lenient rate control. The primary outcome was reached 
in 81 patients (43 in the strict and 38 patients in the lenient rate control group). 
The cumulative incidence of the primary outcome at 3 years was 14.9% in the strict 
and 12.9% in the lenient rate control group. This confirmed the hypothesis of non-









Age – yr 69±8 67±9 0.1
Male sex – no. (%) 205 (65.9) 198 (65.3) 0.9
Total atrial fibrillation duration (months) 16 (6 – 54) 20 (6 – 64) 0.2
Duration permanent atrial fibrillation (months) 3 (1-6) 2 (1-5) 0.2
Previous electrical cardioversions ≥1 – no. (%) 221 (71.1) 220 (72.6) 0.6
Hypertension – no. (%) 200 (64.3) 175 (57.8) 0.1
Coronary artery disease – no. (%) 67 (21.5) 44 (14.5) 0.024
Valvular heart disease – no. (%) 64 (20.6) 60 (19.8) 0.8
Chronic obstructive pulmonary disease – no. (%) 36 (11.6) 43 (14.2) 0.3
Diabetes mellitus – no. (%) 36 (11.6) 32 (10.6) 0.7
Lone atrial fibrillation* – no. (%) 5 (1.6) 6 (2.0) 0.7
Previous heart failure hospitalization – no. (%) 28 (9.0) 32 (10.6) 0.6
CHADS2 score† – no. (%) 1.4±1.0 1.4±1.2 0.6
     0 or 1 178 (57.2) 195 (64.4) 0.3
     2 94 (30.2) 65 (21.6)
     3-6 39 (12.5) 43 (14.2)
Symptoms – no. (%) 173 (55.6) 175 (57.8) 0.8
     Palpitations 62 (19.9) 83 (27.4) 0.03
     Dyspnea 105 (33.8) 109 (36.0) 0.5
     Fatigue 86 (27.7) 97 (32.0) 0.2
Body mass index – kg/m2 29±5 29±5 0.8
Blood pressure – mmHg
     Systolic 137±19 135±16 0.2
     Diastolic 85±11 82±11 0.003
Heart rate in rest –  beats per minute 96±14 96±12 0.5
New York Heart Association functional class 
     I – no. (%) 206 (66.2) 194 (64.0) 0.6
     II – no. (%) 89 (28.7) 96 (31.7)
     III – no. (%) 16 (5.1) 13 (4.3)
Table 1. Baseline characteristics
*   Lone atrial fibrillation was defined as AF in the absence of cardiovascular disease and extracardiac precipitating causes of AF.
†  The CHADS2 score is a measure of the risk of stroke in which congestive heart failure, hypertension, an age of 75 years or older, and 
    diabetes are each assigned 1 point and previous stroke or transient ischemic attack is assigned 2 points; the score is calculated by    
    summing al the points for a given
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Rate control medications in use – no. (%)
     No rate control drugs 36 (11.6) 27 (8.9) 0.3
     Beta-blocker alone 140 (45.0) 136 (44.9) 0.9
     Verapamil/diltiazem alone 18 (5.8) 19 (6.3) 0.8
     Digoxin alone 20 (6.4) 24 (7.9) 0.5
     Beta-blocker + verapamil/diltiazem 7 (2.3) 11 (3.6) 0.3
     Beta-blocker +  digoxin 53 (17.0) 49 (16.2) 0.7
     Verapamil/diltiazem + digoxin 14 (4.5) 14 (4.6) 0.9
     Beta-blocker + verapamil/diltiazem + digoxin 2 (0.6) 5 (1.7) 0.2
     Sotalol 18 (5.8) 13 (4.3) 0.4
     Amiodarone 3 (1.0) 5 (1.7) 0.5
Other medications in use at baseline – no. (%)
     ARB or ACE inhibitor 166 (53.4) 140 (46.2) 0.1
     Diuretic 134 (43.1) 113 (37.3) 0.1
     Statin‡ 103 (33.1) 74 (24.4) 0.017
     Vitamin K antagonist 308 (99.0) 298 (98.3) 0.5
     Aspirin 4 (1.3) 6 (2.0) 0.5
Echocardiographic parameters – mm
     Left atrial size, long axis 46±6 46±7 0.5
     Left ventricular end-diastolic diameter 51±7 51±8 0.7
     Left ventricular end-systolic diameter 36±8 36±9 0.9
     Left ventricular ejection fraction –  % 52±11 52±12 0.4
          ≤ 40% – no. (%) 45 (14.5) 48 (15.8) 0.5
ACE denotes angiotensin-converting enzyme inhibitor and ARB angiontensin-receptor blocker
‡ Statins are defined here as 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors
Design of the current analysis
For the current analysis the primary outcome was a composite of all-cause mortality 
and cardiovascular hospitalizations. All hospitalizations and possible endpoints 
were (prospectively) reported to the Trial Coordination Center (University medical 
Center Groningen, the Netherlands) during the study and were adjudicated by an 
independent adjudication committee. Cardiovascular hospitalization was determined 
by study personnel by considering the primary diagnosis when reviewing the medical 
records of all hospitalizations during the study. Secondary outcome were all-cause 
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hospitalizations and major and minor bleedings requiring hospitalization. A hospital 
admissions required ≥1 overnight stay to be accounted for a hospitalization. The 
outcome events included the first event for each patient. All patients included in 
RACE II were included in the present study.








No. of patients (%)        (95% CI)
Composite outcome 64 (21.7) 67 (23.5) 0.91 (0.65-1.28)
     All-cause mortality 17 (5.6) 18 (6.6) 0.91 (0.47-1.77)
     Death from cardiovascular cause 9 (2.9) 11 (3.9) 0.79 (0.33-1.91)
          Cardiac arrhythmic death 3 (1.0) 4 (1.4)
          Cardiac nonarrhythmic death 1 (0.3) 2 (0.8)
          Noncardiac vascular death 5 (1.7) 5 (1.9)
     Non cardiac, non vascular death 8 (2.7) 7 (2.8) 1.11 (0.40-3.06)
          Cancer 3 (1.0) 4 (1.4)
          Fatal infection 4 (1.3) 3 (1.0)
          Other 1 (0.3) 0
Cardiovascular hospitalization 57 (21.0) 57 (22.2) 0.95 (0.66-1.37)
     Heart failure 11 (3.8) 11 (4.1) 0.97 (0.42-2.24)
     Cardiac surgery 5 (1.6) 2 (0.7)
     Stroke, TIA or systemic embolism 5 (1.9) 13 (4.7) 0.37 (0.13-1.04)
     Severe bleeding 15 (5.3) 13 (4.5) 1.12 (0.53-2.34)
     Minor bleeding requiring hospitalization 2 (0.7) 3 (1.0)
     Arrhythmic event† 16 (5.6) 16 (5.8) 0.96 (0.48-1.92)
     ACS or elective PCI 5 (1.6) 2 (0.7)
     Atypical symptoms‡ 6 (1.9) 6 (2.0)
     AF related hospitalization# 5 (1.6) 1 (0.3)
ACS - acute coronary syndorme; CI - confidecnce interval; PCI - percutaneous coronary intervention; TIA - transient ischemic attack
*  The composite primary outcome include the first event for each patient. In contrast, the tabulation of component events include all such events. 
   The cumulative incidences were determined with the use of Kaplan-Meier analysis.
† Syncope, life threatening adverse effects rate control drugs, sustained ventricular tachycardia or ventricular fibrillation, pacemaker implantation, 
   implantable cardioverter defibrillation implantation (primary or secondary prevention), non life threatening adverse event of rate control drugs 
   drugs, reveal implantation
‡ Hospitalization for chest pain without ACS, hospitalization for collapse without trauma 
# Electrical cardioversion, pulmonary vein isolation, change in rate control drugs
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Statistical analysis
Baseline descriptive statistics are presented as mean ± standard deviation (SD) or 
median (range) for continuous variables and counts with percentages for categorical 
variables. Differences between groups, in terms of patient characteristics, were 
evaluated by Chi-square test or McNemar’s test, depending on normality and type 
of the data. Kaplan-Meier analysis was performed to assess differences in outcome 




In total 614 patients were included in the current study, 311 patients were randomized 
to lenient rate control and 303 to strict rate control (Table 1). Median follow up was 
3.0 (interquartile range 2.4-3.0) years. Clinical characteristics were almost comparable 
between the groups, with the exception of coronary artery disease, statin use and a 
slightly higher diastolic blood pressure in the lenient group.
Primary outcome
The primary outcome of all-cause mortality and cardiovascular hospitalization was 
reached in a total of 131 patients (64 of 311 in the lenient and 67 of 303 in the 
strict group) in the present study (Table 2). In Figure 1 the Kaplan-Meier curves 
for the primary outcome are shown, according to lenient and strict rate control. The 
cumulative incidence of the primary outcome was 21.7% in the lenient and 23.5% in 
the strict group (p=0.6). 












Strict control        303                   279                   266                   251                   236                   199                   117







 In the lenient group 17 patients (5.6%) died during follow-up, as compared 
to 18 (6.6%) in the strict group (p=0.8). Cardiovascular hospitalization occurred in 
57 (21.0%) patients in the lenient group, and in 57 (22.2%) patients in the strict 
group (Figure 2, p=0.8). Cardiovascular hospitalizations were predominantly caused 
by hospitalizations for heart failure, stroke, bleeding and arrhythmic events. AF 
related hospitalizations occurred seldom. There were no differences between both 
randomization groups. Non-cardiovascular death was mostly due to a malignancy or 
infection (Table 2). 
A total of 201 patients were hospitalized during the study. First hospitalization 
occurred in 96 (33.4%) in the lenient, and 105 (38.2%) in the strict group (p=0.3). 
In the lenient group 60 (22.7%) patients were hospitalized for non-cardiovascular 
reasons, and 66 (26.6%) patients in the strict group (Figure 3, p=0.4). 
 In total 32 bleedings occurred during the study, 28 major and 5 minor 
bleedings were reported. There was no difference between the 2 randomization 
strategies in the occurrence of bleedings (Table 3). There was also no difference 
in life threatening or gastrointestinal bleedings between the randomization 
strategies (Table 4). 
























Strict control            303                   279                    266                   251                   236                   199                   117
Lenient control        311                   290                    279                   272                   245                   207                   126
All-cause mortality
Strict control            303                   297                    294                   287                  275                   240                    146
Lenient control        311                   305                    304                   303                  278                   245                    175
Figure 2. All-cause mortality and cardiovascular hospitalization according to lenient 
                and strict rate control








No. of patients (%)         (95% CI)
All Hospitalizations* 96 (33.4) 105 (38.2) 0.86 (0.65-1.14)
     Cardiovascular# 57 (21.0) 57 (22.2) 0.95 (0.66-1.37)
     Non-cardiovascular# 60 (22.7) 66 (26.6) 0.86 (0.60-1.21)
          Surgery 39 (14.4) 40 (17.4)
          Orthopedic 9 (2.9) 11 (3.6)
          Cancer 7 (2.3) 9 (3.0)
          Other surgery 23 (7.4) 20 (6.6)
     Infection 22 (7.1) 24 (7.9)
          Pneumonia 13 (4.2) 12 (4.0)
          Other infection 9 (2.9) 12 (4.0)
     Other 4 (1.6) 4 (1.5)
Table 3. All hospitalizations during study
* First event for each patient
# All hospitalizations during study with ≥1 overnight stay 
CI - confidence interval
Figure 3. All-cause hospitalization and cardiovascular hospitalization according to 













Strict control            303                   278                   256                  228                   207                   168                    89
Lenient control        311                   282                   265                  253                   221                   180                   104
Cardiovascular hospitalization
Strict control            303                  279                    266                  251                   236                   199                   117




















No. of patients (%)         (95% CI)
Major bleeding 15 (5.3) 13 (4.5) 1.12 (0.53-2.34)
     Life threatening 1 (0.3) 4 (1.5)
     Non-life threatening 14 (5.0) 9 (3.1)
     Gastrointestinal* 4 (1.6) 4 (1.5)
     Post surgery 5 (1.6) 1 (0.3)
Minor bleeding 2 (0.7) 3 (1.0)
Major or minor bleeding 16 (5.6) 16 (5.6) 0.96 (0.48-1.93)
Intracranial 0 3 (1.0)
Extracranial 15 (5.3) 10 (3.5)
* gastrointestinal bleedings could be life threatening and non-life threatening
Table 4. Bleedings during study
The present analysis of RACE II showed no difference in all-cause mortality and 
cardiovascular hospitalization between lenient and strict rate control in patients with 
permanent AF. In addition, no differences in all-cause hospitalizations were observed. 
Of note, hospitalizations occurred frequently in this group of AF patients.
 We observed 22% cardiovascular hospitalizations during the study. In the 
Euro Heart survey cardiovascular hospitalization was higher (35%). However, AF 
related hospitalizations (17%) were very frequent, also in the patients with permanent 
AF.6 A post hoc analysis of AFFIRM also showed a higher incidence of cardiovascular 
hospitalization, however, when excluding hospitalizations related to treatment strategy 
(rhythm or rate control) the hospitalization rate dropped. In addition, follow-up was 
longer in AFFIRM as compared to the present study.15 Hospitalization rate in the 
Atrial Fibrillation and Congestive Heart Failure (AF-CHF) was around 60% as 
compared to 22% in the current study. This large difference may be explained by the 
relative low number of patients with heart failure in our cohort. In addition, 30% 
of patients had paroxysmal AF in the AF-CHF, as compared to 100% permanent 
AF in the present study. Patients with paroxysmal AF are more often hospitalized 
as compared to patients with permanent AF.6 In addition, in the present cohort of 
patients with permanent AF, cardiovascular hospitalization was mainly for heart 
failure, stroke and bleeding. Patients with paroxysmal or persistent AF are more 
frequently hospitalized for AF interventions.6 
Discussion
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 AF related hospitalizations were not common in our patient group. 
Considering this, the arrhythmia was recently accepted, i.e. had become permanent. 
This may imply that acceptance of AF creates a more stable situation with less AF 
related hospitalization. A post-hoc analysis of the AF-CHF and Atrial Fibrillation 
Follow-up Investigation of Rhythm Management (AFFIRM) showed that patients 
treated with a rate control strategy were less often hospitalized as compared to patients 
treated with a rhythm control strategy.15,16 The same was observed in the AF-CHF 
study.16 This may also explain the relative low cardiovascular hospitalization rate in our 
cohort. 
 Why was there no difference in all-cause mortality and cardiovascular 
hospitalization between lenient and strict rate control? First, mortality in patients with 
AF is determined by underlying disease rather than heart rate.7,17-19 Post-hoc analyses 
of both AFFIRM and the Rate Control versus Electrical cardioversion for persistent 
atrial fibrillation (RACE) showed no difference in outcome between patients with 
a higher or lower heart rate.17,18 A pooled analysis of these trials confirmed these 
findings.19 
 Second, the cardiovascular hospitalizations in RACE II are largely determined 
by bleedings, strokes and heart failure.14 Development of heart failure was one of the 
main concerns of lenient rate control. Our results show that a heart rate below 110 
beats per minute was low enough to prevent overt heart failure. This is in line with 
previous studies on heart failure and beta-blocker, which show no survival benefit of 
beta-blockers in patients with AF.20-22 Due to the loss of atrial kick and ventricular 
frequency, patients with AF and heart failure may require a higher heart rate.23 
 It should be noted that in the present patient cohort one in every three 
patients is hospitalized for a serious cardiovascular or non-cardiovascular event. This 
indicates that co-morbidities are prevalent in patients with permanent AF. In addition, 
most hospitalizations for non-cardiovascular reasons were for surgery or infection. 
Due to the prevalent use of oral anticoagulation this is a critical moment in patients 
with AF. Temporarily cessation of oral anticoagulation or drug interactions, risk of 
bleeding and stroke may be elevated. Furthermore, the majority of non-cardiovascular 
death is attributable to cancer and infections. Regarding the above, this should remind 
us that AF patients are a high risk group. 
 How does the current study add to the main results of RACE II? The 
non-inferiority of lenient rate control to strict rate control was groundbreaking.14,24 
However, a composite primary outcome was used. The current study shows no 
difference in all-cause mortality, the most firm outcome parameter. In addition, there 
was no difference in cardiovascular hospitalization. Previous studies have shown that 
cardiovascular hospitalization is a useful surrogate outcome for mortality in patients 
with AF.15,25,26 Therefore, the present data strengthen the rationale for a lenient rate 
control in patients with permanent AF. 
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Limitations
The RACE II was not designed to assess differences in all-cause mortality and 
cardiovascular hospitalizations between lenient and strict rate control. In addition, 
there was no pre-defined definition of cardiovascular hospitalization.15,25,26
Conclusion
Patients with permanent AF are frequently hospitalized for cardiovascular and non-
cardiovascular events. There is no difference in the occurrence of cardiovascular 
hospitalization and mortality between patients with permanent AF randomized to 
lenient or strict rate control. Since strict rate control does not improve prognosis, 
lenient rate control should be used as frontline rate control strategy. 
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The aim of this thesis was to evaluate the effect of lenient and strict rate control on 
cardiovascular morbidity, mortality and quality of life in patients with permanent atrial 
fibrillation (AF). The rate versus rhythm control trials established the non-inferiority 
of rate control compared to rhythm control. Therefore, rate control is adopted as a 
frontline therapy in older patients without severe AF associated symptoms. However, 
the optimal level of heart rate control was unknown. The guidelines advised a more 
strict rate control approach, but this was not evidence based.1 The strict rate control 
approach was recommended to reduce symptoms, improve quality of life and exercise 
tolerance, reduce heart failure, and improve survival.1 On the other hand, strict rate 
control may induce more drug-related adverse effects, including bradycardia, syncope, 
and a need for pacemaker implantation. Therefore, the benefit and risk balance in 
terms of cardiovascular morbidity and mortality remained unclear. 
 In order to investigate the optimal heart rate during permanent AF, first, we 
performed a retrospective analysis of patients with permanent AF. The study cohort 
comprised all patients in the RACE trial randomized to rate control. The heart rate 
criterion in RACE for adequate rate control was a resting heart rate <100 beats per 
minute. There was no difference in outcome between patients with a mean resting 
heart rate <80 beats per minute versus ≥80 beats per minute (chapter 2). We then 
showed, in The Rate Control Efficacy in Permanent Atrial Fibrillation: a comparison 
between Lenient versus Strict Rate Control II (RACE II), a prospective, randomized, 
open label, clinical trial, the non-inferiority of lenient compared to strict rate control 
regarding cardiovascular morbidity and mortality (chapter 3). The difficulty to achieve 
strict rate control could have influenced the outcome of the RACE II, in favor of 
lenient rate control. Previous trials investigating strict rate control showed that about 
two-thirds of patients achieve the strict rate control criteria.2 Adequate rate control 
was achieved in 67% of patients randomized to strict rate control in RACE II. 
Notably, there was no difference in outcome between patients with successful strict, 
failed strict, and lenient rate control. Also of importance, there was no difference in 
quality of life between the groups (chapter 4). Considering the equality in the primary 
outcome of the RACE II, patient welfare is important when instituting rate control. 
Therefore, the absence of differences in quality of life between lenient and strict rate 
control is of major importance (chapter 5). In an additional post-hoc analysis of the 
RACE II study we observed no differences in all-cause mortality and cardiovascular 
hospitalizations between lenient and strict rate control (chapter 6). 
Rate Control in Atrial Fibrillation
The first report on AF has been written more than 100 years ago. Already at that 
time AF was a common condition in hospitalized patients.3 In the beginning of the 
20th century, treatment of AF consisted of rhythm control with quinidine and control 
of the ventricular rate with digoxin.4,5 It was not until the 1960’s that the electrical 
cardioversion was introduced.6 However, electrical cardioversion was not always 
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successful.7,8 Furthermore, conversion to sinus rhythm was often not permanent.6 
Only 30% of patients remained in sinus rhythm, regardless of serial cardioversions 
and antiarrhythmic drugs.9 
 During AF several hemodynamic changes occur which lead to symptoms 
of the patient. The atrial contribution to the total stroke volume is about 20-40%. 
This is absent during AF. Furthermore, the irregular ventricular rhythm during AF 
reduces the cardiac output, irrespective of heart rate.10 These two factors may lead to 
a significant reduction in cardiac output. The reduction in cardiac output may be even 
more evident in patients with a reduced left ventricular ejection fraction or impaired 
diastolic function.1 Since one of the key risk factors for AF is hypertension,11,12 and 
hypertensive patients often have an impaired diastolic function,13 this is of importance 
in patients with AF. Thus to maintain a comparable cardiac output, the heart rate may 
have to be higher during AF than during sinus rhythm.14 
 Rate control is the cornerstone of the treatment of AF. The current prevalence 
of AF in the Netherlands is 5.5%.15 It is expected that this will double in the next 
30 to 50 years.16,17 Therefore, to be able to keep the treatment of patients with AF 
manageable a rate control strategy is indispensable. The indifference between rate and 
rhythm control in terms of cardiovascular morbidity, mortality and quality of life was 
shown by the Pharmacological Intervention in Atrial Fibrillation (PIAF), the Atrial 
Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM), the Rate 
Control versus Electrical Cardioversion for Persistent Atrial Fibrillation (RACE), 
the Strategies of Treatment of Atrial Fibrillation (STAF), the How to Treat Chronic 
Atrial Fibrillation (HOT CAFE), and the Japanese Rhythm Management Trials for 
Atrial Fibrillation ( JRhythm).18-25 After these trials, rate control had become therapy 
of choice in older patients without severe symptoms. There were, however, some 
differences in rate control strategies used in the trials which investigated the outcomes 
between rate and rhythm control. Therefore, the optimal level of rate control was still 
unknown.26 In addition, there were no prospective data on rate control and outcome 
in permanent AF. 
Institution of Rate Control in Atrial Fibrillation
The ventricular rate during AF is determined by the conduction characteristics of 
the atrioventricular node, and activity of the sympathetic and parasympathetic tonus. 
Negative dromotropic drugs can be used to lower the ventricular rate during AF. Three 
types of drugs are commonly used: beta-blockers, nondihydropyridine calcium-channel 
blockers, and digoxin. They can be used alone or in combination with each other. 
Beta-blockers reduce the ventricular frequency due to blockade of the sympathetic 
activity (ß1-receptor) in the atrioventricular node. Nondihydropyridine calcium-
channel blockers slow the atrioventricular node by increasing the refractory period 
of the atrioventricular node due to blockade of calcium channels. Digoxin exhibits 
its function through increase of the parasympathetic tonus, and thereby reducing the 
atrioventricular conductance. Therefore, digoxin is not the most appropriate drug in 
patients with a high sympathetic drive i.e., physically active or critically ill patients. 
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Common side effects of beta-blockers include cold extremities, bronchoconstriction, 
impotence, and fatigue. The first two comprise relative contraindications for beta-
blocker use in patients with peripheral vascular disease and pulmonary disease, 
respectively. Constipation is one major side effect associated with the use of 
nondihydropyridine calcium-channel blockers, and therefore this drug is not suitable 
for patients with constipation. In addition, peripheral edema is also a major side effect 
of nondihydropyridine calcium-channel blockers. Digoxin is a reasonable drug for 
older patients who are physically inactive. Sotalol, a beta-blocker with additional 
class III anti-arrhythmic effects, can also be used as a rate control drug.27,28 However, 
the additional class III effects induce QT-prolongation and may cause life threatening 
arrhythmias, i.e. torsades de pointes. Therefore, sotalol is not recommended for 
















































Figure 1. Hemodynamic changes during AF, adapted from Resnekov and colleagues,44 
                with permission from Heart BMJ group
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However, dronedarone may increase the risk of stroke, heart failure, and cardiovascular 
death in patients with permanent AF and major risk factors for cardiovascular events. 
Therefore, dronedarone is contraindicated for rate control.34 Amiodarone is another 
alternative to reduce heart rate.35 However, due to its extensive (non cardiac) adverse 
effects it remains restricted to a small subset of patients,36-38 i.e. critically ill patients 
and those with (acute) heart failure in whom beta-blockers and digoxin are insufficient 
to reduce the heart rate adequately.39 As last resort therapy pacemaker implantation 
in combination with atrioventricular node ablation can be performed in patients in 
whom the heart rate cannot be reduced with drugs or in whom drugs induce severe 
adverse effects necessitating discontinuation.40 However, right ventricular pacing 
can induce heart failure.41,42 Cardiac resynchronization therapy may therefore be the 
pacing mode of choice after atrioventricular node ablation.43 
 What is the optimal heart rate during AF? The previous guidelines 
recommended a resting heart rate between 60 and 80 beats per minute, and between 90 
and 115 beats per minute during moderate exercise.1 However, these recommendations 
were not based on prospective randomized trials investigating different rate control 
strategies. On the contrary, they were based on two small scale studies. The first study 
was performed in 60 patients with AF, and conclusions were based on a mathematical 
model on flow velocity in the ascending aorta and resting heart rate.14 In each individual 
patient the ventricular rate was calculated for the maximal cardiac output. In the entire 
group the maximal cardiac output was achieved at a mean heart rate of 122 beats per 
minute. In 16 patients the resting heart rate was higher than the calculated heart rate 
for maximum cardiac output. All these patients had a resting heart rate above 90 
beats per minute. The second study on the basis of which former guidelines advocated 
a strict rate control strategy assessed hemodynamic parameters in 6 patients before 
and after electrical cardioversion.44 The investigators observed a higher heart rate 
(Figure 1A), and lower cardiac output (Figure 1B) and stroke volume (Figure 1C) 
when the patients were in AF. The beneficial effect of sinus rhythm was well illustrated 
when stroke volume was plotted against heart rate (Figure 1D). The investigators 
concluded that a hemodynamic disadvantage was present during AF. These data, 
however, do not imply that patients in AF should have a heart rate comparable to 
patients in sinus rhythm. In contrast, it is possible that during AF patients may benefit 
from higher heart rates than during sinus rhythm. This is illustrated in Figure 1B. 
Despite the presence of AF, cardiac output is comparable; the loss in stroke volume 
during AF is compensated by an increase in heart rate.
Success of Rate Control Drugs
As stated in the previous guidelines, it was a therapeutic goal to reduce the heart rate 
during AF to a level comparable to the heart rate during sinus rhythm.1 Therefore, from 
the 1970’s, throughout the first decade of the 21st century, studies were performed 
evaluating negative dromotropic drugs in patients with AF (Table 1).28,33,45-55,55-58,58-83 
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However, the numerous trials do not represent a homogeneous patient group. For 
instance, Joglar and colleagues performed an analysis of the effect of carvedilol in 
patients with AF and a left ventricular ejection fraction <35%. In contrast, Farshi 
and colleagues included only patients with AF and a left ventricular ejection fraction 
>35%. Furthermore, the outcome parameters used in the studies were not always 
comparable. Some of the trials used resting heart rate,45,48 others used the mean heart 
rate during 24 hour Holter monitoring.33,50 In addition, follow-up duration differed 
from 1 day to 6 months. Despite a reduction of heart rate, rate control strategies 
do not banish the negative effects of AF, i.e. the loss of atrial kick and ventricular 
irregularity.10 Furthermore, it remained uncertain which rate control drug was the 
most effective. It also remained unclear which patient has the largest advantage of 
which drug. Farshi and colleagues performed a comparison of 5 drug regiments 
on the mean 24-hour heart-rates, circadian patterns, and ventricular response on 
exercise in 12 patients with permanent AF.50 The drug regiments consisted of digoxin, 
diltiazem, atenolol, digoxin and diltiazem, and digoxin and atenolol. The most 
effective treatment, i.e. treatment with the lowest heart rate, was the combination of 
atenolol and digoxin, reflecting the combined effect of these negative dromotropic 
drugs on the atrioventricular node. However, the dose of atenolol was not very 
high (50 mg/day). It is possible that a dose of 100 mg atenolol per day is more effective 
than the regiments used in the study of Farshi and colleagues. The efficacy of rate 
control drugs was also evaluated in AFFIRM trial.2 The rate control criteria used in 
AFFIRM were a resting heart rate ≤80 beats per minute, and ≤110 beats per minute 
during moderate exercise. In addition, on Holter a mean HR ≤100 beats per minute, 
and not >110% of the maximum predicted heart rate.84 In this post-hoc analysis of the 
AFFIRM all patients randomized to the rate control group were included. The data of 
2027 patients were evaluated. In 58% of patients adequate rate control was achieved 
with the first drug or combination of drugs. A change or addition was required in 
37% of patients, 23% switched from calcium-channel blockers to beta-blockers, 19% 
changed from beta-blockers to calcium-channel blockers, and 34% started either a 
beta-blocker or calcium-channel blocker, when they were already using digoxin. In the 
RACE II study only 25% of patients used ≥2 rate control drugs at baseline (Figure 2). 
After the dose adjustment phase 35% of patients required ≥2 more rate control drugs 
in the lenient group, as compared to 68% in the strict rate control group (chapter 3). 
The AFFIRM investigators concluded from their analysis that beta-blockers were 
most effective in controlling heart rate. There were, however, frequent medication 
changes necessary to achieve the strict rate control criteria as defined in the AFFIRM 
trial (Figure 3). Eventually the rate control criteria were achieved in 68% of patients. 
It is important to consider that in AFFIRM also patients with paroxysmal AF were 
included. This means that not all patients were in AF during the complete follow-up 
period. At baseline, 48% of the patients were in AF; this was 42, 44, and 51% at 1, 
3 and 5 years follow-up, respectively.2 In RACE II, however, over 90% of patients 
were in AF during follow-up (Figure 4). In RACE II, 67% of patients randomized to 
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Study Design Drugs Number 
of patients
Type of AF 
Patients
Beta-blocker versus placebo






Atwood, 199947 Randomized crossover 
study
Betaxolol vs. placebo 12 Permanent 
AF
Joglar, 200148 Randomized placebo 
controlled, double blind 
retrospective analysis
Carvedilol vs. placebo 136 AF and 
heart failure
Kochiadakis, 200129 Randomized, crossover, 
single blind









Khalsa, 197860 † Open label clinical trial Digoxin + metoprolol 




David, 197962 Open label crossover 
study




DiBianco, 198463 Randomized double-blind 
crossover study 




Atwood, 198764 † Randomized double-blind 
crossover study




Ang, 199065 Randomized crossover 
study 
Digoxin vs. xamoterol 13 Permanent 
AF
Channer, 199466 Randomized single blind 
cross over study
Digoxin + atenolol vs. 
digoxin + pindolol 
8 Permanent 
AF
Lawson, 199567 † Randomized double blind 
crossover study
Xamoterol vs. 




Lanas, 199549 Randomized double blind 
crossover study
Digoxin versus atenolol 13 Permanent 
AF
Koh, 199558 Randomized, cross over Control vs. betaxolol + 




Table 1. Heart rate control assessment with negative dromotropic drugs
AF= atrial fibrillation; LVEF = left ventricular ejection fraction; NYHA= New York Heart Association.
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Follow-up Endpoint Results - Heart rate Results - Exercise time 
or LVEF
2 weeks Resting HR, exercise HR HR decreased with both No improvement of 
exercise capacity
n.a. HR rest and exercise; 
exercise capacity
Reduction of HR at rest and 
during exercise
Maximal oxygen uptake 
reduced with betaxolol
6 months LVEF NA LVEF improved with 
carvedilol
4 weeks Mean HR; HR during 
exercise
Both lower mean HR compared 
to placebo; sotalol reduced HR 
more during moderate exercise
NA
2 - hours Resting HR, exercise HR Resting and exercise HR was 
lower with digoxin + practolol
NA
NA Resting HR, exercise HR Resting and exercise HR was 




Resting HR, exercise HR Resting and exercise HR lower 
with digoxin + timolol
NA
8 weeks Resting HR, exercise HR Resting and exercise HR was 
lower with digoxin + nadolol
No increase in exercise 
capacity
NA Resting HR, exercise HR Lower resting and exercise HR Celiprolol reduces 
exercise capacity
2 weeks Resting HR, exercise HR Resting HR lower with 
digoxin, exercise HR lower with 
xametorol
No differences in 
exercise time were 
observed
2 weeks Minimum and maximum 
HR
Digoxin + pindolol increases 
nocturnal HR, digoxin + atenolol 
decreases the nocturnal HR
NA





2 weeks Resting HR; exercise HR 
exercise capacity; symptoms
Resting HR similar; HR at 
maximal exercise lower
Exercise time longer 
with atenolol
4 weeks Resting HR; HR during 
exercise; exercise capacity
Resting HR more reduced with 
betaxolol
Exercise capacity 
improved in both 
compared to control
AF= atrial fibrillation; HR= heart rate; LVEF = left ventricular ejection fraction; 6 MWT= 6 min walking test
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Study Design Drugs Number of 
patients
Type of AF 
Patients
Farshi, 199950 Randomized cross over Digoxin vs. diltiazem 
vs. atenolol vs. digoxin 






Khand, 200351 Randomized, controlled, 
double blind
Digoxin vs. digoxin + 
carvedilol
47 AF> 1 
month
LVEF <40% 
Calcium channel blocker versus placebo
Lewis, 198767 † Open label cross over Verapamil 12 Permanent 
AF
Lewis, 198858 † Open label cross over Digoxin vs. verapamil 




Atwood, 198853 Open label clinical trial Diltiazem vs. control 9 Permanent 
AF






Calcium channel blocker versus digoxin




Waxman, 198169 † Randomized double-
blind crossover study 




Stern, 198270 Randomized double-
blind crossover study 




Panidis, 198371 Randomized double-
blind crossover study 




Lang, 198355 Open label cross over 
study
Verapamil vs. digoxin 52 Permanent 
AF
Lang, 198355 Double-blind crossover 
study




Roth, 198673 Open label clinical trial Digoxin vs. diltiazem 
vs. digoxin + diltiazem
12 Permanent 
AF
Myers, 198774 Randomized double-
blind study 
Digoxin vs. digoxin + 




Table 1. Heart rate control assessment with negative dromotropic drugs (continued)
AF= atrial fibrillation; LVEF = left ventricular ejection fraction; NYHA= New York Heart Association.
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Follow-up Endpoint Results - Heart rate Results - Exercise time 
or LVEF
2 weeks Mean HR;
HR during exercise
Digoxin + atenolol most effective 







mean HR and submaximal 
exercise; improved symptoms
Improved LVEF; 6 
MWT unaltered and 
not different
6 weeks Exercise HR Exercise HR lower with 
verapamil treatment
No improvement of 
exercise capacity
1 day Resting HR; 
HR during exercise; exercise 
tolerance; cardiac output
Best reduction exercise HR by 
digoxin + diltiazem
No difference in exercise 
capacity or cardiac 
output
1 week Resting HR; exercise HR;
Exercise capacity
Diltiazem reduced resting HR 
and exercise HR.




Verapamil and diltiazem 
decreased HR
Modest improvement of 
exercise tolerance
NA Resting HR, exercise HR Digoxin and verapamil reduce 
HR response during exercise
NA
NA Resting HR Resting HR is lower with 
digoxin + verapamil
NA
2 weeks Resting HR, exercise HR Resting and peak exercise 
HR was lower with digoxin + 
verapamil
NA
2 weeks Resting HR, exercise HR Resting and exercise HR lower 
with digoxin +verapamil
NA
4 months Exercise HR Verapamil reduced resting HR 
and HR during execise 
Verapamil increased 
exercise capacity
4 weeks Resting HR, exercise HR Resting and peak exercise 
HR was lower with digoxin + 
verapamil
NA
4 weeks Resting HR, exercise HR Resting and exercise HR was 
lower with digoxin + diltiazem
NA
4 weeks Resting HR, exercise HR
exercise capacity
Lower resting and exercise HR 
with digoxin + celiprolol or + 
diltiazem
Digoxin + celiprolol 
reduced VO2 at 
maximum exercise
HR= heart rate; LVEF = left ventricular ejection fraction; 6 MWT= 6 min walking test
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Table 1. Heart rate control assessment with negative dromotropic drugs (continued)
Study Design Drugs Number of 
patients
Type of AF 
Patients








Maragno, 198876 Open label clinical trial Digoxin vs. diltiazem 
vs. digoxin + diltiazem
19 Permanent 
AF
Pomfret, 198877 † Double blind placebo 
controlled study
Digoxin vs. verapamil 
vs digoxin + verapamil
8 Permanent 
AF
Lewis, 198858 † Open label clinical trial Digoxin vs. digoxin + 




Lewis, 198853 Randomized double blind 
crossover study




James, 198978 † Randomized crossover 
study
Digoxin vs. digoxin + 




Wong, 199079 Randomized double-blind 
crossover study













Dahlström, 199281 Randomized double-blind 
crossover study
Digoxin vs. digoxin + 
diltiazem vs. digoxin 
+ propranolol vs. 




Koh, 199549 Randomized open label 
study
Digoxin vs. betaxolol + 




Botto, 199856 Randomized crossover
study
Gallopamil vs. 




Farshi, 199950 Randomized cross over Digoxin vs. diltiazem 
vs. atenolol vs.








Follow-up Endpoint Results - Heart rate Results - Exercise time 
or LVEF
NA Resting HR, exercise HR Lower resting and exercise HR 
with digoxin + diltiazem
NA
1 week Resting HR, exercise HR,
Exercise capacity
Resting HR and exercise HR 
lower with digoxin + diltiazem
No differences in 
exercise capacity
2 weeks Resting HR, exercise HR Resting and exercise HR were 
lower with digoxin + diltiazem
NA
2 weeks Resting HR, HR during 
exercise, LV function
Resting and exercise HR were 
lower with digoxin + verapamil
No deterioration of 
LVEF
1 day Resting HR, 
exercise HR, and tolerance
Digoxin + diltiazem reduced 
exercise heart rate the most
No improvement of 
exercise tolerance
1 day Resting HR, HR during 
exercise
Resting HR and HR during 
exercise lower with combination 
treatment
No improvement of 
exercise tolerance
NA Mean 24 hour HR Mean 24 hour HR lower with 
digoxin + pindolol
NA
2 weeks Resting HR, exercise HR Peak exercise HR was lower 
with labetolol (with or without 
digoxin)
No differences in 
exercise capacity
NA Mean HR, exercise capacity Resting and exercise HR lower 
with diltiazem and verapamil
Exercise capacity 
modestly improved
NA Resting HR, exercise HR Resting and exercise HR lower 
with digoxin + diltiazem
No effect on exercise 
capacity
12 weeks Resting HR, exercise HR Resting and exercise HR were 
lower with the combination 
treatments
No improvement of 
exercise capacity
4 weeks Resting HR, exercise 
capacity
Digoxin + betaxolol and digoxin 
+ diltiazem reduce resting and 
exercise HR more effectively
No effect on exercise 
capacity
1 week HR during exercise Gallopamil, diltiazem and 
verapamil superior for rate 
control
NA
2 weeks Mean HR;
HR during exercise
Digoxin + atenolol most effective 
for mean 24-hour HR and 
exercise; Digoxin and diltiazem 
least effective
NA
AF= atrial fibrillation; HR= heart rate; LVEF = left ventricular ejection fraction; 6 MWT= 6 min walking test; NYHA= New York Heart Association.
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Table 1. Heart rate control assessment with negative dromotropic drugs (continued)
Study Design Drugs Number of 
patients
Type of AF 
Patients
Digoxin versus amiodaron






Digoxin versus sotalol and placebo
Brodsky, 199427 Randomized double blind 
study




Digoxin versus beta-blocker versus calcium channel blocker





Lewis, 198983 † Randomized crossover 
study
Digoxin vs. digoxin + 
atenolol vs. digoxin + 





Davy, 200833 Randomized controlled 
trial
Drondarone vs. 






AF= atrial fibrillation; HR= heart rate; LVEF = left ventricular ejection fraction; NYHA= New York Heart Association.
strict rate control had adequate rate control at the end of the dose-adjustment phase, 
(chapter 3 and 4) which is comparable to the AFFIRM. However, as mentioned 
above, more patients in AFFIRM were in sinus rhythm. Since heart rate is lower in 
patients in sinus rhythm, as compared to patients in AF, the achievement of the strict 
rate control criteria in RACE II may be considered even more successful as compared 
to AFFIRM.
Rate Control and Outcome
Most importantly, what is the effect of heart rate and rate control strategies on 
outcome? A subanalysis of AFFIRM evaluated the effect of intensity of rate control 
on outcome.85 In this study patients randomized to the rate control arm of AFFIRM 
who were in AF at baseline and at 2 months follow-up were included. The patients 
were stratified according to the quartiles of resting heart rate at 2 months. There was 
no difference in outcome between the quartiles of resting heart rate. RACE II was the 
first prospective randomized clinical trial evaluating the effect of two different rate 
control strategies on outcome. In RACE II we observed that lenient rate control was 
non-inferior as compared to strict rate control in terms of cardiovascular morbidity 
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Follow-up Endpoint Results - Heart rate Results - Exercise time 
or LVEF
24 weeks Mean HR
Exercise capacity
Similar effect of digoxin and 
amiodaron on mean HR
Both less effective 
during exercise
4 weeks Resting HR, exercise HR Resting and exercise HR were 
lower with digoxin + sotalol
NA
1 day Resting HR, exercise HR Resting HR and exercise HR 
were lower with propranolol and 
digoxin
No difference in oxygen 
uptake
4 weeks Exercise HR and tolerance Exercise HR lower with 
digoxin + atenolol, verapamil or 
xametorol
Atenolol and xametorol 
reduced exercise 
tolerance
6 months Mean HR Reduction of mean HR and  
at maximal exercise with 
dronadarone
NA
AF= atrial fibrillation; HR= heart rate; LVEF = left ventricular ejection fraction; 6 MWT= 6 min walking test; NYHA= New York Heart Association.
and mortality (chapter 3). This outcome led to changes in all AF guidelines and it 
changed treatment strategies.16,86,87
 However, strict rate control is difficult to achieve, as was observed in the 
AFFIRM.2 This was also observed in RACE II (chapter 3 and 4). The failure of strict 
rate control may have influenced outcome of RACE II, in favor of lenient rate control. 
Nevertheless, there was also no difference in outcome between successful strict, failed 
strict, and lenient rate control (chapter 4). Thus, the non-inferiority of lenient rate 
control compared to strict rate control is not a consequence of failure of strict rate 
control.
 We also assessed all-cause mortality and cardiovascular hospitalizations in 
RACE II. There was no difference between lenient and strict rate control regarding 
all-cause mortality and cardiovascular hospitalizations (chapter 6). This may seem 
of less importance, but this is not the case. The ideal outcome parameter to assess 
differences in treatment strategies is all-cause mortality. However, due to the relative 
good prognosis of patients with AF nowadays (Figure 5), a large number of patients 
would be required to assess possible treatment differences. One way to overcome this 













































































0 1 2 3
A. Entire RACE II cohort
Figure 2. Number of rate control drugs in RACE II
B. Successful strict rate control
C. Failed strict rate control D. Lenient rate control
endpoint. A good surrogate endpoint should occur sooner and more frequently than 
the true endpoint, and is easy to detect.88 In addition, there should be an association 
between the surrogate and the true endpoint.89,90 Cardiovascular hospitalization 
is a good surrogate endpoint for all-cause mortality.88,91,92 Thus the equality in all-
cause mortality and cardiovascular hospitalization of the two treatment strategies in 
RACE II adds to the recommendations to start treatment in patients with permanent 
AF using a lenient rate control strategy (chapter 6). 
 In a retrospective analysis of the patients randomized to rate control in the 
first RACE trial there was no difference in outcome between patients with a low (<80 
beats per minute) versus high (≥80 beats per minute) heart rate (chapter 2). Previously, 


























Figure 3. Time to change in rate control therapy, adapted from Olshansky and 






















No. of patients, events (%)
Beta-blocker          777, 0 (100)        598, 147 (81)     500, 191 (75)     315, 210 (71)      164, 213 (70)       35, 216 (68)
Calcium blocker    631, 0 (100)        461, 139 (77)     379, 167 (69)     246, 220 (62)      128, 238 (56)       20, 247 (48)
Digoxin                 315, 0 (100)        190, 104 (66)     142, 140 (53)      92, 160 (45)        43, 165 (42)         5, 172 (29)
Figure 4. Percentage of patients in AF during follow-up in RACE II and AFFIRM
No data available on percentage of patients in AF at 3 years in AFFIRM
between patients treated with the intention to obtain a higher (< 100 bpm in RACE) 
and a lower heart rate (<80 bpm in AFFIRM).93 In that study patients were included 
if they met a combination of overlapping in- and exclusion criteria of AFFIRM and 
RACE. The primary endpoint was a composite of all-cause mortality, cardiovascular 
hospitalization, and myocardial infarction. In total, 1091 patients were included, 
874 from AFFIRM and 217 from RACE. The mean heart rate in the AFFIRM 





















Figure 5. Cumulative incidence of cardiovascular morbidity and mortality in patients 
                with AF
CV mortality - cardiovascular mortality
RACE RACE II
definitions (76.1 versus 83.4 beats per minute). There was no difference in outcome 
between the patients included in AFFIRM or RACE. However, a mean heart rate 
>100 beats per minute was associated with a worse outcome. In RACE II there was 
no association between heart rate after the dose-adjustment phase and outcome. The 
difference in heart rate between the lenient and strict group was also larger (93 versus 
76 beats per minute, respectively) as compared to the difference between the patients 
included in AFFIRM and RACE. Furthermore, in the lenient group more than 60% 
of patients had a heart rate >90 beats per minute, while only a limited number of 
patients had a heart rate >100 beats per minute (chapter 3).
 In AFFIRM digoxin use at 2 months was associated with higher all-cause 
mortality.85 In the patients randomized to rate control in the RACE study there was 
also an association between a worse outcome and use of digoxin (chapter 2). In contrast, 
in RACE II there was no association between digoxin and cardiovascular morbidity 
and mortality, nor was there a relation between the individual components of the 
primary outcome and digoxin use (chapter 3 and 4).  In a pooled post-hoc analysis 
of AFFIRM and RACE, which was mentioned above, there was also no association 
between digoxin use and a worse outcome.93 Therefore, no definite conclusions can 
be made whether digoxin affects outcome in patients with AF. However, considering 
the risk of digoxin intoxication, it should be used with care in elderly patients and in 
patients with renal failure. 
 Patients require different drugs and dosing regiments for rate control, as 
can be observed in daily clinical practice, and in the aforementioned studies. This is 
possibly due to differences in body size, liver and renal function, and differences in the 
atrioventricular-conduction system (i.e., frailty in older patients), which is commonly 
seen in patients with permanent AF. Thus, institution of rate control is a strategy which 
requires a patient tailored approach and should be titrated depending on symptoms 
and the development or deterioration of heart failure. As has been demonstrated in 
this thesis, a lenient rate control therapy approach is reasonable. In addition, it reminds 
us to treat the patients, not the electrocardiogram.94
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Rate Control in Atrial Fibrillation and Heart Failure
Heart failure and AF often coincide, and the incidence of AF increases with the severity 
of heart failure.95,96 AF may deteriorate prognosis in patients with AF, especially 
in patients with recent onset AF, although this association is not fully elucidated 
yet.95,97-106 There may be differences in outcome depending on whether patients 
hospitalized for AF and heart failure had developed AF or heart failure first.107 
Considering the high incidence of coexisting AF and heart failure, the AFFIRM and 
RACE did not yet elucidate the rate versus rhythm issue in patients with AF and heart 
failure. Both studies included a relative low number of patients with heart failure.18,20 
A predefined substudy of RACE assessed all heart failure patients in New York Heart 
Association functional class II and III.108 Fractional shortening was comparable 
between the rate (29±10) and rhythm control (28±9) groups. There was no difference 
in the incidence of the primary outcome between rate and rhythm control (29% versus 
32%, respectively). The first prospective study on outcome in rate versus rhythm control 
in AF and heart failure was the Atrial Fibrillation and Congestive Heart Failure (AF-
CHF). This study showed that, also in patients with AF and heart failure, rate control 
is non-inferior as compared to rhythm control.109 In the AF-CHF patients with an 
ejection fraction <35%, symptoms of heart failure, and a history of AF were included. 
A total of 694 patients were randomized to rate control, and 682 patients to rhythm 
control. The mean left ventricular ejection fraction was 27%. There was no difference 
in cardiovascular morbidity between the two groups (25% in the rate control versus 
27% in the rhythm control group, p=0.59). Therefore, rate control can also be used in 
patients with heart failure, even more since (non) pharmacological rhythm control 
outcome is relatively low.9,110 It is, therefore, unknown whether rate control would also 
be non-inferior if rhythm control strategies would be more effective. Whether lenient 
rate control can also be instituted in patients with heart failure is unknown. However, 
due to the reduced left ventricular function in addition to the adverse hemodynamic 
effects of AF, patients with heart failure and AF may need a higher heart rate as 
compared to patients with heart failure and sinus rhythm.
 Development of heart failure was one of the presupposed risks of lenient 
rate control. The development or deterioration of heart failure was not increased in 
the lenient rate control group in the RACE II (Figure 6 A and B, chapter 3 and 4). 
However, the number of patients included in RACE II with systolic heart failure 
was limited. Diastolic heart failure was not separately assessed. Since the majority of 
patients suffered from hypertension as associated disease it may be presumed that a 
majority of patients in RACE II had diastolic heart failure, and were therefore at risk 
to develop overt heart failure. Our data, nevertheless, suggest that a heart rate just 
below 110 beats per minute is low enough to prevent patients from developing heart 
failure in the group of patients included.
 There are several retrospective post-hoc analyses on heart rate in patients 
with AF and heart failure. Rienstra and colleagues evaluated the effect of heart 
rate in a cohort of patients with AF and heart failure.111 In this post-hoc analysis 
of the Second Prospective Randomized Study of Ibopamine on Mortality and 
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Efficacy (PRIME II) 77 patients were included.112 PRIME II was a survival study on 
ibopamine in patients with severe heart failure. Mean left ventricular ejection fraction 
was 23%. The investigators found no differences between patients with a lower (≤80 
beats per minute) and a higher (>80 beats per minute) baseline heart rate. In contrast 
to what was expected, a low heart rate was independently associated with all-cause 
mortality in this study. However, this was a retrospective study including a very 
limited number of patients and no data were available on heart rate during follow-up. 
Furthermore, at the time of PRIME II, beta-blockers were only rarely instituted in 
heart failure. In the cohort of Rienstra and colleagues only 6.5% of patients used a 
beta-blocker. 
 Despite the proven efficacy of beta-blockers in patients with heart failure 
and sinus rhythm on survival, the benefit in patients with AF is still unclear.47,102,113,114 
Of 4 major studies on beta-blocker use in heart failure, post-hoc analyses were 
performed assessing the effect of beta-blockers in patients with AF and heart failure 
(Table 2).47,102,115,116 In the post-hoc analysis of the Cardiac Insufficiency Bisoprolol 
Study II (CIBIS II) there was no difference in all-cause mortality between patients 
in sinus rhythm or in AF. However, the survival benefit of bisoprolol was only present 
in the patients in sinus rhythm.115 Furthermore, in the post-hoc analysis of the U.S. 
Carvedilol Heart Failure Study Group there was no significant difference in outcome 
between the patients treated with a beta-blocker or placebo.47 The Metoprolol CR/XL 
Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF) also showed 
no survival benefit in the patients with AF who were treated with a beta-blocker, in 
contrast to the patients in sinus rhythm.102 In addition, in elderly patients with AF and 
heart failure, beta-blocker treatment did not improve outcome.116
 Why do beta-blockers not improve outcome in patients with AF? First, the 












Strict control        303                   301                   295                   289                   277                  240                   144
Lenient control    311                   302                   300                   298                   274                  242                   154





baseline heart rate in all three aforementioned studies was relatively low. It is possible 
that the additional heart rate reduction does not improve survival in patients with 
AF. Due to the loss of atrial kick and ventricular irregularity, these patients might 
require a higher heart rate than patients in sinus rhythm. Second, the place of action 
in AF is in the atrioventricular node, as compared to the sinus node in patients in 
sinus rhythm. Therefore, beta-blockers may be less effective and act differently in 
AF as compared to sinus rhythm. This difference may play a role in the absence of a 
survival benefit for beta-blockers in patients with AF and heart failure. Third, a low 
heart rate may be a marker of underlying conduction disturbances, which may reduce 
prognosis on itself.111
 Other small scale studies on the efficacy of beta-blocker therapy in patients 
with AF and heart failure showed an improvement of left ventricular function. There 
was, however, no effect on survival but these studies were not powered to assess the 
effect of treatment on survival (Table 2).51,117-120 Khand and colleagues performed a 
double blind, parallel-arm study investigating the effects of digoxin alone, carvedilol 
alone, and the combination of both.51 This study was performed in 47 patients with 
heart failure and AF. They concluded that the combination of a beta-blocker and 
digoxin was more effective than the use of a beta-blocker alone or digoxin alone. 
Furthermore, left ventricular ejection fraction improved during treatment with the 
combination of the two drugs. In a retrospective observational cohort, Fauchier and 
colleagues evaluated the effect of beta-blockers and digoxin in 1,269 patients with 
heart failure and AF. In their cohort 46% of patients had systolic heart failure (left 
ventricular ejection fraction <45%).120 In contrast to the post-hoc analysis of the studies 
on beta-blockers in heart failure, the use of beta-blockers, with or without digoxin, 
was associated with decreased all-cause mortality compared to no beta-blocker use. 












Failed strict           98                     93                     90                     87                      82                    68                      39
Successful strict    203                   200                   198                   195                    193                  167                     99
Lenient control    307                   301                   299                   296                    283                  272                    153














(%) (%) (%) (%)
Substudy of RCT on beta-blockers in HF
Lechat, 2001115
     Bisoprolol 257 63 84 27 0/0/80/20 26
     Placebo 264 62 82 27 0/0/80/20 25
Joglar, 200147
     Carvedilol 84 66 90 - 0/42/55/4 54
     Placebo 52 63 90 - 0/42/56/2 46
Van Veldhuisen, 2006102
     Metoprolol CR/XL 274 66 86 28 0/34/167/13 52
     Placebo 282 66 87 28 0/34/60/6 55
Mulder, 2012116
     Nebivolol 361 77 64 36 2/48/48/2 62
     Placebo 377 77 65 36 2/47/46/5 63
Other studies on beta-blockers in AF and HF
Fung, 2002118
     Bisoprolol/ carvedilol 12 64 75 26 0/25/75/0 17
Khand, 200351
     Carvedilol 24 69 58 24 4/46/38/12 33
     Placebo 23 68 65 25 4/70/26/0 48
Meng, 2003119
     Metoprolol/ carvedilol 24 64 83 33 - 0
Cioffi, 2006117
     Carvedilol 39 76 64 31 - 31
Fauchier, 2009120
     Beta-blocker 260 73 60 48 - 34
     Digoxin 402 76 56 50 - 14
Table 2. Studies on beta-blockers in Atrial Fibrillation and Heart Failure
LVEF - left ventricular ejection fraction; NYHA - New York Heart Association; HF - heart failure; HT - hypertension




ACE-i Digoxin Amiodarone Outcome 
(%) (%) (%) (%) (%)
18 85 96 83 18 No change in all-cause mortality
16 90 96 86 18
- - 95 100 1 No change in HF hospitalization and
- - 95 95 2 all-cause mortality, improvement of LVEF
39 85 89 89 - No change in all-cause mortality
42 84 93 90 -
64 83 - - - No change in all-cause mortality
60 83 - - -
50 78 92 - - Improvement of LVEF, no change exercise 
capacity
- 89 71 100 - Improvement of LVEF
- 82 71 100 -
- 74 88 79 - Improvement of LVEF
51 82 51 87 - No change in HF hospitalization
53 - 63 0 29 Digoxin associated with 
38 - 80 100 35 worse survival
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There was no survival benefit in patients who only used digoxin, compared to the 
control group (no beta-blocker or digoxin). As mentioned, this was an observational 
study, and only a third of the patients used a beta-blocker. Furthermore, almost half 
of the patients in the no-therapy group used anti-arrhythmic drugs, which could have 
affected outcome. 
 There is one absolute contra-indication for lenient rate control: Cardiac 
Resynchronization Therapy (CRT). Previously, CRT was only indicated in patients 
who were in sinus rhythm.121 However, the present ESC recommendations state 
that CRT may also be considered in patients with AF and heart failure.122 There are, 
however some major issues concerning AF and CRT. The irregular high spontaneous 
ventricular heart rate reduces the percentage of biventricular pacing. Furthermore, 
during exercise the ventricular rate can exceed the upper rate of the device,123 also 
reducing the amount of biventricular pacing. Therefore, it is essential that when 
patients with permanent AF receive CRT, they are instituted on a strict rate control 
strategy, or undergo AV node ablation.124,125 A strict rate control strategy in AF and 
heart failure can be instituted with beta-blockers, digoxin, and amiodarone. When the 
strict approach cannot be achieved with drugs, an atrioventricular node ablation can 
be performed. Considering the evaluation of the percentage of biventricular pacing, 
it is essential that this is adequately performed, also when evaluating the success 
of CRT therapy. Evaluating the parameters supplied by the device is not enough. 
One of the most simple and cheap methods to evaluate biventricular pacing is with 
the electrocardiogram. Also an exercise test or 24-hour Holter monitoring can be 
performed to evaluate the amount of biventricular pacing during exercise.123 Care for 
patients with CRT devices should therefore be performed by dedicated cardiologists. 
Major Cardiovascular Endpoints in Patients with Atrial Fibrillation
Adequate evaluation of patients with AF is important. Lone AF is not very common, 
especially not in patients with permanent AF (chapter 3). The majority of patients 
with AF have vascular, valvular, internal or pulmonary disease.18,20 Prognosis is 
probably determined by these underlying diseases, rather than by AF.126,127 During the 
last decade AF treatment has improved, with a reduction in cardiovascular morbidity 
and mortality (Figure 6). However, major cardiovascular events still occur in patients 
with AF. 
During the course of the RACE II there was no specific moment on which more 
endpoints occurred (chapter 3). Since the drug-titration phase was a period in which 
more or new drugs were prescribed to the patients, this may have resulted in more 
events. This however, was not the case. The arrhythmic events (being syncope, life-
threatening adverse effect of rate control drugs, sustained ventricular tachycardia 
or ventricular fibrillation, cardioverter-defibrillator implantation, and pacemaker 
implantation) are of special interest during this episode. In the strict rate control 
group, the endpoints seemed to occur earlier during the study. During the first 12 
months, 3 pacemaker implantations, 2 syncopes, and 1 serious adverse event of rate 
control drugs (hospitalization for AV conduction disturbances) occurred in the strict 
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group, as compared to no pacemaker implantations, 2 syncopes and 2 serious adverse 
events of rate control drugs in the lenient group (Figure 7). This may be caused by the 
addition or increase of dosages of rate control drugs. 
 One of the treatment goals of patients with AF is prevention of 
thromboembolic complications.16 Risk stratification for these events is essential 
in all AF patients. The CHA2DS2 VASc score is a useful tool to assess the risk of 
thromboembolic complications in patients with AF.128 The CHA2DS2 VASc score 
consists of intermediate and high risk factors (Table 3). The maximum score is 9 points, 
with 0 being low risk patients, 1 intermediate risk, and ≥2 high risk patients. The yearly 
risk of a thromboembolic complication is 0%, 0.6%, and 3.0%, respectively.128 The 
current European guidelines recommend the use of oral anticoagulation in patients 
with a score ≥2, either aspirin or oral anticoagulation in patients with a score of 1, where 
oral anticoagulation is preferred, and either aspirin or no antithrombotic therapy in 
patients with a risk score of 0, where no antithrombotic therapy is preferred.16 Aspirin 
is no longer advocated since it increases bleeding risk without reducing the stroke 
risk.129 Regardless of the use of oral anticoagulation, stroke and peripheral emboli may 
occur, even in patients with a low CHA2DS2 VASc score.16,130-132
 In the RACE II the median CHA2DS2 VASc score was 2 (interquartile 
range 1-4). There was no difference between the two randomization groups. Patients 
with a stroke during the study had a higher CHA2DS2 VASc score, compared to 
patients without a stroke (3, interquartile range 3-4 versus 2, interquartile range 
1-4, respectively, p=0.02). The percentage of strokes in RACE II was comparable 
to The Randomized Evaluation of Long-term Anticoagulation Therapy (RELY) 
and Apixaban for Reduction in Stroke and Other Thromboembolic Events in 
Atrial Fibrillation (ARISTOTLE) trials. However, follow-up in both these trials 
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was shorter as compared to RACE II, indicating a higher incidence in RELY and 
ARISTOTLE. In the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition 
Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial 
in Atrial Fibrillation (ROCKET-AF) study the incidence of stroke was higher (Table 
4).18,20,109,130-134 However, the patient cohort in ROCKET-AF was a high risk group 
with a higher CHADS2 score. Considering the possible instability of the International 
Normalized Ratio (INR) during the drug-titration phase due to changes in medication, 
the incidence of strokes could be elevated during this episode. However, there was no 
indication for an increased stroke incidence during this phase, or any other phase 
during the study (Figure 8).
 It is striking that there seemed to be a trend for a higher incidence of strokes 
in the strict rate control group of the RACE II study. In 11 patients the INR value was 
known at the moment of the stroke. In 5 patients with an ischemic stroke the INR was 
too low. There were 5 hemorrhagic strokes during the study, of which 2 patients had a 
normal INR, and 1 patient had an elevated INR (3.6). In 2 patients no INR value was 
available at the moment of the event. Although the numbers were small, there seemed 
to be no difference in INR values at the moment of the stroke between the lenient 
and strict groups. There was also no difference in INR between lenient (2.9±0.9) and 
strict (2.9±0.9) rate control in the patients without a stroke. Considering the higher 
Risk Score Letter Clinical characteristic Points
CHA2DS2 VASc128 C Congestive heart failure or left ventricular dysfunction 1
H Hypertension 1
A Age ≥75 years 2
D Diabetes 1
S Stroke 2
V Vascular disease* 1
A Age 65-74 years 1
Sc Sex category (female) 1
HAS-BLED139 H Hypertension 1
A Abnormal liver of renal function 1 or 2
S Stroke 1
B Bleeding 1
L Labile INRs 1
E Elderly† 1
D Drugs or alcohol 1 or 2
Table 3. CHA2DS2-VASc score and HAS BLED score
*  Vascular disease – previous myocardial infarction, peripheral artery disease, aortic plaque; 
† Elderly is defined as an age >65 years; 
   INR – international normalized ratio
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incidence of strokes in the strict group, it should be emphasized that RACE II was not 
powered to make a definite conclusion on this issue. 
 When instituting oral anticoagulation in patients it is important to assess 
the bleeding risk.135,136 Several patient characteristics were associated with increased 
risk of bleeding and specific bleeding risk scores were developed assessing this major 
complication of oral anticoagulation.137-143 The HAS-BLED score is easy to use in 
daily clinical practice (Table 3).139 This score was developed using all patients from 
the Euro Heart Survey of AF with 1-year follow-up status. During the follow-up 
period 53 (1.5%) major bleeds occurred in the 3456 included patients. The score ranges 
between 0 and 9, with a score ≥3 implying a high risk of bleeding.16,139 Patients with 
a HAS-BLED score ≥3 should therefore be regularly reviewed, and some caution is 
needed when instituting oral anticoagulation in these patients. 
 The median HAS-BLED score of the patients in RACE II was 1 
(interquartile range 1-2). There was no difference between the two treatment 
groups. Even in this low risk group of patients bleeding occurred relatively frequent, 
especially in comparison with the other outcome events in the present population. 
Fatal bleeding events were uncommon, 3 patients died due to a bleeding (2 intra-
cranial bleedings and 1 retroperitoneal bleeding). The patients with a major bleeding 
during the study were older (73±5 versus 68±8, p<0.001), and had a higher HAS-
BLED score as compared to the patients without a bleeding event during the study 
(2, interquartile range 1-2 versus 1, interquartile range 1-2, respectively, p=0.04). The 
incidence of bleeding events in RACE II was higher as compared to AFFIRM (total 
of 9.2% in 5 years) and RACE (total of 4% in 2.5 years). At the time of AFFIRM 
and RACE oral anticoagulation was stopped when patients remained in sinus 
rhythm, in contrast to RACE II, where patients were continuously treated with oral 
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(%) (%) (%) (%) (%) (%)
AFFIRM18 4,060 70 61 51 26 23 -
RACE20 522 68 63 19 10 19 11
AF-CHF109 1,376 66 82 48 48 100 21
RACE IIchapter 3 614 68 66 61 18 10 11
ANDROMEDA133 627 71 75 37 65 100 22
ATHENA134 4,628 72 53 86 30 21 -
RELY130 18,113 72 63 79 17 32 23
ROCKET-AF131 14,264 73 60 91 17 62 40
ARISTOTLE132 18,201 70 65 87 14 36 25
Table 4. Patient characteristics of large AF studies
* Cumulative incidence at end of follow-up 
† fractional shortening
# percentage during total follow-up.
anticoagulation. This may have caused the higher incidence of bleedings in RACE II. 
The bleeding risk was, however, not as high as in the high risk population of RELY and 
ROCKET (Table 6).18,20,130,131 Considering the increased risk of bleeding during the 
initiation phase of oral anti-coagulation,144 the additional negative dromotropic drugs, 
on which the patients were instituted during the dose-adjustment phase, may have 
influenced the stability of the INR. However, bleedings occurred at similar moments 
and in similar numbers of patients in both groups (Figure 9). 
 The incidence of acute coronary syndromes was low in the RACE II, the 
cumulative incidence in the lenient group being 1.4% (4 patients), as compared 
to 0.4% (1 patient) in the strict group. There was no difference between the two 
groups (p=0.2). 
 Considering the adverse events that occur in patients with AF, it is important 
that patients with AF are adequately evaluated. A thorough disease specific history 
and an adequate physical examination should be performed when patients are 
referred for new onset AF. Thereafter, patients should be instituted on adequate 
rate control, and, based on their CHA2DS2 VASc and HAS-BLED scores, should 
start with oral anticoagulation. Furthermore, additional diagnostic tests should be 
performed to exclude any underlying heart disease, for instance heart failure, valve 
disease or coronary artery disease. The follow-up of AF patients can be performed 
by a general practitioner, and the patient can be referred to the cardiologist when 
needed. Future care for patients with newly diagnosed AF may be performed by a 
nurse specialized in AF. Underlying disease and adequate oral anticoagulation should 
be the focus of treatment. This may improve guideline adherence, and, subsequently, 
prognosis. Guideline adherence in the Euro Heart Survey was associated with 




CHADS2 LVEF Follow-up Mortality Stroke Bleeding
(%) (%) yrs (%) n (%) n (%)
- na 55 3.5 666 (26.3)* 211 (8.2)* 203 (7.3)*
14 1.1±1.0 30† 2.3 40 (6.9)* 35 (6.7)* 21 (4.0)*
10 na 27 3.0 445 (32.5)# 20 (1.5)# 55 (4.0)#
8 1.4±1.1 52 3.0 35 (6.1)* 15 (2.7)* 28 (4.9)*
- na - 0.2 37 (6.4)# 7 (5.8)# -
- na - 1.8 255 (5.8)# - -
20 2.1±1.1 - 2.0 1371 (7.6)# 478 (2.6)# 1094 (6.0)#
55 3.5±1.0 - 1.9 1214 (8.5)# 429 (3.0)# 781 (5.5)#
20 2.1±1.1 - 1.8 1272 (7.0)# 449 (2.5)# 789 (4.3)# 
Figure 9. Cumulative incidence of major bleeding in RACE II
No. at Risk
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Recently, Hendriks and colleagues showed a reduction in mortality in patients treated 
in a nurse-led AF clinic.147 In this study, 111 patients were treated by a specialized 
nurse, supervised by a cardiologist and supported by a dedicated ICT program. Also, 
guideline adherence was higher in the AF-clinic patients compared to patients treated 
by the cardiologist (70% versus 96%, respectively).148 The effect of treatment in AF-
clinics will be studied in RACE 4.
Quality of life is reduced in patients with AF.25,149 Despite a positive effect of 
maintenance of sinus rhythm on quality of life, there is no difference in quality of 
life between rate and rhythm control strategies.24,25,150,151 The indifference in quality 
of life between these strategies is probably due the failure of current rhythm control 
strategies. The hypothesis of the RACE II concerning quality of life was that there 
would be no difference in quality of life between lenient and strict rate control.26 Strict 
rate control may reduce symptoms due to a lower heart rate, but, on the other hand, 
it may also cause more drug related side effects, resulting in reduced quality of life. A 
post-hoc analysis of the AFFIRM trial showed no difference in quality of life between 
the quartiles of resting heart rates.85 In RACE there was also no difference in quality 
of life between patients with a lower (rate <80 beats per minute) as compared to 
patients with a higher (≥80 beats per minute) mean resting heart rate (chapter 2). 
The RACE II showed no effect of the two treatment strategies on quality of 
life (chapter 5). In the RACE II quality of life was assessed with three questionnaires: 
the Medical Outcome Study Short Form-36 (SF-36) assessed general health 
related quality of life.152,153 The University of Toronto AF Severity Scale (AF severity 
scale) assessed the severity of AF related symptoms, and is AF specific.149,154,155 The 
Multidimensional Fatigue Inventory-20 (MFI-20) assessed the severity of fatigue.156,157 
At baseline there were no differences in quality of life between lenient and strict rate 
control in any of the questionnaires used. Importantly, at one year follow-up, and at 
end of study there were also no differences in quality of life between lenient and strict 
rate control, measured with the SF-36, AF severity scale, and the MFI-20 (chapter 5). 
There was also no difference in quality of life between patients with successful or failed 
strict rate control (chapter 4). 
 How can the absence of a relation between stringency of rate control and 
quality of life be explained? First, all patients included in the RACE II had permanent 
AF. The symptoms of patients with permanent AF are different from those with 
paroxysmal AF and also relate to the age of the patient (chapter 5).158,159 The majority 
of patients included in RACE II suffered from fatigue and dyspnea, rather than 
palpitations, which is a major symptom in patients with paroxysmal AF.160 Symptoms 
of the patients included in RACE II may be associated with the associated disease, 
e.g. diastolic dysfunction, rather than the arrhythmia. Therefore, stringency of rate 
control may have less effect on symptoms, and consequently on the quality of life that 
the patients experience, as long as the heart rate is not extremely high, e.g. above our 
lenient rate control target. Furthermore, almost half of the patients included in RACE 





















II had no symptoms of AF. The relative low symptom burden is also reflected in the 
AF severity scale (Figure 10). Compared to patients with paroxysmal AF (FACET,157 
Dorian and colleagues149), persistent AF,155 and those eligible for catheter ablation 
(Reynolds and colleagues161), patients included in RACE II scored intriguingly low on 
the AF symptom severity scale.  In addition, it seems obvious that symptoms are not 
affected by different rate control strategies in patients without symptoms, although 
during any one of the strategies e.g. adverse drug effects may affect symptoms.
 There is a significant difference in number of rate control drugs used 
between the strategies (Figure 2, chapter 3 and 5). In addition, the strict rate control 
strategy required more outpatient department visits (chapter 5). This shows that in 
RACE II two completely different strategies were used. Despite the different 
strategies, the difference in heart rate was not as marked as would have been expected 
from the design of the study. However, no difference in quality of life between lenient 
and strict rate control was observed (chapter 4 and 5). It is possible that the positive 
effects of a lower heart rate during a strict rate control strategy were abolished due to 
more and higher dosages of rate control drugs with more adverse effects, and more 
frequent outpatient department visits with additional exercise tests or 24 hour Holter 
monitoring.  
 Another explanation why there is no difference in quality of life between 
lenient and strict rate control could be that patients with failed strict rate control have 
a lower quality of life than those with successful strict rate control. This could have 
influenced outcome in favor of lenient rate control. However, there was no difference 
in quality of life between patients with successful strict or failed strict rate control 
(chapter 4 and 5). Finally, irrespective of a lower or higher heart rate, the ventricular 












Figure 10. Symptom severity measured with the AF severity scale
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Therapeutic implications
After the landmark trials AFFIRM and RACE, rate control has become frontline 
therapy in older patients without severe AF related symptoms. With the results of 
the RACE II in hand, we have more evidence that the patient should be treated 
rather than the ECG.16,94 The current guidelines have also incorporated the outcome 
of RACE II in the recommendations regarding rate control. There are, however, 
some differences in the interpretation and recommendations made in the different 
guidelines (Table 5).16,86,87 The American guideline recommends not to use a strict 
approach in patients with a stable left ventricular function, and acceptable symptoms 
of AF. The Canadian guideline recommends a rate control strategy with adequate rate 
control defined as a resting heart rate <100 beats per minute. The major difference 
between the guidelines is the different heart rate criterion used in the Canadian 
guideline. This was done because the number of patients with a heart rate >100 beats 
per minute in RACE II was limited, and therefore the result may not be extrapolated 
when all patients had a heart rate between 100 and 110 beats per minute. The European 
guideline advocates to start with a lenient rate control strategy, and when symptoms 
endure or develop, a stricter rate control strategy can be used.
 Considering the above, the outcome of RACE II has simplified treatment of 
patients with permanent AF. Therefore less outpatient visits are required, which is a 
benefit for both the patients and the physician. 
Guideline Heart rate recommendation Recommendation
ESC Guidelines for the 
management of AF16
It is reasonable to initiate treatment with 
a lenient rate control protocol aimed at a 
resting heart rate <110 beats/min
Class IIa, level of 
evidence B
It is reasonable to adopt a stricter rate 
control strategy when symptoms persist 
or tachycardiomyopathy occurs, despite 
lenient rate control
Class IIa, level of 
evidence B
ACCF/ AHA/ HRS 
focused update on AF87
Treatment to achieve strict rate control 
of heart rate is not beneficial compared 
to achieving a resting heart rate <110 
beats/min in patients with persistent AF 
who have stable ventricular function and 
no or acceptable symptoms related to the 
arrhythmia
Class III – No 
benefit
Canadian Cardiovascular 
Society AF guidelines: Rate 
and Rhythm management86
We recommend that treatment for rate 
control of persistent or permanent AF or 






Table 5. Recommendations of AF guidelines regarding rate control
ESC - European Society of Cardiology; ACCF - American College of Cardiology; AHA - American Heart Association; 
HRS - Heart Rhythm Society; AFL - atrial flutter
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 Rate control is adequate when the ventricular rate is <110 beats per minute, 
and the patient does not have (severe) symptoms. When the patient does experience 
symptoms, or symptoms endure, a more strict approach can be used (Figure 11). 
Figure 11. Flowchart for rate control
Future perspectives
Rate control has settled as an appropriate treatment strategy, and a more lenient 
approach can now also be implicated in patients without severe AF related symptoms. 
Despite the results of AFFIRM and RACE, rhythm control remains an important 
treatment strategy in patients with AF. The last decades more and new techniques have 
been developed to improve the efficacy of rhythm control. The current cornerstone of 
rhythm control is pulmonary vein isolation (PVI). During the AFFIRM and RACE 
trial PVI was not yet mainstream therapy. It is possible that with superior rhythm 
control strategies in terms of maintenance of sinus rhythm, rhythm control will improve 
outcome. Currently the Catheter ablation versus anti arrhythmic drugs therapy for 
atrial fibrillation trial (CABANA, ClinicalTrials.gov Identifier NCT00911508) 
and the Early treatment of Atrial fibrillation for stroke Prevention Trial (EAST, 
ClinicalTrials.gov Identifier NCT01288352) are investigating the effect of PVI on 
cardiovascular morbidity and mortality. The primary endpoint in the CABANA is all-
cause mortality. In the EAST the primary outcome is a composite of cardiovascular 
death, stroke, hospitalization for worsening heart failure or due to acute coronary 
syndrome. Rhythm control may also become more effective when upstream therapy 
is applied. Currently the RACE 3 (ClinicalTrials.gov Identifier NCT00877643) is 
 Patient eligible for rate 
control 
ICD or CRT device 
Strict rate control 
Symptoms of AF 
No or tolerable 
symptoms 
Lenient rate control 
24h Holter for safety Exercise test if patients has 







Choice of rate control drug 
Underlying disease 
No or hypertension 
 beta-blocker, nondihydropirydine 
calcium channel blocker, digoxin 
Heart failure 
 beta-blocker, digoxin, amiodarone 
COPD 
 nondihydropirydine calcium 
channel blocker, digoxin 
Inactive lifestyle 
 digoxin 
COPD - chronic obstructive pulmonary disease; 
ICD - Implantable cardioverter defibrillator; 
CRT - Cardiac resynchronization therapy; 
Modified from Camm and colleagues, Europace 201016
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investigating the effect of a combination of upstream therapies including physical 
exercise compared to conventional rhythm control on maintenance of sinus rhythm in 
patients with early AF. 
 Besides more effective means to maintain sinus rhythm, early detection of 
AF may also improve outcome. Since some patients present with a stroke as a first 
symptom of AF, early detection of AF may reduce cardiovascular morbidity and 
mortality. 
 Reviewing the results of the RACE II, it is striking that 28 out of 81 
primary endpoints were major bleedings. Thus despite the anticoagulation clinics in 
the Netherlands, bleedings remain a major issue when instituting patients on oral 
anticoagulation. Several studies on the risk of stroke in AF, with the risk of bleeding 
as safety outcome, have been published (Table 6). The RELY investigated whether 
dabigatran (a direct thrombin inhibitor) was as effective as warfarin in preventing 
stroke or systemic embolism.130 The primary safety outcome was major bleeding. 
Patients were eligible if they had AF and a risk factor for stroke. In total, 18,113 
patients were randomized to either 110 mg dabigatran, 150 mg dabigatran, both twice 
daily, or warfarin. In Table 6 the results of the RELY are displayed. The 110 mg dose of 
dabigatran was non-inferior as compared to warfarin in preventing stroke or systemic 
embolism. The 150 mg dose dabigatran was superior as compared to warfarin in 
preventing stroke or systemic embolism. The risk of bleeding was lower with 110 mg 
dabigatran, as compared to warfarin. There was no difference in bleeding risk between 
150 mg dabigatran and warfarin. The ROCKET AF investigated the efficacy and 
safety of preventing stroke and systemic embolism with rivaroxaban (a direct factor Xa 
inhibitor) as compared with warfarin.131 The primary safety outcome was a composite 
of major and non-major clinically relevant bleeding events. Patients were eligible 
if they had AF and a CHADS2 score of 2 or more. In total 14,264 patients were 
included in the trial. There was no difference in stroke or systemic embolism between 
Table 6. Studies on new drugs preventing stroke or systemic embolism in AF
Study Medication used and outcome
RELY130 Dabigatran Warfarin*
110 mg b.i.d. 150 mg b.i.d.
     Stroke or systemic embolism (% per year) 1.53 1.11 1.69
     Bleeding (% per year) 2.71 3.11 3.36
ROCKET AF131 Rivaroxaban 20 mg once daily Warfarin*
     Stroke or systemic embolism (% per year) 1.7 2.2
     Bleeding (% per year) 3.6 3.4
ARISTOTLE132 Apixaban 5 mg twice daily Warfarin*
     Stroke or systemic embolism (% per year) 1.27 1.60
     Bleeding (% per year) 2.13 3.09
b.i.d. - bis in die, twice a day
* Dose adjusted
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rivaroxaban and warfarin. There was also no difference in bleeding risk (Table 6). 
However, the patients randomized to rivaroxaban suffered less intracranial and fatal 
bleedings. The ARISTOTLE investigated the efficacy and safety of preventing stroke 
and systemic embolism with apixaban (a direct factor Xa inhibitor) as compared to 
warfarin.132 The primary safety outcome was major bleeding. In total 18,201 patients 
were included in the trial. The rate of stroke and systemic embolism was lower in the 
apixaban group, as compared to warfarin. The risk of bleeding was also reduced in the 
apixaban group (Table 6). Furthermore, all-cause mortality was lower in the apixaban 
group. The RELY, ROCKET AF, and ARISTOTLE illustrate that there is still a lot 
to gain in the prevention of thromboembolic complications and the risk of bleeding 
due to anticoagulation in treatment of AF. 
 Since our current rate control drugs are ineffective in controlling the heart rate 
and subsequently improving outcome, rhythm control strategies and anticoagulation 
should be optimized and new studies on rate control in patients with permanent AF 
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In Europe more than 6 million patients have atrial fibrillation currently. It is expected 
that this number will double in the next 30 – 50 years. Atrial fibrillation is not a benign 
disease. The risk of death, stroke and heart failure is increased, in addition exercise 
capacity and quality of life are reduced. Despite efforts to maintain a normal rhythm, 
atrial fibrillation is a progressive arrhythmia; the arrhythmia is present occasionally at 
first but will be present continuously in the end. This means that atrial fibrillation is 
continuously present in a lot of patients. The treatment of this specific patient group is 
not evidence based. An evidence based treatment strategy is indispensable. 
 Atrial fibrillation has been known for a long time. Treatment consisted of 
maintenance of the normal rhythm with quinidine and control of the ventricular rate 
with digoxin. In 1960 the electrical cardioversion was introduced. Atrial fibrillation 
remained a progressive arrhythmia despite this new method because after successful 
restoration of sinus rhythm AF easily relapsed. It was not until the beginning of this 
decade that it became apparent that it was not the rhythm that mattered, i.e. there 
was no difference in outcome between rate (treatment aimed at heart rate reduction) 
and rhythm control (treatment aimed at maintenance of normal rhythm). However, 
different definitions of adequate rate control were used in the rate versus rhythm 
control studies. The guidelines advocated a strict rate control strategy, but this was 
based on small studies which did not investigate prognosis. Thus, an evidence based 
rate control strategy was lacking. Studies which investigated different rate control 
strategies showed no difference in outcome between patients with a high and low 
heart rate. However, these were all retrospective analysis. 
 Quality of life and heart rate are also assumed to be related. A higher heart 
rate could cause more or more severe symptoms than a lower heart rate. However, 
instituting a stricter rate control strategy requires more negative dromotropic drugs. 
Prospective data on quality of life and different rate control studies were also lacking. 
Aim of this thesis was to investigate different rate control strategies in patients with 
atrial fibrillation. In chapter 1 the general introduction and background is discussed, 
as is summarized above. 
 In chapter 2 we performed a retrospective analysis on prognosis in patients 
with permanent AF with a low and high heart rate. The study cohort consisted of 
all patients randomized to rate control in the RACE study. Patients were divided 
according to the mean heart rate during follow-up. Low heart rate was defined as a 
mean heart rate below 80 beats per minute, high heart rate was defined as a mean heart 
rate equal to or above 80 beats per minute. We observed no difference in outcome 
between a low and high heart rate. In addition, there was no difference in quality of 
life or left ventricular function between a low and high mean heart rate. 
 The abovementioned results are consistent with previous studies on 
heart rate and prognosis, but all these studies were retrospective. Therefore, a 
randomized clinical trial was performed evaluating lenient and strict rate control 
in terms of cardiovascular morbidity and mortality, i.e. the Rate Control Efficacy 
in Permanent Atrial Fibrillation: a comparison between Lenient and Strict Rate 
Control II (RACE II) study. The hypothesis was that there was no difference in 
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outcome between lenient and strict rate control. The results of the RACE II are 
presented in chapter 3. In RACE II more than 600 patients were randomized to 
lenient or strict rate control. The primary outcome was a composite of cardiovascular 
death, hospitalization for heart failure, stroke, systemic embolism, major bleeding, 
or arrhythmic events, including syncope, sustained ventricular tachycardia, cardiac 
arrest, life-threatening adverse effects of rate control drugs, and pacemaker or 
cardioverter-defibrillator implantation. Heart rate was lowered with beta-blockers, 
non-dihydropyridine calcium-channel blockers, and digoxin, alone or in combination. 
After the dose-adjustment phase there was a significant difference in heart rate 
between the two groups. This difference remained present during the study. After a 
follow-up of 3 years there was no difference in primary outcome between lenient and 
strict rate control. This showed that lenient rate control was non-inferior to strict rate 
control, which confirmed our hypothesis. 
 Previous studies on rate control in atrial fibrillation have shown that strict 
rate control is difficult to achieve. We also observed this in RACE II, 67% of patients 
randomized to strict rate control achieved the strict rate control criteria, as compared 
to 97% of patients randomized to lenient rate control. This large difference could 
have influenced the outcome of RACE II, in favor of lenient rate control. Therefore 
we performed an additional analysis investigating outcome in patients with failed 
strict, adequate strict and lenient rate control. The results of this study are presented
in chapter 4. We observed no difference in the primary outcome, as described above, 
between failed strict, successful strict and lenient rate control. This showed that failure 
of strict rate control did not influence the results of RACE II. This is another clue 
that lenient rate control can now be adopted as frontline therapy in patients with 
permanent atrial fibrillation. 
 Quality of life is another important outcome parameter in treatment of 
patients with permanent atrial fibrillation. Therefore we performed a predefined 
analysis on difference in quality of life between lenient and strict rate control. The 
hypothesis was that there would be no difference in quality of life between lenient 
and strict rate control. Quality of life was assessed with the SF-36, MFI-20 and 
AF-severity scale. At the end of the study there was no difference in quality of life 
measured with the SF-36, MFI-20 an AF-severity scale between lenient and strict 
rate control. In addition, heart rate did not influence quality of life. The results of 
this study are presented in chapter 5. This again showed that lenient rate control is 
treatment of choice in patients with permanent atrial fibrillation. 
 The ideal outcome parameter in a study on prognosis is mortality. However, 
this would require a very large patient cohort due to the good prognosis in patients with 
atrial fibrillation. Therefore a composite outcome was used in RACE II. Cardiovascular 
hospitalization is an alternative outcome parameter which is associated with mortality. 
To further investigate difference between lenient and strict rate control we performed 
an additional analysis on cardiovascular hospitalization and mortality. These results are 
presented in chapter 6. We observed no difference in cardiovascular hospitalization 
and mortality between lenient and strict rate control. It is, however, striking that many 
patients were hospitalized during the study, showing the vulnerability of patients with 
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permanent atrial fibrillation. 
 Finally, in chapter 7 we discuss the general clinical and therapeutical 
implications of different rate control strategies with respect to the results presented 
in this thesis. Treatment on atrial fibrillation is simplified due to the results of RACE 
II. Lenient rate control is easy to achieve, requires fewer drugs, outpatient department 
visits and additional examinations. However, patients with atrial fibrillation are fragile 






Op dit moment hebben meer dan 6 miljoen mensen in Europa boezemfibrilleren 
en de verwachting is dat dit aantal zich de komende 30 tot 50 jaar zal verdubbelen, 
mede door de vergrijzing. Boezemfibrilleren is geen goedaardige aandoening. Er 
bestaat een verhoogde kans op overlijden, hersenberoerte, hartfalen, een afgenomen 
inspanningstolerantie en een afgenomen kwaliteit van leven. Ondanks pogingen 
het normale ritme te herstellen, is het een progressieve ritmestoornis. Dit betekent 
dat de ritmestoornis aanvankelijk af en toe aanwezig is, en uiteindelijk continu. Er 
zijn veel patiënten bij wie de ritmestoornis continu aanwezig is. Een evidence based 
behandelstrategie ontbreekt op dit moment bij deze patiënten en is vanwege het grote 
aantal patiënten van groot belang.
 Boezemfibrilleren is al zeer lang een bekende ritmestoornis. Vroeger werd 
de hartfrequentie verlaagd met digoxine of er werd geprobeerd het normale ritme 
terug te krijgen met quinidine. In de jaren 60 van de vorige eeuw is de electrische 
cardioversie geïntroduceerd. Ondanks deze nieuwe methode bleef boezemfibrilleren 
een progressieve ritmestoornis. Er waren, en zijn, twee behandelstrategiën voor 
boezemfibrilleren: ritme controle en frequentie controle. Een ritme controle strategie 
is gedefiniëerd als een behandeling gericht op het behoud van normaal ritme 
(sinusritme). Een frequentie controle strategie is gedefiniëerd als een behandeling 
gericht op verlaging van de hartfrequentie tijdens de ritmestoornis. 
 Het is nu 10 jaar geleden dat duidelijk is geworden dat er geen verschil in 
prognose is tussen een behandeling volgens een ritme controle of een behandeling 
volgens een frequentie controle strategie. De studies die dit hebben laten zien gebruikten 
verschillende definities voor goede hartfrequentie controle. De richtlijnen op dat 
moment adviseerden een strenge frequentie controle. Dit advies was echter gebaseerd 
op kleine studies die niet naar de prognose van de patiënt keken. Er was daarmee geen 
goed bewijs hoe patiënten behandeld moesten worden volgens een frequentie controle 
strategie. Er werd verondersteld dat bij boezemfibrilleren hartfrequentie en prognose 
aan elkaar gerelateerd zijn. Studies die verricht zijn naar frequentie controle, lieten 
geen verschil in prognose zien tussen patiënten met een hoge of lage hartfrequentie. 
Hierbij moet worden aangemerkt dat dit retrospectieve studies zijn. 
Ook is verondersteld dat hartfrequentie en kwaliteit van leven aan elkaar gerelateerd 
zijn. Een hogere hartfrequentie zou meer en ernstigere klachten kunnen veroorzaken. 
Maar, een strenge behandel strategie behoeft meer medicatie, met mogelijk meer 
bijwerkingen. Er zijn geen prospectieve gegevens over de relatie tussen kwaliteit van 
leven en hartfrequentie, noch ook tussen kwaliteit van leven en verschillende frequentie 
controle strategieën. 
Het doel van dit proefschrift is om verschillende frequentie controle strategieën voor 
de behandeling van boezemfibrilleren met elkaar te vergelijken. In hoofdstuk 1 zijn de 
algemene introductie en achtergrond van dit proefschrift behandeld, zoals hierboven 
is samengevat.
 Vervolgens hebben we in een retrospectieve studie gekeken naar de prognose 
bij patiënten met een hoge en lage hartfrequentie. Deze resultaten zijn gepresenteerd 
in hoofdstuk 2. De patiëntengroep bestond uit patiënten geincludeerd in de RACE 
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studie die gerandomiseerd (willekeurig ingedeeld) waren naar frequentie controle. De 
patiënten zijn daarna ingedeeld op basis van de gemiddelde hartfrequentie tijdens de 
studie. Een hartfrequentie onder de 80 slagen per minuut is in deze studie gedefinieerd 
als een lage hartfrequentie en een frequentie gelijk aan, of hoger dan, 80 slagen per 
minuut als een hoge hartfrequentie. Hierbij is naar voren gekomen dat er geen 
verschil was in prognose tussen de patiënten met een lage en een hoge hartfrequentie. 
Daarnaast is er ook geen verschil in kwaliteit van leven of verslechtering van de linker 
ventrikelfunctie bij patiënten met een hoge hartfrequentie. 
 Bovengenoemde uitkomsten komen overeen met de resultaten van eerdere 
onderzoeken naar hartfrequentie controle tijdens boezemfibrilleren. Hierbij moet 
worden aangemerkt dat evenals in ons onderzoek eerdere studies naar frequentie 
controle bij boezemfibrilleren retrospectief waren. Om die reden hebben we een 
prospectief, dubbel blind, gerandomiseerde studie verricht naar het effect van 
frequentie controle op de prognose bij patiënten met permanent boezemfibrilleren. 
In hoofdstuk 3 zijn de resultaten van ‘The Rate Control Efficacy in Permanent 
Atrial Fibrillation: a Comparison between Lenient versus Strict Rate Control II 
study (RACE II)’ gerapporteerd. In de RACE II hebben we meer dan 600 patiënten 
gerandomiseerd naar een strenge frequentie controle of gematigde frequentie controle. 
Een strenge frequentie controle is gedefinieerd als een rust-frequentie onder de 80 
slagen per minuut én tijdens gematigde inspanning onder de 110 slagen per minuut. 
Een gematigde frequentie controle is gedefinieerd als een rust-frequentie onder de 
110 slagen per minuut. De hypothese was dat gematigde frequentie controle niet 
slechter zou zijn dan strenge frequentie controle. Het primaire eindpunt was een 
combinatie van cardiovasculair overlijden, opname voor hartfalen, beroerte, bloedingen, 
pacemaker of interne defibrillator implantatie, levensbedreigende complicaties van de 
frequentie controle medicatie, syncope of levensbedreigende kamer ritmestoornissen. 
De hartfrequentie werd verlaagd met beta-blockers, calcium antagonisten of digoxine. 
Na de dosis-titratie fase was er een significant verschil in hartfrequentie tussen de 
beide groepen. Tijdens de studie bleef er een significant verschil in hartfrequentie 
bestaan. Na een studieduur van 3 jaar was er geen verschil in het optreden van het 
primaire eindpunt tussen de gematigde en strenge frequentie controle groep. Dit 
betekent dat de gematigde frequentie controle strategie niet slechter is dan de strenge 
frequentie controle strategie. Hiermee is onze hypothese bevestigd, en is een gematigde 
frequentie controle de eerste keus behandelstrategie bij patiënten met permanent 
boezemfibrilleren.
 Eerdere studies naar frequentie controle bij permanent boezemfibrilleren 
lieten zien dat het moeilijk is om patiënten in te stellen op een strenge frequentie 
controle. Dit probleem hebben we ook gezien in de RACE II. In de strenge 
frequentie controle strategie van de RACE II heeft 67% van de patiënten de 
hartfrequentie criteria gehaald tegenover 98% van de patiënten in de gematigde 
frequentie controle groep. Dit grote verschil zou, in het voordeel van de gematigde 
behandel strategie, de uitkomsten van de RACE II beïnvloed kunnen hebben. 
We hebben daarom een aanvullende analyse verricht naar het verschil in prognose 
tussen patiënten met succesvolle strenge frequentie controle, niet succesvolle strenge 
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frequentie controle en gematigde frequentie controle. De resultaten van deze studie 
zijn in hoofdstuk 4 gepresenteerd. Deze studie laat zien dat er geen verschil is in het 
primaire eindpunt, zoals hierboven beschreven, tussen succesvolle en niet succesvolle 
strenge frequentie controle en gematigde frequentie controle. Dit betekent dat het 
door patiënten niet behalen van de strenge frequentie controle geen invloed heeft 
gehad op de uitkomsten van de RACE II. Deze bevinding wijst er wederom op dat 
gematigde frequentie controle de eerste keus behandelstrategie is bij patiënten met 
permanent boezemfibrilleren. 
 Naast de prognose van de patiënt is kwaliteit van leven een belangrijk aspect bij 
de behandeling van boezemfibrilleren. Daarom hebben we in de RACE II een analyse 
verricht naar het verschil in kwaliteit van leven tussen de patiënten met gematigde 
en strenge frequentie controle strategie. De hypothese was dat er geen verschil in 
kwaliteit van leven zou zijn tussen deze twee groepen. Kwaliteit van leven is gemeten 
met 3 vragenlijsten, de SF-36, MFI-20 en AF-severity scale. Dit zijn vragenlijsten 
naar respectievelijk algemene gezondheid, vermoeidheid en klachten gerelateerd 
aan boezemfibrilleren. Aan het einde van de studie was er geen verschil in kwaliteit 
van leven tussen de twee behandelstrategieën. Daarnaast had ook hartfrequentie 
geen invloed op verschil in kwaliteit van leven. Deze resultaten zijn gepresenteerd 
in hoofdstuk 5 en laten wederom zien dat gematigde frequentie controle de eerste 
keus behandelstrategie is bij patiënten met permanent boezemfibrilleren.
 Een studie die wetenschappelijk bewijs moet leveren heeft in het ideale 
geval overlijden als primair eindpunt. Patiënten met boezemfibrilleren hebben een 
dermate goede prognose dat er zeer veel patiënten nodig zijn om zo’n studie statistisch 
verantwoord uit te voeren. In de RACE II is daarom gebruik gemaakt van een 
gecombineerd eindpunt. Opname vanwege cardiovasculaire redenen is een alternatief 
eindpunt dat gerelateerd is aan overlijden. Om toch een uitspraak te kunnen doen 
over overlijden hebben we in de RACE II een aanvullende analyse verricht naar 
overlijden en opname vanwege cardiovasculaire redenen. Deze studie is gepresenteerd 
in hoofdstuk 6. In deze studie zien we dat er geen verschil is tussen de gematigde en 
strenge frequentie controle groep in overlijden en opname vanwege cardiovasculaire 
redenen. Het is wel opvallend dat veel van de patiënten tijdens de studieduur zijn 
opgenomen. Dit laat zien dat patiënten met boezemfibrilleren kwetsbaar zijn. 
 Tot slot behandelen we in hoofdstuk 7 de algemene klinische en 
therapeutische implicaties van rate control strategieën in boezemfibrilleren waarbij 
we verwijzen naar de bevindingen van dit proefschrift. In de toekomst denken we dat 
de behandeling van boezemfibrilleren mede door de resultaten van dit proefschrift 
vereenvoudigd kan worden. Gematigde frequentie controle is eenvoudiger te behalen, 
met minder medicatie, minder ziekenhuis bezoeken en minder aanvullend onderzoek. 
Hierbij moet wel aangetekend worden dat patiënten met boezemfibrilleren kwetsbaar 
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Alleen is maar alleen, ook in de wetenschap. Zonder begeleiding, inspiratie, motivatie 
en steun van anderen is het lastig een promotie traject succesvol af te ronden. Nu dit 
boekje klaar is wil ik graag een aantal mensen bedanken. 
 Allereerst mijn eerste promotor prof. dr. I.C. van Gelder, beste Isabelle, 
jouw motivatie is grenzeloos, dat is voor een promovendus af en toe wel lastig, maar 
daardoor heb ik in de afgelopen jaren meer bereikt, gedaan, meegemaakt en gezien 
dan ik vooraf had verwacht. Ik soliciteerde bij de ritmegroep om mijn naam eens in 
Groningen te laten vallen, ik was tenslotte nog niet afgestudeerd. Desondanks stelde 
je het vertrouwen in me om aan een belangrijke onderzoek te gaan werken. Nu zijn we 
5 jaar verder met een fantastisch resultaat. Dank voor je steun en enthousiasme in de 
wetenschap en de cardiologie. 
 Mijn tweede promotor prof. dr. D.J. van Veldhuisen, beste Dirk Jan, mijn 
eerste wetenschappelijk onderzoek heb ik gedaan onder jouw leiding. Desondanks 
ben ik niet bij de hartfalen-groep terecht gekomen. Graag wil ik je bedanken voor je 
heldere ideeën en kritische blik op het werk dat ik je in de afgelopen jaren onder ogen 
heb gelegd. 
 Mijn derde promotor prof. dr. M.P. van den Berg, beste Maarten, elke twee 
weken hadden we de RACE vergadering waarin de lopende zaken van de RACE II 
besproken werden. Tijdens die vergaderingen werd er altijd al vooruitgedacht over 
aanvullende analyses en hoe problemen op te vangen. Dank voor je heldere ideeën en 
commentaar op stukken van de afgelopen jaren. Daarnaast dank voor het vertrouwen 
de opleiding tot cardioloog te mogen volgen.
 Daarnaast wil ik nog twee mensen speciaal bedanken die mij met regelmaat 
te hulp zijn geschoten. Geachte professor Hillege, beste Hans, met regelmaat liep ik 
langs op de 2e in het Triade gebouw als ik weer eens een vraag had, óf om te vragen 
of je mijn uitkomsten even wilde narekenen. Je maakte altijd tijd, en met regelmaat 
was je ook op de 1e te zien als je gewoon even langs kwam of als je bij één van je 
eigen promovendi langs liep. Zo’n schouderklopje af en toe doet veel goeds, dank 
daarvoor. Geachte professor Tijssen, beste Jan, het kostte vaak wat moeite om je te 
kunnen spreken, maar dat was het zeker waard! De telefoongesprekken waren niet 
al te lang maar altijd zeer vruchtbaar, je commentaar was duidelijk en opbouwend. 
Dank voor je heldere analyses en richting gevende kritiek.
 De basis van mijn proefschrift is gelegd toen de RACE II is opgezet. 
Nadat de RACE studie was afgerond was de RACE II een logisch vervolg, maar de 
RACE II is wel de enige studie in zijn soort. Voor het bedenken, ontwerpen, opzetten 
en uitvoeren van deze studie ben ik de steeringcommissie ontzettend dankbaar. Beste 
Harry, Jan, Hans, Dirk Jan, Maarten, Ype, Marco, Hans, Jan-Hein, Otto en Isabelle, 
dank voor jullie vooruitstrevende ideeën en werk.
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 Een volgend struikelblok voor een studie als de RACE II is inclusie... zonder 
patiënten geen studie. De RACE II heeft in veel centra succesvol gelopen. Zonder de 
inzet van research nurses en cardiologen was het nooit gelukt om de RACE II af te 
ronden zoals we nu hebben gedaan. Veel dank hiervoor. Aangaande de inclusie nog 
een speciaal dankwoord voor de collega’s in het UMCG, beste Sheba, Michiel, Martin, 
Sandra en Marcelle, dank voor het includeren van de UMCG patiënten!
 Het huzaren stukje van dit proefschrift is natuurlijk het hoofdartikel van de 
RACE II. Er zijn vele late uurtjes gemaakt om er iets moois van te maken, daarom veel 
dank aan de co-auteurs. 
 De eindpunt-beoordelingscommissie was één van de belangrijkste ‘organen’ 
binnen het RACE II onderzoek. Zo eens in de 2 tot 3 maanden was er een vergadering. 
Dit was een samenzijn waarbij alle eindpunten kritisch beoordeeld werden. Beste 
Johan en Gert Jan, ik wil jullie bedanken voor de inzet en tijd die het heeft gevraagd 
om alle eindpunten te beoordelen. Helaas is Jan van der Meer ons gedurende het 
onderzoek ontvallen. Zijn overlijden hebben we als een groot verlies ervaren.  
 Daarnaast wil ik graag professor Wellens, professor Hauer en professor Wilde 
bedanken voor hun werkzaamheden binnen de data safety monitoring commissie van 
de RACE II. 
 Het uitvoeren van een multicenter studie is een enorme klus, gelukkig heeft 
de TCC de nodige ondersteuning geboden. Beste Janneke, de eerste jaren van mijn 
promotie hebben we intensief samengewerkt, elke 2 weken het RACE II overleg, 
monitoren in de verschillende centra, en regelmatig even bij elkaar langslopen als er 
iets niet liep zoals het zou moeten. Dank voor de gezelligheid en je tomeloze inzet 
voor de RACE II! Zonder jouw hulp en toewijding was de RACE II niet zo’n succes 
geworden. Daarnaast wil ik ook Myke bedanken, jij hebt, met succes, het stokje van 
Janneke overgenomen wat betreft het monitoren. Ook dank voor jouw inzet. Het is, 
denk ik, niet voor niets dat je nu ‘de baas’ bent over de RACE 3. 
 Daarnaast is er nog een aantal mensen binnen de TCC met wie ik met veel 
plezier heb samengewerkt en die hebben bijgedragen aan het resultaat van dit boekje.
Beste Marco, Nic, Olga en Annefleure dank voor jullie inzet voor de RACE II. 
Daarnaast wil ik Bregtel speciaal bedanken, als ik Hans nodig had kon dat eigenlijk 
alleen via jou.... daarnaast heb je ook veel practische zaken geregeld, onder andere de 
vragenlijsten voor de kwaliteit van leven. Veel dank voor je tijd en geduld. 
 Beste Eric, dank voor je hulp en steun tijdens de kwaliteit van leven analyses. 
Jij kon ervoor zorgen ik door de bomen het bos weer kon zien. 
 Tijdens mijn promotietraject heb ik met veel plezier elke week 1 of 2 poli’s 
gedaan, afhankelijk van het aantal ritme promovendi op dat moment. Beste Bas, Ans, 
en Alexander ik wil jullie bedanken voor het superviseren van mijn poli’s. Daarnaast 
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wil ik de dames die cluster A ondersteunden op de poli bedanken, Antoinette, Agnes, 
Didie, Hayat, Anne en Jolanda. In verband met de studies naar devices heb ik ook 
regelmatig in de pacemaker kamer gestaan, Pieter, Dick, Meint, Henk, Hanny, Esther 
en Henk, dank voor de prettige samenwerking en de tijd die jullie namen om mij 
uitleg te geven over de devices en instellingen. Daarnaast ook Diane, Esther en Liesje 
in verband met de planning van de implantaties. Ook wil ik Anke, Yoran, Berdy 
bedanken als ik weer eens kwam leuren om een echo die binnen een week gedaan 
moest worden. Datzelfde geldt voor iedereen op de Holter kamer, Jaap, Joke, Tallien, 
Carien, Jeanet, Hendrina en Patricia dank voor de samenwerking en jullie inzet als er 
weer eens een onderzoek vervroegd moest worden. 
 Naast de werkzaamheden op de poli heb ik ook met veel plezier cardioversies 
gedaan op C1. Dit was mede zo leuk door het team dat daar werkt. Han we moeten 
nog steeds een keer gaan hardlopen, misschien moeten we daar maar eens werk van 
maken nu dit boekje klaar is. Beste Gea, Bauk, Hans, Han, Lydia en Robbert, dank 
voor de prettige samenwerking bij de vele cardioversies die we gedaan hebben. 
 Naast een eigen proefschrift wordt er ook aan ander onderzoek gewerkt. 
Beste Greetje, Carlien, Carla, Anja, Trienke, Peter, Margriet, Maaike, Geert en Karin 
dank voor de prettige samenwerking en gezellige momenten. 
 Beste Alma en Audrey, een draaiende afdeling staat of valt bij een goed 
secretariaat. Elke afspraak of formulier dat ondertekend moet worden komt via jullie 
op de juiste plaats. Veel dank al het werk dat jullie doen en de vele zaken die er geregeld 
worden, op eigen verzoek, én de zaken die ‘vanzelf ’ lijken te gaan.
 Toen ik in april 2007 voor het eerst in het poortgebouw kwam ben ik me rot 
geschrokken. Een klein warm kamertje met 4 collega’s, vijf bureau’s en bergen papier. 
Sheba ging me even het CRF van de RACE II laten zien, een boel hokjes, geklik 
en patiëntennummers, en ik was het overzicht volledig kwijt. Toen ik in november 
echt begon kwam ik terecht in een hechte groep collega’s, die met grote regelmaat 
met elkaar de kroeg in ging. Daarnaast was niemand te beroerd om iets voor een 
ander te doen. Promoveren is een leuke, maar ook hectische tijd. Een paar goede 
collega’s die je gevloek, getier of tranen opvangen bij het mislukken of kwijtraken 
van analyses danwel data, zijn dan onmisbaar. Beste Willem-Peter, Anne, Liza, Jardi, 
Sheba, Sandra, Lucas, Walter, Ismaël, Rob, Ernaldo, Pieter, Kevin, Vincent, Marlies, 
Arjen, Imke, Daan, Jasper, Jan-Pieter, Frank, Nicolas, Ali, Lennaert, Suzan, Renée, 
Caroline, Mariusz, Anne-Margreet, Lieuwe, Matthijs, Pieter-Jan, Youlan, Marthe, 
Wouter, Chris, Marieke, Karim, Mirjam, Ymkje en IJsbrand dank voor de gezelligheid 
en collegialiteit van de afgelopen jaren. 
 Het eerste jaar vooropleiding heb ik nu achter de rug, graag wil ik de 
internisten en collega’s in het Martini bedanken voor de stimulerende, leerzame  en 
gezellige omgeving waarin ik dit heb gedaan.
180 Dank je wel
 Terschelling heeft een speciaal plaatsje in mijn hart. Oerol is daar ook 
onderdeel van geworden. Lieve poekelaars, dank voor jullie gezelligheid en steun! 
 Beste Marieke, Isabelle, Marcia, Christie, Debbie, Linda, Dana, Stieneke en 
Nathalie, het is alweer 5 jaar geleden dat ik Froukje ‘mee heb genomen’  uit het westen. 
Ik wil jullie bedanken voor de steun die jullie hebben geboden aan mij, en aan Froukje 
niet te vergeten, in de afgelopen jaren. 
 Beste Jorn, Daniel, Robbert Jan, Laurens, Edward, Ivo, Erik, Marten-
Pieter, Piet, Tjeerd, Schelte en Geert Joost, ik wil jullie bedanken voor de steun en 
interresse  die jullie geuit hebben tijdens de huwelijken, poppeslokken, vrijgezellen en 
clubweekenden van de afgelopen jaren. 
 Lieve Roos, in eerste instantie zou je ook in Groningen gaan studeren. Nadat 
je met de Kei-week in Groningen was begonnen werd je alsnog in Rotterdam ingeloot 
voor geneeskunde. Door de afstand was het wat lastiger om te zien hoe je je tijdens 
de studie aan het ontwikkelen was. Dit is wel veranderd sinds je in Enschede aan het 
werk bent op de IC, en op de chirurgie. Ik ben toch regelmatig jaloers geweest op alles 
wat je meemaakt, en je ervaringen in de kliniek. Ik geniet ervan als je weer met een 
mooi verhaal thuis komt over de beslommeringen met collega’s, verpleegkundigen en 
patiënten. Hopelijk blijven we onze passie delen, en onze ervaringen en vaak mooie 
verhalen uitwisselen!
 Beste Bart, op vrijdagmiddag een borrel in het feithhuis....en dan werd de 
week even doorgenomen, en vaak was er veel om door te nemen. In het Triade gebouw 
was het altijd gezellig en er was genoeg ruimte voor practical jokes, hopelijk wordt dit 
een traditie! Daarnaast ben ik er trots op dat jij de data van de RACE II van me hebt 
overgenomen. Niemand minder die het meer verdient! Hopelijk zitten we ook nog 
eens samen in de kliniek.
 Paranimf zijn is toch wel een beetje speciaal, dat heb ik zelf mogen 
ondervinden.  Beste Marcelle, jij was al enige tijd bezig met onderzoek toen ik begon 
in het poortgebouw. Ik heb de afgelopen jaren ontzettend veel van je geleerd. Naast de 
wetenschap hebben we tijdens de afgelopen jaren nog veel meer gedeeld. We hebben 
hectische periodes meegemaakt in het Triadegebouw, en altijd was er de mogelijkheid 
om even op je terug te vallen. Waarvoor veel dank. Ik ben er trots op dat jij mijn 
reserve paranimf bent, en kijk ernaar uit om in de kliniek weer met je samen te werken. 
Daarnaast misschien nog eens hardlopen, genieten van lekker eten en wijn, samen met 
Froukje en Dion en onze grote kleine mannen! 
  Hey Twente boys, lieve Daan en Mieke, Nick en Alice, en Michiel en 
Floor, graag wil ik jullie bedanken voor de ontspannende en relativerende gesprekken. 
Vaak gebeurde dit onder het genot van een drankje en hapje in Groningen, Friesland, 
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Twente of Londen. Hopelijk blijven we dit nog jaren met elkaar doen, ik blijf er 
namelijk van genieten. 
 
 Lieve Lesley en Maartje, en Yuri en Mariëlle, onder het genot van een glaasje 
bier of wijn hebben we vaker de stand van zaken doorgenomen, op meerdere vlakken. 
Dit dan naast de vuurkorf in Enschede, dobberend in de sloep of randmeer over de 
Langweerder Wielen, of met een dikke jas aan op het balkon in Dorfgastein. Ik hoop 
dat we dit nog lang zullen blijven doen. Daarnaast altijd de gezelligheid van Imke, 
Tjemme, Suze, Mats, Bente en Sepp. Hopelijk kunnen we met z’n allen nog lang 
genieten van elkaars gezinnen (jah, dat mag ik nu ook zeggen).
 Lieve Arie en Inger, en Frans en Mariëlle, Maarten en Lenna, en Renske 
en Remco, de vraag:” Hoe is het met je proefschrift?”, is zo vaak door jullie gesteld, 
missschien ook omdat het wat langer duurde dan gepland, maar altijd was er de 
interresse in hoe het ging en waar ik mee bezig was. De afgelopen jaren hebben we 
gelukkig met elkaar genoten van zon, zee, strand, sneeuw, en vele andere goede dingen 
van het leven. Lieve schoonfamilie, ik bof met jullie!
 Lieve Roel en Annemieke, in ’99 ging ik m’n grote broer achterna richting 
Groningen. Uiteindelijk zijn we bijna 6 jaar huisgenoten geweest en hebben vele 
uurtjes samen doorgebracht in de GK, kroeg en ook de UB. Waar we begonnen als 
toch wel enigszins lakse studenten, zijn we nu beide wel druk met onze carriere. Ik 
vind het altijd erg prettig om met jullie te kunnen sparren over alles dat ons bezig 
houdt. Veel dank voor jullie steun.
 Lieve Menno, Marie Louise, Olaf, en Sybrig, allen hebben jullie de afgelopen 
jaren een eigen rol gehad. Mede door jullie sta ik waar ik nu ben. De passie voor 
geneeskunde is ontstaan in de praktijk in Reutum. Daarnaast hebben jullie me 
geholpen en gesteund in de keuzes van de afgelopen jaren. Ik kan ik altijd op jullie 
terugvallen, ook met vragen op het professionele vlak. Veel dank voor jullie steun, 
vertrouwen en natuurlijk alle gezelligheid tijdens het klussen, zeilen, skieen en andere 
mooie momenten.
 Lieve Froukje, de keuze die je in 2007 hebt gemaakt was helemaal niet 
vanzelfsprekend. Voor jou wel, daar ben ik je heel erg dankbaar voor. De afgelopen 
jaren ben je van onschatbare waarde voor me geweest. Als er in het Triadegebouw weer 
iets aan de knikker was, steunde je me en wist je me er altijd weer bovenop te krijgen. 
Dit, ondanks dat het voor jou aanvankelijk lastig was in Groningen. In de eerste versie 
van mijn dankwoord schreef ik dat we hopelijk nog veel grote stappen zullen zetten 
in het grote mensen leven. Inmiddels is pukkie geboren! Dank voor al je steun, ik hou 
van je!
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